

10/513699

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaéal1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUN 06 EPFULL enhanced with 260,000 English abstracts
NEWS 3 JUN 06 KOREAPAT updated with 41,000 documents
NEWS 4 JUN 13 USPATFULL and USPAT2 updated with 11-character
patent numbers for U.S. applications
NEWS 5 JUN 19 CAS REGISTRY includes selected substances from
web-based collections
NEWS 6 JUN 25 CA/CAPLUS and USPAT databases updated with IPC
reclassification data
NEWS 7 JUN 30 AEROSPACE enhanced with more than 1 million U.S.
patent records
NEWS 8 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional
options to display authors and affiliated
organizations
NEWS 9 JUN 30 STN on the Web enhanced with new STN AnaVist
Assistant and BLAST plug-in
NEWS 10 JUN 30 STN AnaVist enhanced with database content from EPFULL
NEWS 11 JUL 28 CA/CAPLUS patent coverage enhanced
NEWS 12 JUL 28 EPFULL enhanced with additional legal status
information from the EPOline Register
NEWS 13 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 14 JUL 28 STN Viewer performance improved
NEWS 15 AUG 01 INPADOCDB and INPAFAMDB coverage enhanced
NEWS 16 AUG 13 CA/CAPLUS enhanced with printed Chemical Abstracts
page images from 1967-1998
NEWS 17 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 18 AUG 15 CAPLUS currency for Korean patents enhanced
NEWS 19 AUG 27 CAS definition of basic patents expanded to ensure
comprehensive access to substance and sequence
information
NEWS 20 SEP 18 Support for STN Express, Versions 6.01 and earlier,
to be discontinued
NEWS 21 SEP 25 CA/CAPLUS current-awareness alert options enhanced
to accommodate supplemental CAS indexing of
exemplified prophetic substances
NEWS 22 SEP 26 WPIDS, WPINDEX, and WPIX coverage of Chinese and
and Korean patents enhanced
NEWS 23 SEP 29 IFICLS enhanced with new super search field
NEWS 24 SEP 29 EMBASE and EMBAL enhanced with new search and
display fields
NEWS 25 SEP 30 CAS patent coverage enhanced to include exemplified

<12/04/2007>

Erich Leese

prophetic substances identified in new Japanese-language patents
 NEWS 26 OCT 07 EPFULL enhanced with full implementation of EPC2000
 NEWS 27 OCT 07 Multiple databases enhanced for more flexible patent number searching
 NEWS 28 OCT 22 Current-awareness alert (SDI) setup and editing enhanced
 NEWS 29 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
 AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:39:01 ON 22 OCT 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.26	1.26

FILE 'REGISTRY' ENTERED AT 16:42:26 ON 22 OCT 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 OCT 2008 HIGHEST RN 1064205-90-8
 DICTIONARY FILE UPDATES: 21 OCT 2008 HIGHEST RN 1064205-90-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

10/513699

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10524123allow.str



chain nodes :
10 12 13 14 15
ring nodes :
1 2 3 4 5 6 7 8 9 17 18 19 20
ring/chain nodes :
21
chain bonds :
5-14 6-12 6-13 9-10 9-15 10-21
ring bonds :
1-2 1-6 2-3 2-17 3-4 3-20 4-5 4-7 5-6 5-9 7-8 8-9 17-18 18-19 19-20
exact/norm bonds :
1-2 1-6 2-3 2-17 3-4 3-20 4-5 4-7 5-6 5-9 5-14 6-12 6-13 7-8 8-9
9-10 9-15 10-21 17-18 18-19 19-20
isolated ring systems :
containing 1 :

G1:C,O,S,N

G2:C,N

G3:H,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS 17:Atom 18:Atom 19:Atom 20:Atom
21:CLASS

<12/04/2007>

Erich Leese


10/513699

L1 STRUCTURE UPLOADED

$\Rightarrow d \mid 11$

L1 HAS NO ANSWERS

L1 STR



G1 C,O,S,N

G2 C.N

G3 H. Ak

Structure attributes must be viewed using STN Express query preparation.

```
=> s ll full
```

FULL SEARCH INITIATED 16:43:36 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1551 TO ITERATE

100.0% PROCESSED 1551 ITERATIONS

736 ANSWERS

SEARCH TIME: 00.00.01

L2 736 SEA SSS FUL L1

```
=> file caplus
```

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.82

180.08

FILE 'CAPLUS' ENTERED AT 16:43:42 ON 22 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The Ca Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

<12/04/2007>

Erich Leese

10/513699

FILE COVERS 1907 - 22 Oct 2008 VOL 149 ISS 17
FILE LAST UPDATED: 21 Oct 2008 (20081021/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:



<http://www.cas.org/legal/infopolicy.html>

=> s 12 full
L3 16 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:1364471 CAPLUS
 DOCUMENT NUMBER: 148:33768
 TITLE: Preparation of bridged aryl piperazines derivatives
 useful for the treatment of CNS, gastrointestinal and
 reproductive disorders
 INVENTOR(S): Creighton, Christopher John; Ross, Tina Morgan; Reitz,
 Allen B.; Kordik, Cheryl P.; Paget, Steven
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 122pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007137168	A2	20071129	WO 2007-US69256	20070518
WO 2007137168	A3	20080912		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA US 20080070919 A1 20080320 US 2007-750629 20070518 PRIORITY APPLN. INFO.: US 2006-801439P P 20060518 OTHER SOURCE(S): MARPAT 148:33768 GI				



AB Title compds. represented by the formula I [wherein m = 0 or 1; L1, L2 = independently -alkyl-, -CH2-alkenyl-, -CH2-alkynyl-, etc.; R1, R2 = H, (cyclo)alkyl, aryl, etc.; n = 0 or 1; and pharmaceutically acceptable

salts thereof] were prepared as serotonin transport inhibitors and/or modulators of 5HT1A. For example, II was provided in a multi-step synthesis starting from the reaction of allylglycine Me ester with 2,4-dimethoxybenzaldehyde. I were tested for radioligand binding to the human 5-HT1A receptor and to human 5-HTT, and for [35S]GTPγS binding of 5-HT1A receptor activation and inhibition. Thus, I and their pharmaceutical compns. are useful for the treatment of depression and related disorders.

IT 959408-36-7P 959408-37-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bridged aryl piperazines derivs. useful for treatment of CNS, gastrointestinal and reproductive disorders)

RN 959408-36-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[[(1S,6S)-9-(2-naphthalenyl)-7,9-diazabicyclo[4.2.2]dec-3-en-7-yl]methyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 959408-37-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[[(1S,6S)-9-(2-naphthalenyl)-7,9-diazabicyclo[4.2.2]dec-3-en-7-yl]methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

10/513699



<12/04/2007>


Erich Leese

L3 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:936801 CAPLUS
 DOCUMENT NUMBER: 149:215053
 TITLE: Pharmacophore mapping of tricyclic isoxazoles for their affinity towards alpha-2 adrenoreceptors
 AUTHOR(S): Samanta, Soma; Alam, Sk. Mahasin; Panda, Parthasarathi; Jha, Tarun
 CORPORATE SOURCE: Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, 700 032, India
 SOURCE: Internet Electronic Journal of Molecular Design (2006), 5(10), 503-514
 CODEN: IEJMAT; ISSN: 1538-6414
 URL: http://biochempress.com/Files/iejmd_2006_5_0503.pdf
 PUBLISHER: BioChem Press
 DOCUMENT TYPE: Journal; (online computer file)
 LANGUAGE: English

AB Motivation: Blockage of alpha-2 adrenoreceptors in brain enhances noradrenergic neurotransmission and increases extracellular dopamine as well as serotonin (5-HT) levels, which is beneficial for depressant patients. To identify pharmacophoric requirements, a quant. structure activity relationship (QSAR) study was performed using electrotopol. state atom (ETSA) indexes and refractotopol. state atom (RTSA) indexes on tricyclic isoxazole derivs. for their affinity towards the alpha-2 adrenoreceptors. Method: Correlation anal. and multiple linear regression anal. were employed to model the exptl. activity. Results: The QSAR models were obtained sep. for alpha-2A and 2C adrenoreceptor binding affinity. Some atoms played important roles to both the activities and some other atoms played different roles in selectivity of compound towards alpha-2A and 2C adrenoreceptor binding affinity. Conclusions: Electrotopol. state atom (ETSA) and refractotopol. state atom (RTSA) indexes have potentiality to determine or recognize the pharmacophoric atoms and combination of these two helps to map pharmacophore of tricyclic isoxazoles.


IT 452318-38-6 1042685-16-4 1042685-19-7
 1042685-26-6 1042685-29-9 1042685-33-5
 1042685-37-9 1042685-40-4 1042685-43-7
 1042685-46-0 1042685-48-2 1042685-50-6
 1042685-52-8 1042685-54-0 1042685-57-3
 1042685-59-5 1042685-61-9 1042685-63-1
 1042685-66-4 1042685-67-5 1042685-69-7
 1042685-71-1 1042685-73-3 1042685-75-5
 1042685-77-7 1042685-79-9 1042685-81-3
 1042685-82-4 1042685-84-6 1042685-85-7
 1042685-86-8 1042685-87-9 1042685-88-0
 1042685-90-4 1042685-92-6 1042685-94-8
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (pharmacophore mapping of tricyclic isoxazoles for their affinity towards alpha-2 adrenoreceptors and possible antidepressant use)

RN 452318-38-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-16-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA
INDEX NAME)



RN 1042685-19-7 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]- (CA INDEX NAME)



RN 1042685-26-6 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-buten-1-yl)-1-
piperazinyl]methyl]- (CA INDEX NAME)

10/513699




RN 1042685-29-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-33-5 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-(3-phenyl-2-propen-1-
yl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-37-9 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-(2-
naphthalenylmethyl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-40-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 1042685-43-7 CAPLUS


CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxamide, N-ethyl-3a,4-dihydro-3-[[4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-46-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxylic acid, 3a,4-dihydro-3-[[4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-, ethyl ester (CA INDEX NAME)


10/513699




RN 1042685-48-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1042685-50-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1042685-52-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-54-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-57-3 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-buten-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-59-5 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy- (CA INDEX NAME)




RN 1042685-61-9 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 1042685-63-1 CAPLUS


CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-66-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy- (CA INDEX NAME)


10/513699



RN 1042685-67-5 CAPLUS
 CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-5-methyl-3-
 [[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX
 NAME)




RN 1042685-69-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1042685-71-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


10/513699




RN 1042685-73-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1042685-75-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-77-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-
(CA INDEX NAME)



RN 1042685-79-9 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-(2-methoxyethoxy)-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]- (CA INDEX NAME)



RN 1042685-81-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-[2-(2-ethoxyethoxy)ethoxy]-3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-
propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—CH₂—OEt


RN 1042685-82-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-(cyclopentyl-oxo)-3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-84-6 CAPLUS

CN Ethanamine, 2-[[3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-N,N-
dimethyl- (CA INDEX NAME)




RN 1042685-85-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-
, 7-acetate (CA INDEX NAME)




RN 1042685-86-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-
, 7-propanoate (CA INDEX NAME)




RN 1042685-87-9 CAPLUS

CN Acetic acid, 2-methoxy-, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester (CA INDEX NAME)



RN 1042685-88-0 CAPLUS


CN Cyclopropanecarboxylic acid, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester (CA INDEX NAME)



RN 1042685-90-4 CAPLUS


CN 2-Propenoic acid, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-

piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester (CA INDEX NAME)




RN 1042685-92-6 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester (CA INDEX NAME)



RN 1042685-94-8 CAPLUS

CN 4-Pyridinecarboxylic acid, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester (CA INDEX NAME)



REFERENCE COUNT:

23


THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/513699

<12/04/2007>

Erich Leese

L3 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:474148 CAPLUS
 DOCUMENT NUMBER: 146:492615
 TITLE: Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α 2-adrenoceptor antagonism
 AUTHOR(S): Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.; Alvarez, Rosa M.; Bakker, Margot H.; Biesmans, Ilse; Cid, Jose M.; De Lucas, Ana I.; Drinkenburg, Wilhelmus; Fernandez, Javier; Font, Luis M.; Iturrino, Laura; Langlois, Xavier; Lenaerts, Ilse; Martinez, Sonia; Megens, Anton A.; Pastor, Joaquin; Pullan, Shirley; Steckler, Thomas
 CORPORATE SOURCE: Research & Early Development-EU, CNS-Psychiatry, Division of Janssen-Cilag, Medicinal Chemistry Department, Johnson & Johnson Pharmaceutical Research & Development, Toledo, 45007, Spain
 SOURCE: Bioorganic & Medicinal Chemistry (2007), 15(11), 3649-3660
 CODEN: BMECEP; ISSN: 0968-0896
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 146:492615
 GI



AB In previous articles we have described the discovery of a new series of tricyclic isoxazolines combining central serotonin (5-HT) reuptake inhibition with α 2-adrenoceptor antagonistic activity. We report now on the synthesis, the in vitro binding potency and the primary in vivo activity of six enantiomers within this series, one of which was selected for further pharmacol. evaluation and assigned as R226161 (I). Some addnl. in vivo studies in rats are described with this compound, which proved to be centrally and orally active as a combined 5-HT reuptake inhibitor and α 2-adrenoceptor antagonist.


IT 452313-46-1P 452313-65-4P 452313-68-7P
 452313-71-2P 452314-01-1P 452318-73-9P
 452318-75-1P 722545-47-3P 936362-34-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and $\alpha 2$ -adrenoceptor antagonism)

RN 452313-46-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-65-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452313-68-7 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-71-2 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aS)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452314-01-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



10/513699


RN 452318-73-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-75-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-)- (CA
INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 722545-47-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 936362-34-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



IT 452313-36-9 452318-26-2


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(Tricyclic isoxazolines: Identification of R226161 as a potential new
antidepressant that combines potent serotonin reuptake inhibition and
 α 2-adrenoceptor antagonism)

RN 452313-36-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-26-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT 936362-26-4P 936362-28-6P 936362-31-1P

936362-33-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(Tricyclic isoxazolines: Identification of R226161 as a potential new
 antidepressant that combines potent serotonin reuptake inhibition and
 α 2-adrenoceptor antagonism)

RN 936362-26-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
 [1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-, 1,1-dimethylethyl ester,
 rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 936362-28-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-, 1,1-dimethylethyl ester, rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 936362-31-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.




RN 936362-33-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel-(+)-

10/513699

(CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.





REFERENCE COUNT:

26

THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:511158 CAPLUS
 DOCUMENT NUMBER: 145:27976
 TITLE: Isoxazoline-indole derivatives with an improved
 antipsychotic and anxiolytic activity
 INVENTOR(S): Andres-Gil, Jose Ignacio; Bartolome-Nebreda, Jose
 Manuel; Alcazar-Vaca, Manuel Jesus; Garcia-Martin,
 Maria de las Mercedes; Megens, Antonius Adrianus
 Hendrikus Petrus
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006056600	A1	20060601	WO 2005-EP56229	20051125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005308778	A1	20060601	AU 2005-308778	20051125
CA 2585857	A1	20060601	CA 2005-2585857	20051125
EP 1819713	A1	20070822	EP 2005-816247	20051125
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101084225	A	20071205	CN 2005-80040127	20051125
JP 2008521771	T	20080626	JP 2007-541989	20051125
US 20080113988	A1	20080515	US 2007-791510	20070524
PRIORITY APPLN. INFO.:			EP 2004-106123	A 20041126
			WO 2005-EP56229	W 20051125
OTHER SOURCE(S):	MARPAT 145:27976			
GI				



- AB Title compds. I [X = CH₂, S, O, (un)substituted-N; V = S, O, NH, or NR₄ wherein R₄ = alkyl or covalent bond between the N and the (CH₂)_n moiety; R₁ and R₂ independently = H, halo, OH, aryl, etc.; R₃ = H, CN, halo, alkyl, etc.; q = 0-2; m = 0-3; n = 0-4; A = bivalent radical chosen from (un)substituted piperidinyl which is optionally partially unsatd. or (un)substituted alkyl amine], and their pharmaceutically acceptable salts are prepared and disclosed as having a binding affinity towards dopamine receptors, in particular towards dopamine D₂ and/or D₃ receptors, with selective serotonin reuptake inhibition (SSRI) properties and showing an affinity for the 5-HT_{1A} receptor. Thus, e.g., II was prepared by substitution of 3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazole-3-methanol methanesulfonate ester with 5-fluoro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole. In binding assays for 5-HT_{1A} receptor, I possessed pIC₅₀ values ranging from 6.0-8.9. Further disclosed are pharmaceutical compns. comprising I, the use thereof for the prevention and/or treatment of a range of psychiatric and neurol. disorders, in particular certain psychotic disorders, most in particular schizophrenia and processes for their production
- IT 888727-48-8P 888727-56-8P 888727-58-0P
888727-84-2P 888727-97-7P 888727-98-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of isoxazoline-indole derivs. with antipsychotic and anxiolytic activity)
- RN 888727-48-8 CAPLUS
- CN 1H-Indol-5-ol, 3-[1-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-, rel- (CA INDEX NAME)

10/513699


Relative stereochemistry.



RN 888727-56-8 CAPLUS

CN Ethanol, 2-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-, 1-acetate, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-58-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888727-84-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)

3-[[3,6-dihydro-4-(1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 888727-97-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

3-[[4-(5-bromo-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888727-98-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

3-[[3,6-dihydro-4-(5-methoxy-1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT	888727-46-6P	888727-47-7P	888727-49-9P
	888727-50-2P	888727-51-3P	888727-52-4P
	888727-53-5P	888727-54-6P	888727-55-7P
	888727-57-9P	888727-59-1P	888727-60-4P
	888727-61-5P	888727-62-6P	888727-63-7P
	888727-65-9P	888727-66-0P	888727-67-1P
	888727-68-2P	888727-69-3P	888727-71-7P
	888727-72-8P	888727-73-9P	888727-74-0P
	888727-75-1P	888727-76-2P	888727-77-3P
	888727-78-4P	888727-79-5P	888727-80-8P
	888727-81-9P	888727-82-0P	888727-83-1P
	888727-85-3P	888727-86-4P	888727-87-5P
	888727-88-6P	888727-89-7P	888727-91-1P
	888727-92-2P	888727-93-3P	888727-94-4P
	888727-95-5P	888727-96-6P	888727-99-9P
	888728-00-5P	888728-01-6P	888728-02-7P
	888728-03-8P	888728-04-9P	888728-05-0P
	888728-06-1P	888728-08-3P	888728-09-4P
	888728-10-7P	888728-32-3P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of isoxazoline-indole derivs. with antipsychotic and anxiolytic activity)

RN 888727-46-6 CAPLUS

3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-47-7 CAPLUS

CN 1H-Indol-5-ol, 3-[1-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-4-piperidinyl]-, rel- (CA
INDEX NAME)


Relative stereochemistry.



RN 888727-49-9 CAPLUS

CN 1H-Indol-6-ol, 1-[1-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-4-piperidinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-50-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[[4-(5-methyl-1H-indol-3-yl)-1-piperidinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888727-51-3 CAPLUS

CN 1H-Indol-5-amine, 3-[1-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-4-piperidinyl]-, rel- (CA INDEX NAME)

10/513699

INDEX NAME)


Relative stereochemistry.



RN 888727-52-4 CAPLUS

CN Acetamide, N-[3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-4-piperidinyl]-1H-indol-5-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-53-5 CAPLUS

CN Urea, N-[3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]-N'-ethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




10/513699

RN 888727-54-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[3,6-dihydro-4-(1-methyl-1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-55-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(5-methoxy-1H-indol-3-yl)-1-
piperidinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-57-9 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-
3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-, rel-
(CA INDEX NAME)


Relative stereochemistry.



RN 888727-59-1 CAPLUS

CN Acetamide, N-[(3R,3aS)-3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.





RN 888727-60-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[5-[(2-methoxyethoxy)methoxy]-1H-indol-3-yl]-1-piperidinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 888727-61-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(5-phenyl-1H-indol-3-yl)-1-
piperidinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-62-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine,
N-[3-(5-fluoro-1H-indol-3-yl)propyl]-3a,4-dihydro-7,8-dimethoxy-,
(3R,3aS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 888727-63-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine,

10/513699

N-[3-(5-fluoro-1H-indol-3-yl)propyl]-3a,4-dihydro-7,8-dimethoxy-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-65-9 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-(1H-indol-3-yl)-1-piperidinyl]methyl]-7,8-dimethoxy-,
ethanedioate (1:1), (3R,3aS)-rel- (CA INDEX NAME)

CM 1

CRN 888727-64-8

CMF C26 H29 N3 O4

Relative stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 888727-66-0 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

<12/04/2007>

Erich Leese

3-[[4-(4-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-67-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-68-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)- (CA INDEX NAME)

Absolute stereochemistry.




10/513699

RN 888727-69-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3S,3aR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 888727-71-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-8-
methoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888727-72-8 CAPLUS

CN Acetic acid, 2-ethoxy-, 2-[[[(3R,3aS)-3-[[4-(5-fluoro-1H-indol-3-yl)-1-
piperidinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-
c]isoxazol-7-yl]oxy]ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




RN 888727-73-9 CAPLUS

CN Carbamic acid, ethyl-, 2-[[[(3R,3aS)-3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




RN 888727-74-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

10/513699


Relative stereochemistry.



RN 888727-75-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 888727-76-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3S,3aR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 888727-77-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,

10/513699

3-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-78-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7-(4-morpholinyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-79-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(7-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




10/513699

RN 888727-80-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-chloro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-81-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-bromo-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-82-0 CAPLUS

CN 1H-indole-5-carbonitrile, 3-[1-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-4-piperidinyl]-, rel- (CA
INDEX NAME)


Relative stereochemistry.



RN 888727-83-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[3,6-dihydro-4-(1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 888727-85-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(4-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888727-86-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(4-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-

10/513699

dihydro-7,8-dimethoxy-, (3S,3aR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 888727-87-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(4-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 888727-88-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)- (CA INDEX NAME)

Absolute stereochemistry.




10/513699

RN 888727-89-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3S,3aR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 888727-91-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-92-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-7-(4-morpholinyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-93-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888727-94-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-7-[(2-methoxyethoxy)methoxy]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A



—OMe


RN 888727-95-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
 dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888727-96-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-(5-chloro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
 dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-99-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[3,6-dihydro-4-(5-methyl-1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-
 dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888728-00-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[3,6-dihydro-4-(5-nitro-1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888728-01-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[3,6-dihydro-4-(5-phenyl-1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888728-02-7 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-[1-[[3(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-

10/513699

, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888728-03-8 CAPLUS

CN Urea, N-[3-[1-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]-N'-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.





RN 888728-04-9 CAPLUS

CN Glycine, N-[[[3-[1-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]amino]carbonyl]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 888728-05-0 CAPLUS

CN Acetamide, N-[3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]-2-methoxy-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888728-06-1 CAPLUS

CN Acetic acid, 2-[[3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]amino]-2-oxo-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888728-08-3 CAPLUS

CN Methanesulfonamide, N-[3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-

10/513699


[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]-, rel-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888728-07-2

CMF C27 H30 N4 O6 S

Relative stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 888728-09-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(5-fluoro-1H-indol-3-yl)methyl]-1-piperidinyl)methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



<12/04/2007>


Erich Leese

10/513699

RN 888728-10-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(6-fluoro-3-benzofuranyl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888728-32-3 CAPLUS


CN 1H-Indol-5-amine, 3-[1-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-
rel-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888728-31-2

CMF C26 H28 N4 O4

Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 888728-28-7P 888728-29-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of isoxazoline-indole derivs. with antipsychotic and anxiolytic activity)

RN 888728-28-7 CAPLUS

CN Carbamic acid, [3-[1-[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 888728-29-8 CAPLUS

CN Carbamic acid, [(3R,3aS)-3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:505909 CAPLUS

DOCUMENT NUMBER: 145:95782

TITLE: Synthesis of 7-amino-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazole derivatives displaying combined α_2 -adrenoceptor antagonistic and 5-HT reuptake inhibiting activities

AUTHOR(S): Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.; De Lucas, Ana I.; Iturrino, Laura; Biesmans, Ilse; Megens, Anton A.

CORPORATE SOURCE: Medicinal Chemistry Department, Division of Janssen-Cilag, Johnson & Johnson Pharmaceutical Research and Development, Toledo, 45007, Spain

SOURCE: Bioorganic & Medicinal Chemistry (2006), 14(13), 4361-4372

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:95782

AB Following a program searching for dual 5-HT reuptake inhibitors and α_2 -adrenoceptor antagonists started at Johnson & Johnson Pharmaceutical Research & Development, we now report on the synthesis of a series of 7-amino-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazole derivs., some of which proved to be the most potent α_2 -adrenoceptor blockers within this chemical class of tricyclic isoxazolines, while keeping potent 5-HT reuptake inhibiting activity.

IT 612074-52-9P 612074-56-3P 612074-57-4P
612074-68-7P 612074-81-4P 612074-88-1P
612074-89-2P 612074-90-5P 612074-92-7P
612074-93-8P 612074-94-9P 612074-95-0P
612074-98-3P 612074-99-4P 612075-02-2P
612075-03-3P 612075-07-7P 612075-09-9P
612075-10-2P 612075-11-3P 612075-12-4P
612075-13-5P 612075-15-7P 612075-88-4P
770707-27-2P 895169-63-8P 895169-64-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(benzopyranoisoxazole derivs. displaying combined α_2 -adrenoceptor antagonistic and 5-HT reuptake inhibiting activities)

RN 612074-52-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-56-3 CAPLUS

CN Acetamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-57-4 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-[(3,4-dimethoxyphenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 612074-68-7 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-ethyl-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-81-4 CAPLUS
CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-88-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-phenyl-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-89-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,


3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-phenyl-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-90-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
N-(4-fluorophenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-92-7 CAPLUS
CN Benzonitrile, 3-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-93-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-N-(2-methylphenyl)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-94-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
N-(3,4-dimethylphenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-95-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-

piperazinyl)methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-98-3 CAPLUS

CN Propanamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2,2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-99-4 CAPLUS

CN Cyclopropanecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




10/513699

RN 612075-02-2 CAPLUS

CN 2-Propenamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-03-3 CAPLUS

CN Benzamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-07-7 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-ethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-09-9 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(1,1-dimethylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-10-2 CAPLUS

CN Urea, N-cyclohexyl-N'-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 612075-11-3 CAPLUS

CN Glycine, N-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]carbonyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-12-4 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-phenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-13-5 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(3-fluorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




10/513699

RN 612075-15-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-88-4 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 770707-27-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 895169-63-8 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 895169-64-9 CAPLUS

CN Ethanol, 2-[[[(3S,3aR)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 452318-26-2 452319-41-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(benzopyranoisoxazole derivs. displaying combined α 2-adrenoceptor antagonistic and 5-HT reuptake inhibiting activities)

RN 452318-26-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-41-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT 452319-29-8P 612074-55-2P 895169-62-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(benzopyranoisoxazole derivs. displaying combined α 2-adrenoceptor antagonistic and 5-HT reuptake inhibiting activities)

RN 452319-29-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.




RN 612074-55-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 895169-62-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 7-bromo-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:920735 CAPLUS

DOCUMENT NUMBER: 142:219240

TITLE: Discovery of a New Series of Centrally Active
Tricyclic Isoxazoles Combining Serotonin (5-HT)
Reuptake Inhibition with α 2-Adrenoceptor
Blocking ActivityAUTHOR(S): Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.;
Alvarez, Rosa M.; Bakker, Margot H.; Biesmans, Ilse;
Cid, Jose M.; De Lucas, Ana I.; Fernandez, Javier;
Font, Luis M.; Hens, Koen A.; Iturrino, Laura;
Lenaerts, Ilse; Martinez, Sonia; Megens, Anton A.;
Pastor, Joaquin; Vermote, Patrick C. M.; Steckler,
ThomasCORPORATE SOURCE: Johnson Johnson Pharmaceutical Research Development
Division of Janssen-Cilag Medicinal Chemistry dept.,
Jarama s/n, Toledo, 45007, SpainSOURCE: Journal of Medicinal Chemistry (2005), 48(6),
2054-2071

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:219240


AB The synthesis and pharmacol. of a new series of
3-piperazinylmethyl-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles that
combine central serotonin (5-HT) reuptake inhibition with
 α 2-adrenoceptor blocking activity is described as potential
antidepressants. Four compds. were selected for further evaluation, and
the combination of both activities was found to be stereoselective,
residing mainly in one enantiomer. Reversal of the loss of righting
induced by the α 2-agonist medetomidine in rats confirmed the
 α 2-adrenoceptor blocking activity in vivo and also demonstrated CNS
penetration. Antagonism of p-chloroamphetamine (PCA)-induced excitation
as well as blockade of the neuronal 5-HT depletion induced by p-CA
administration in rats confirmed their ability to block the central 5-HTT,
even after oral administration. Replacement of the oxygen atom at the
5-position of the tricyclic scaffold by a nitrogen or a carbon atom, as
well as O-substitution at position 7, led also to active compds., both in
vitro and in vivo.IT 452313-54-1P 452318-20-6P 452318-95-5P
608146-13-0PRL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN
(Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of centrally active tricyclic isoxazoles combining 5-HT
reuptake inhibition with α 2-adrenoceptor blocking activity)

RN 452313-54-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.


Double bond geometry as shown.



RN 452318-20-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-95-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.




RN 608146-13-0 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.




IT 452319-41-4
RL: PAC (Pharmacological activity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α 2-adrenoceptor blocking activity)
RN 452319-41-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452313-65-4P 452319-33-4P 452320-36-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α 2-adrenoceptor blocking activity)
RN 452313-65-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-33-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-36-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-
propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT 452313-36-9P 452313-59-6P 452313-77-8P
452318-26-2P 452318-93-3P 452319-43-6P
452319-55-0P 452319-57-2P 452319-59-4P
452319-61-8P 452319-63-0P 452319-65-2P
452319-67-4P 452319-69-6P 452319-71-0P
452320-40-0P 452320-52-4P 452320-54-6P
452320-60-4P 452320-62-6P 452320-64-8P

10/513699

452320-66-0P 452320-70-6P 452321-33-4P
452321-35-6P 452321-37-8P 452321-39-0P
452321-41-4P 789484-08-8P 815632-62-3P
815632-63-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(preparation of centrally active tricyclic isoxazoles combining 5-HT
reuptake inhibition with α 2-adrenoceptor blocking activity)

RN 452313-36-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452313-59-6 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-(2-
naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452313-77-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452318-26-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-93-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-43-6 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-(2-methoxyethoxy)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-55-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-57-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 7-propanoate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-59-4 CAPLUS

CN Acetic acid, 2-methoxy-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-61-8 CAPLUS

CN Cyclopropanecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-63-0 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




10/513699

RN 452319-65-2 CAPLUS

CN 2-Propenoic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-67-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopentyloxy)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-69-6 CAPLUS

CN 4-Pyridinecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-71-0 CAPLUS

CN Ethanamine, 2-[[{(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-(1-benzopyrano[4,3-c]isoxazol-7-yl]oxy]-N,N-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-40-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-52-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-[(2E)-3-

10/513699


phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-54-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-5-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-60-4 CAPLUS
CN Ethanone, 1-[(3R,3aR)-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]isoxazolo[4,3-c]quinolin-5(3H)-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-62-6 CAPLUS

CN Ethanone, 1-[(3R,3aR)-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]isoxazolo[4,3-c]quinolin-5(3H)-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-64-8 CAPLUS

CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxylic acid, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, ethyl ester, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-66-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxamide, N-ethyl-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-70-6 CAPLUS

CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452321-33-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-35-6 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452321-37-8 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452321-39-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452321-41-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

10/513699

Relative stereochemistry.




RN 789484-08-8 CAPLUS

CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 815632-62-3 CAPLUS

CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 815632-63-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-[2-(2-ethoxyethoxy)ethoxy]-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

10/513699

Double bond geometry as shown.



IT 452313-56-3P 452318-24-0P 452318-97-7P

608146-12-9P

RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)


(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α 2-adrenoceptor blocking activity)

RN 452313-56-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)-rel(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

Double bond geometry as shown.




RN 452318-24-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)-rel(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.


Double bond geometry as shown.



RN 452318-97-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 608146-12-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



IT 452321-75-4P 452321-82-3P 452322-19-9P
452322-21-3P 452322-23-5P 815632-58-7P

815632-59-8P 815632-60-1P 815632-61-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with $\alpha 2$ -adrenoceptor blocking activity)

RN 452321-75-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-82-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-19-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aR)-3,3a,4,5-tetrahydro-7,8-dimethoxy-5-(2,2,2-trifluoroacetyl)isoxazolo[4,3-c]quinolin-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-21-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aR)-3,3a,4,5-tetrahydro-7,8-dimethoxyisoxazolo[4,3-c]quinolin-3-yl)methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-23-5 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 815632-58-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aR)-3,3a,4,5-tetrahydronaphth[1,2-c]isoxazol-3-yl)methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

10/513699


Relative stereochemistry.



RN 815632-59-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aR)-3,3a,4,5-tetrahydro-7-methoxynaphth[1,2-c]isoxazol-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 815632-60-1 CAPLUS

CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-(1-piperazinylmethyl)-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 815632-61-2 CAPLUS

CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-(1-piperazinylmethyl)-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

10/513699



REFERENCE COUNT:

41

THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:760314 CAPLUS

DOCUMENT NUMBER: 141:384410

TITLE: A screening strategy for the development of enantiomeric separation methods in capillary electrophoresis

AUTHOR(S): Jimidar, M. Ilias; van Ael, Willy; van Nyen, Patrick; Peeters, Margot; Redlich, Dirk; de Smet, Maurits

CORPORATE SOURCE: Pharmaceutical Research & Development (J&J-PRD) A division of Janssen Pharmaceutica n.v., Global Analytical Development, Johnson and Johnson, Beerse, Belg.

SOURCE: Electrophoresis (2004), 25(16), 2772-2785

CODEN: ELCTDN, ISSN: 0173-0835

PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Method development of enantiomeric sepns. in capillary electrophoresis (CE) is a time-consuming task, since finding the appropriate chiral selector is usually a "trial and error" process. It is impossible to predict the selectivity of a selector towards a certain enantiomer. Therefore, the affinity of all selectors has to be examined one at a time. In order to speed up this process, a strategy is proposed based on simple exptl. design methodol. The approach includes first a screening in function of the pH to determine the optimal migration conditions followed by a selection of the right chiral selector by means of Taguchi designs. In the approach several variables, such as the type and concentration of cyclodextrin, the concentration of buffer electrolyte, and the percentage of organic modifier, are varied simultaneously to find initial separation conditions rapidly. The resulting initial separation conditions can be optimized in further steps to be more reproducible. We discuss the results of the approach when applied on a number of selected compds. that are recently in development at Johnson & Johnson - Pharmaceutical Research and Development. Parameters, such as quality of the separation and anal. time, are evaluated to determine initial separation conditions for each compound

IT 452318-73-9

RL: ANT (Analyte); ANST (Analytical study)


(screening strategy for development of enantiomeric separation methods in capillary electrophoresis)

RN 452318-73-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:362586 CAPLUS
 DOCUMENT NUMBER: 141:123602
 TITLE: Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HT uptake inhibiting and α 2-adrenoceptor antagonistic activities. Part 2: Further exploration on the cinnamyl moiety
 AUTHOR(S): Pastor, Joaquin; Alcazar, Jesus; Alvarez, Rosa M.; Andres, J. Ignacio; Cid, Jose M.; De Lucas, Ana I.; Diaz, Adolfo; Fernandez, Javier; Font, Luis M.; Iturrino, Laura; Lafuente, Celia; Martinez, Sonia; Bakker, Margot H.; Biesmans, Ilse; Heylen, Lieve I.; Megens, Anton A.
 CORPORATE SOURCE: Division of Janssen-Cilag, Medicinal Chemistry Department, Johnson & Johnson Pharmaceutical Research & Development, Toledo, 45007, Spain
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(11), 2917-2922
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:123602
 AB The synthesis of a series of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, as novel dual 5-HT reuptake inhibitors and α 2-adrenoceptor antagonists is reported.
 IT 452313-36-9P 452313-85-8P 452316-95-9P
 452316-97-1P 452318-26-2P 452318-71-7P
 452318-73-9P 452318-77-3P 452318-83-1P
 452318-87-5P 452318-93-3P 452319-01-6P
 452319-03-8P 452319-07-2P 452319-09-4P
 452320-98-8P 452321-14-1P 452321-21-0P
 452321-29-8P 452321-31-2P 722545-47-3P
 722545-48-4P 722545-55-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as combined 5-HT uptake inhibitors and α 2-adrenoceptor antagonists)
 RN 452313-36-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452313-85-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452316-95-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452316-97-1 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-26-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-71-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-73-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-77-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-methyl-2-
propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



10/513699


RN 452318-83-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2,5-difluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-87-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2,3-difluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-93-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-01-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-03-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-07-2 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2-furanyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-09-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-pyridinyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-98-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452321-14-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452321-21-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2,4-difluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452321-29-8 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-thienyl)-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-31-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2-furanyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 722545-47-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

10/513699




RN 722545-48-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 722545-55-3 CAPLUS

CN Phenol, 4-[(1E)-3-{4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-methyl-1-
propen-1-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT 452321-75-4

<12/04/2007>

Erich Leese


10/513699

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as combined 5-HT uptake inhibitors and α_2 -adrenoceptor antagonists)

RN 452321-75-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel- (CA
INDEX NAME)

Relative stereochemistry.




IT 452321-85-6P 452321-97-0P 452321-99-2P
722545-56-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as combined 5-HT uptake inhibitors and α_2 -adrenoceptor antagonists)

RN 452321-85-6 CAPLUS

CN 2-Propanone, 1-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-, rel- (CA
INDEX NAME)


Relative stereochemistry.



RN 452321-97-0 CAPLUS

CN 1,2-Propanediol, 3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-, rel- (CA
INDEX NAME)


Relative stereochemistry.



RN 452321-99-2 CAPLUS

CN 1-Piperazineacetaldehyde, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 722545-56-4 CAPLUS

CN Phosphonic acid, [2-[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-2-oxoethyl]-, diethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 722545-57-5P 722545-58-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as combined 5-HT uptake inhibitors and

10/513699


α 2-adrenoceptor antagonists)

RN 722545-57-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-penten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 722545-58-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(3,3-diphenyl-2-propen-1-yl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:


15

THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2004:182890 CAPLUS
 DOCUMENT NUMBER: 140:217631
 TITLE: Preparation of fused heterocyclic isoxazoline derivatives as anti-depressants
 INVENTOR(S): Andres-Gil, Jose Ignacio; Alcazar-Vaca, Manuel Jesus; Bartolome-Nebreda, Jose Manuel; Fernandez-Gadea, Francisco Javier; Bakker, Margaretha Henrica Maria; Megens, Antonius Adrianus Hendrikus Petrus
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018483	A1	20040304	WO 2003-EP50377	20030813
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2494557	A1	20040304	CA 2003-2494557	20030813
AU 2003262573	A1	20040311	AU 2003-262573	20030813
EP 1554286	A1	20050720	EP 2003-792431	20030813
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1675224	A	20050928	CN 2003-819462	20030813
JP 2005538144	T	20051215	JP 2004-530272	20030813
US 20060116378	A1	20060601	US 2005-524123	20050210
PRIORITY APPLN. INFO.:			EP 2002-78373	A 20020815
			WO 2003-EP50377	W 20030813
OTHER SOURCE(S):	MARPAT 140:217631			
GI				

10/513699



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 666233-95-0 CAPLUS


CN 3H-Isioxazolo[3',4':4,5]pyrano[2,3-c]pyridine,
3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-,
ethanedioate (1:1), (3R,3aS)-rel- (CA INDEX NAME)

CM 1

CRN 666233-94-9

CMF C25 H26 N4 O2

Relative stereochemistry.



CM 2

CRN 144-62-7


CMF C2 H2 O4

10/513699



RN 666233-96-1 CAPLUS
CN 3H-Isloxazolo[3',4':4,5]pyrano[2,3-c]pyridine,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 666233-98-3 CAPLUS
CN 3H-Isloxazolo[3',4':4,5]pyrano[2,3-c]pyridine,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-, ethanedioate (1:1), (3R,3aS)-rel- (CA
INDEX NAME)

CM 1

CRN 666233-97-2
CMF C24 H27 F N4 O2

Relative stereochemistry.
Double bond geometry as shown.



CM 2


CRN 144-62-7
CMF C2 H2 O4

10/513699



RN 666234-00-0 CAPLUS
CN 3H-Isioxazolo[3',4':4,5]pyrano[2,3-b]pyridine,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, ethanedioate (1:1), (3R,3aS)-rel- (CA INDEX NAME)
CM 1
CRN 666233-99-4
CMF C24 H28 N4 O2

Relative stereochemistry.
Double bond geometry as shown.




CM 2
CRN 144-62-7
CMF C2 H2 O4



RN 666234-02-2 CAPLUS
CN 3H-Isioxazolo[3',4':4,5]pyrano[3,2-b]pyridine,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, ethanedioate (1:2), (3R,3aS)-rel- (CA INDEX NAME)
CM 1
CRN 666234-01-1
CMF C24 H28 N4 O2

Relative stereochemistry.
Double bond geometry as shown.

10/513699



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 666234-03-3 CAPLUS

CN 3H-Isloxazolo[3',4':4,5]pyrano[3,2-b]pyridine,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 666234-04-4 CAPLUS

CN 3H-Isloxazolo[3',4':4,5]pyrano[3,2-b]pyridine,
3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.

10/513699



RN 666234-05-5 CAPLUS
CN 3H-Isioxazolo[3',4':4,5]pyrano[3,2-b]pyridine,
3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:182889 CAPLUS
 DOCUMENT NUMBER: 140:235700
 TITLE: Preparation of chromenoisoxazole derivatives and their use as anti-depressants
 INVENTOR(S): Andres-Gil, Jose Ignacio; Alcazar-Vaca, Manuel Jesus; Matesanz-Ballesteros, Maria Encarnacion; Bakker, Margaretha Henrica Maria; Megens, Antonius Adrianus Hendrikus Petrus
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018482	A2	20040304	WO 2003-EP9532	20030819
WO 2004018482	A3	20040401		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2495058	A1	20040304	CA 2003-2495058	20030819
AU 2003271567	A1	20040311	AU 2003-271567	20030819
EP 1532155	A2	20050525	EP 2003-753363	20030819
EP 1532155	B1	20080227		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005538143	T	20051215	JP 2004-530256	20030819
AT 387455	T	20080315	AT 2003-753363	20030819
ES 2301816	T3	20080701	ES 2003-753363	20030819
US 20060122167	A1	20060608	US 2005-524989	20050218
PRIORITY APPLN. INFO.:			EP 2002-78844	A 20020821
			WO 2003-EP9532	W 20030819

OTHER SOURCE(S): MARPAT 140:235700
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = CH₂, NR₇, S or O; R₇ = H, alkyl, (un)substituted-aryl, -arylalkyl; R₁, R₂, R₁₄, R₁₅ = independently H, halo, OH, alkyloxy, CN, etc.; m = 1-4; R₃ = (un)substituted aromatic homocyclic or heterocyclic ring; R₈ = independently OH, amino, nitro, CN, halo, or alkyl; n = 0-5; R₉ = H, alkyl, or formyl], a process for their preparation, pharmaceutical compds. comprising them and their use as a

medicine, in particular for the treatment of depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders is disclosed. Thus, e.g., II, was prepared by substitution of 6-bromo-7,8-dimethoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole (preparation given) with N-methylpiperazine. The compds. according to the invention have surprisingly been shown to have a serotonin (5-HT) reuptake inhibitor activity in combination with addnl. α 2-adrenoceptor antagonist activity and show a strong anti-depressant activity without being sedative. I produced an inhibition at least at the α 2A site (but often at the α 2B and α 2C sites) and simultaneously at the 5-HT transporter site of more than 50 % (pIC50) at a test concentration ranging between 10^{-6} M and 10^{-9} M in a concentration-dependent manner. The invention also relates to novel combination of isoxazoline derivs. according to the invention with one or more other compds. selected from the group of antidepressants, anxiolytics, anti-psychotics and anti-Parkinson's disease drugs to improve efficacy and/or onset of action.

IT 667454-35-5P 667454-39-9P 667454-52-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of chromenoisoxazole derivs. as antidepressants)

RN 667454-35-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
6-bromo-3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 667454-39-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-6-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.




RN 667454-52-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-6-iodo-7,8-dimethoxy-, (3R,3aS)-rel- (CA
 INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



IT 667454-36-6P 667454-37-7P 667454-38-8P
 667454-40-2P 667454-41-3P 667454-42-4P
 667454-43-5P 667454-44-6P 667454-45-7P
 667454-46-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (drug candidate; preparation of chromenoisoxazole derivs. as
 antidepressants)
 RN 667454-36-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 6-(4-bromo-1-piperazinyl)-3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-
 3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX
 NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 667454-37-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-6-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 667454-38-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-6-carboxylic acid,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 667454-40-2 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazol-6-ol,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 667454-41-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-6-amine,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-N-4-pyridinyl-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-42-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-9-ol,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 667454-43-5 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-6-yl]oxy]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 667454-44-6 CAPLUS

CN Acetic acid, 2-methoxy-, 2-[[[(3S,3aR)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-6-yl]oxy]ethyl ester, rel-(-) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

Double bond geometry as shown.




RN 667454-45-7 CAPLUS

CN Acetic acid, 2-methoxy-, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-6-yl]oxy]ethyl ester, rel-(+) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.

Double bond geometry as shown.




RN 667454-46-8 CAPLUS

CN Carbamic acid, ethyl-, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-9-yl]oxy]ethyl ester, rel- (9CI) (CA INDEX NAME)



Relative stereochemistry.

Double bond geometry as shown.



L3 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:162696 CAPLUS
 DOCUMENT NUMBER: 140:217662
 TITLE: Preparation of piperazinylalkylchromenoisoxazolines as antidepressants.
 INVENTOR(S): Andres-gil, Jose Ignacio; Bartolome-nebreda, Jose Manuel; Alvarez-escobar, Rosa Maria; Bakker, Margaretha Henrica Maria; Megens, Antonius Adrianus Hendrikus Petrus
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004016621	A1	20040226	WO 2003-EP50374	20030812
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2494235	A1	20040226	CA 2003-2494235	20030812
AU 2003262571	A1	20040303	AU 2003-262571	20030812
EP 1537124	A1	20050608	EP 2003-787817	20030812
EP 1537124	B1	20070801		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1675222	A	20050928	CN 2003-819483	20030812
CN 1329396	C	20070801		
JP 2005537304	T	20051208	JP 2004-528523	20030812
AT 368669	T	20070815	AT 2003-787817	20030812
ES 2290537	T3	20080216	ES 2003-787817	20030812
US 20050256119	A1	20051117	US 2005-524197	20050210
PRIORITY APPLN. INFO.:			EP 2002-78322	A 20020812
			WO 2003-EP50374	W 20030812
OTHER SOURCE(S):	MARPAT 140:217662			
GI				



AB Title compds. [I; X = CH₂, NR₇, S, O; R₇ = H, alkyl aryl, aralkyl, alkylcarbonyl, alkoxy carbonyl, aminocarbonyl; R₁, R₂ = H, halo, OH, OSO₂H, OSO₂Me, alkoxy, alkyl, aryl, heterocyclyl, etc.; R₁R₂ = (CH₂)₄, CH:CHCH₂CH₂, CH:CHCH:CH, etc.; Pir = (substituted) piperazinyl, aminomethylpiperidinyl; m = 1-4; R₃ = (substituted) alkylaryl, alkylheteroaryl; with provisos], were prepared Thus, title compound (II) (preparation via intramol. nitrile oxide cycloaddn. given) bound to human platelet 5-HT transporter protein with pIC₅₀ = 7.7.

IT 1055723-13-1 1055723-14-2


RL: PRPH (Prophetic)

(Preparation of piperazinylalkylchromenoisoxazolines as antidepressants.)

RN 1055723-13-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1055723-14-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-bromo-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 452320-31-9P 663933-45-7P,
 8-Methyl-3-[4-(3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-46-8P,
 8-Methoxy-7-methyl-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-47-9P,
 [8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazol-7-yl]methanol 663933-48-0P,
 7-Methoxymethyl-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-49-1P
 663933-50-4P 663933-51-5P,
 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-7-phenoxy-7-methyl-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-52-6P 663933-53-7P,
 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-7-morpholin-4-ylmethyl-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-54-8P
 663933-55-9P 663933-56-0P,
 3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole-7-carbonitrile 663933-57-1P
 663933-58-2P, 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole-7-carboxylic acid ethylamide 663933-59-3P,
 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-7-phenyl-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-60-6P,
 1-[5-[8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazol-7-yl]thiophen-2-yl]ethanone 663933-61-7P 663933-62-8P 663933-63-9P
 663933-65-1P 663933-66-2P 663933-68-4P
 663933-69-5P 663933-70-8P 663933-71-9P
 663933-72-0P 663933-74-2P 663933-76-4P
 663933-77-5P 663933-78-6P 663933-79-7P
 663933-80-0P 663933-81-1P 663933-89-9P
 663933-90-2P 663933-91-3P 663933-92-4P
 663933-93-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of piperazinylalkylchromenoisoxazolines as antidepressants)

RN 452320-31-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-phenyl-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.




RN 663933-45-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-7-methyl-3-[[4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-
(CA INDEX NAME)



RN 663933-46-8 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-7-methyl-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 663933-47-9 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol,
3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-

piperazinyl)methyl]- (CA INDEX NAME)



RN 663933-48-0 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-(methoxymethyl)-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl)methyl]- (CA INDEX NAME)



RN 663933-49-1 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-7-[[[2-methoxyethoxy)methoxy)methyl]-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl)methyl]- (CA INDEX NAME)

PAGE 1-A




—CH₂—CH₂—OMe


RN 663933-50-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol,
 3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
 piperazinyl]methyl]-, 7-acetate (CA INDEX NAME)



RN 663933-51-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
 piperazinyl]methyl]-7-(phenoxyethyl)- (CA INDEX NAME)




RN 663933-52-6 CAPLUS
 CN Ethanol, 2-[[[3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
 piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-
 yl]methyl]methylamino]- (CA INDEX NAME)




RN 663933-53-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]-7-(4-morpholinylmethyl)- (CA INDEX NAME)




RN 663933-54-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde,
3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-
, oxime (CA INDEX NAME)




RN 663933-55-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde,
3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-
, O-methyloxime (CA INDEX NAME)




RN 663933-56-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carbonitrile,
3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-
(CA INDEX NAME)




RN 663933-57-1 CAPLUS

CN Acetamide, N-[[3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methyl]- (CA INDEX NAME)




RN 663933-58-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxamide,
N-ethyl-3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 663933-59-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]-7-phenyl- (CA INDEX NAME)



RN 663933-60-6 CAPLUS

CN Ethanone, 1-[5-[3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-
yl)-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-
thienyl]- (CA INDEX NAME)



RN 663933-61-7 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

10/513699

3a,4-dihydro-8-methoxy-7-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 663933-62-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 663933-63-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

10/513699



● 2 HCl


RN 663933-65-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-7-[[[(2-methoxyethoxy)methoxy]methyl]-3-[[4-[(2E)-2-
methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, ethanedioate (1:1),
(3R,3aS)-rel- (CA INDEX NAME)

CM 1

CRN 663933-64-0

CMF C31 H41 N3 O6

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7

CMF C2 H2 O4



<12/04/2007>

Erich Leese


10/513699

RN 663933-66-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 663933-68-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(phenoxymethyl)-, ethanedioate (1:1), (3R,3aS)-rel- (CA INDEX NAME)


CM 1

CRN 663933-67-3

CMF C33 H37 N3 O4

Relative stereochemistry.

Double bond geometry as shown.



CM 2

CRN 144-62-7

CMF C2 H2 O4

10/513699




RN 663933-69-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-7-(4-morpholinylmethyl)-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 663933-70-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, oxime, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as described by E or Z.




RN 663933-71-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carbonitrile,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 663933-72-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanamine,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 663933-74-2 CAPLUS

CN Acetamide, N-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methyl]-, ethanedioate (1:1), rel- (CA INDEX NAME)


CM 1

CRN 663933-73-1

CMF C28 H34 N4 O3

Relative stereochemistry.

Double bond geometry as shown.



CM 2

10/513699

CRN 144-62-7
CMF C2 H2 O4




RN 663933-76-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7'-carboxamide,
N-ethyl-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, ethanedioate (1:1), (3R,3aS)-rel- (CA INDEX NAME)

CM 1

CRN 663933-75-3
CMF C29 H36 N4 O4

Relative stereochemistry.
Double bond geometry as shown.




CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 663933-77-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 663933-78-6 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methyl]methylamino]-, hydrochloride (1:2), rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




● 2 HCl

RN 663933-79-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(4-morpholinylmethyl)-, (3S,3aR)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




10/513699

RN 663933-80-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(4-morpholinylmethyl)-, (3R,3aS)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 663933-81-1 CAPLUS

CN Ethanone, 1-[4-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-thienyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 663933-89-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-(cyclopropylmethyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 663933-90-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-(methoxymethyl)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




● 2 HCl

RN 663933-91-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




10/513699

RN 663933-92-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanamine,
N-ethyl-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(1-methylethyl)-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 663933-93-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-[(4-methyl-1-
piperidinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



PAGE 1-B

Me

IT 663933-88-8P

<12/04/2007>

Erich Leese


10/513699

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of piperazinylalkylchromenoisoxazolines as antidepressants)
RN 663933-88-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-bromo-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-
yl]-1-piperazinyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:892834 CAPLUS

DOCUMENT NUMBER: 139:365764

TITLE: Diblock copolymers for use in pharmaceutical dosage forms

INVENTOR(S): Arieen, Albertina Maria Eduarda; Brewster, Marcus Eli; Nathan, Aruna; Rosenblatt, Joel; Ould-Ouali, Louisa Myriam; Preat, Veronique

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093344	A1	20031113	WO 2003-EP4368	20030424
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2483282	A1	20031113	CA 2003-2483282	20030424
AU 2003222310	A1	20031117	AU 2003-222310	20030424
EP 1504047	A1	20050209	EP 2003-717321	20030424
EP 1504047	B1	20071212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009688	A	20050222	BR 2003-9688	20030424
NZ 536294	A	20050527	NZ 2003-536294	20030424
CN 1649932	A	20050803	CN 2003-809579	20030424
CN 1290893	C	20061220		
JP 2005524730	T	20050818	JP 2004-501483	20030424
AT 380834	T	20071215	AT 2003-717321	20030424
ES 2298510	T3	20080516	ES 2003-717321	20030424
MX 2004PA10778	A	20050307	MX 2004-PA10778	20041029
ZA 2004008854	A	20051102	ZA 2004-8854	20041102
NO 2004005283	A	20050107	NO 2004-5283	20041202
US 20060034797	A1	20060216	US 2005-522456	20050121
PRIORITY APPLN. INFO.:			US 2002-377901P	P 20020503
			WO 2003-EP4368	W 20030424

AB In a diblock copolymer of formula A-B, polymer block A represents a linear pharmaceutically acceptable hydrophilic polymer and polymer block B represents a polymer comprising monomers selected from L-lactic acid, D-lactic acid, D,L-lactic acid, glycolic acid, propiolactone, γ -butyrolactone, δ -valerolactone, γ -valerolactone, ϵ -caprolactone, trimethylene carbonate, p-dioxanone, tetramethylene carbonate, ϵ -lactone, 1,5-dioxepan-2-one or mixts. thereof characterized in that the diblock copolymer is liquid at a temperature below 50°. A polymer was prepared from ϵ -caprolactone,

10/513699

trimethylene carbonate, and polyethylene glycol monomethyl ether initiator.


IT 452314-01-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diblock copolymers for use in pharmaceutical dosage forms)

RN 452314-01-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA
INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:796712 CAPLUS
 DOCUMENT NUMBER: 139:307799
 TITLE: Preparation of isoxazoline derivatives as antidepressants
 INVENTOR(S): Andres-Gil, Jose Ignacio; Alcazar-Vaca, Manuel Jesus; Bakker, Margaretha Henrica Maria; De Lucas Olivares, Ana Isabel
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082878	A1	20031009	WO 2003-EP3245	20030327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2480113	A1	20031009	CA 2003-2480113	20030327
AU 2003219111	A1	20031013	AU 2003-219111	20030327
BR 2003008309	A	20041228	BR 2003-8309	20030327
EP 1492796	A1	20050105	EP 2003-714897	20030327
EP 1492796	B1	20070905		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1642960	A	20050720	CN 2003-807419	20030327
CN 100349897	C	20071121		
JP 2005522469	T	20050728	JP 2003-580343	20030327
NZ 536109	A	20060630	NZ 2003-536109	20030327
AT 372342	T	20070915	AT 2003-714897	20030327
ES 2292949	T3	20080316	ES 2003-714897	20030327
TW 286138	B	20070901	TW 2003-92107328	20030401
MX 2004PA08626	A	20041206	MX 2004-PA8626	20040906
IN 2004DN02809	A	20050401	IN 2004-DN2809	20040921
ZA 2004007904	A	20051020	ZA 2004-7904	20040930
US 20050222125	A1	20051006	US 2004-510220	20041001
US 7265103	B2	20070904		
NO 2004004645	A	20041027	NO 2004-4645	20041027
PRIORITY APPLN. INFO.:			EP 2002-76239	A 20020402
			WO 2003-EP3245	W 20030327
OTHER SOURCE(S):	MARPAT	139:307799		
GI				



- AB The title isoxazoline derivs. having a piperazinyl subunit with general formula of I [wherein X = CH₂, S, O, or (un)substituted NH; R₁ and R₂ = independently H, OH, CN, halo, OSO₂H, OSO₂Me, alkoxy, alkoxyalkoxy, alkoxyalkoxyalkoxy, tetrahydrofuranlyloxy, alkylthio, (alkoxy)alkylcarboxy, pyridylcarboxy, alkylcarboxyalkoxy, alkoxycarboxy, alkenyloxy, alkenylcarboxy, alkylaminoalkoxy, dialkylaminoalkoxy, or (un)substituted NH₂, with provisos; m = 1-4; A = (un)substituted piperazinyl, piperidinyl, or amino; R₃ = (un)substituted aromatic (hetero)cyclyl] and pharmaceutically acceptable salts, stereoisomers, N-oxides, or prodrugs thereof are prepared as antidepressants for the treatment of depression, anxiety, and/or body weight disorders (no data). For example, the compound II •2HCl was prepared in a multi-step synthesis in moderate yield. II showed pIC₅₀ of 8.9, 9.0, and 8.2 against human *ha2A*, *ha2C*, and 5-HT transporter receptor sites, resp.
- IT 612074-52-9P 612074-55-2P 612074-58-5P
612074-59-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of isoxazoline derivs. as antidepressants)
- RN 612074-52-9 CAPLUS
- CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-55-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-58-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 612074-59-6 CAPLUS

CN 1,2-Ethanediamine, N2-[(3R,3aR)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N1-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT	612074-51-8P	612074-53-0P	612074-54-1P
	612074-56-3P	612074-57-4P	612074-60-9P
	612074-61-0P	612074-67-6P	612074-68-7P
	612074-69-8P	612074-70-1P	612074-71-2P
	612074-72-3P	612074-73-4P	612074-74-5P
	612074-75-6P	612074-76-7P	612074-77-8P
	612074-78-9P	612074-79-0P	612074-80-3P
	612074-81-4P	612074-82-5P	612074-83-6P
	612074-84-7P	612074-85-8P	612074-86-9P
	612074-87-0P	612074-88-1P	612074-89-2P
	612074-90-5P	612074-91-6P	612074-92-7P
	612074-93-8P	612074-94-9P	612074-95-0P
	612074-96-1P	612074-97-2P	612074-98-3P
	612074-99-4P	612075-00-0P	612075-01-1P
	612075-02-2P	612075-03-3P	612075-04-4P
	612075-05-5P	612075-06-6P	612075-07-7P
	612075-08-8P	612075-09-9P	612075-10-2P
	612075-11-3P	612075-12-4P	612075-13-5P
	612075-14-6P	612075-15-7P	612075-16-8P
	612075-17-9P	612075-18-0P	612075-19-1P
	612075-20-4P	612075-21-5P	612075-22-6P
	612075-23-7P	612075-24-8P	612075-25-9P
	612075-26-0P	612075-27-1P	612075-28-2P
	612075-29-3P	612075-30-6P	612075-31-7P
	612075-32-8P	612075-33-9P	612075-34-0P
	612075-35-1P	612075-40-8P	612075-42-0P
	612075-43-1P	612075-44-2P	612075-45-3P
	612075-46-4P	612075-47-5P	612075-48-6P
	612075-49-7P	612075-50-0P	612075-51-1P
	612075-52-2P	612075-53-3P	612075-54-4P
	612075-55-5P	612075-56-6P	612075-57-7P
	612075-58-8P	612075-59-9P	612075-60-2P
	612075-61-3P	612075-62-4P	612075-63-5P
	612075-64-6P	612075-65-7P	612075-66-8P
	612075-67-9P	612075-68-0P	612075-69-1P
	612075-70-4P	612075-71-5P	612075-72-6P
	612075-73-7P	612075-74-8P	612075-75-9P
	612075-76-0P	612075-77-1P	612075-78-2P
	612075-79-3P	612075-80-6P	612075-81-7P
	612075-82-8P	612075-83-9P	612075-84-0P

612075-85-1P 612075-86-2P 612075-87-3P

612075-88-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of isoxazoline derivs. as antidepressants)

RN 612074-51-8 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, hydrochloride (1:2), rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




● 2 HCl

RN 612074-53-0 CAPLUS


CN Benzenesulfonamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-4-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




PAGE 1-A




RN 612074-54-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-8-(4-morpholinyl)-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 612074-56-3 CAPLUS
 CN Acetamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-
 1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel-
 (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 612074-57-4 CAPLUS
 CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-
 yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(3,4-
 dimethoxyphenyl)-, rel- (CA INDEX NAME)

10/513699


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-60-9 CAPLUS

CN Acetamide, N-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-61-0 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-67-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-methyl-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-68-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 N-ethyl-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 612074-69-8 CAPLUS


CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-

10/513699

propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-
c]isoxazol-7-yl]-N1-methyl-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




● HC1

RN 612074-70-1 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-
propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-
c]isoxazol-7-yl]-N2-methyl-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



● HC1

PAGE 1-A

PAGE 1-B

—NHMe

RN 612074-71-2 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-

<12/04/2007>


Erich Leese

10/513699

propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

NHMe

RN 612074-72-3 CAPLUS
CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, hydrochloride (1:2), rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




● 2 HCl

—NMe₂

RN 612074-73-4 CAPLUS
 CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




● HCl

—NMe₂

RN 612074-74-5 CAPLUS
 CN 1,2-Ethanediamine, N2-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N1-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

NMe₂


RN 612074-75-6 CAPLUS

CN 1,2-Ethanediamine, N1,N1-diethyl-N2-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N2-methyl-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A




● HCl

-NEt₂


RN 612074-76-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 612074-77-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




PAGE 1-A



RN 612074-78-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-N-[2-(1-pyrrolidinyl)ethyl]-,
 (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 612074-79-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[2-(1-pyrrolidinyl)ethyl]-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 612074-80-3 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-N-[2-(4-morpholinyl)ethyl]-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




10/513699

RN 612074-81-4 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl)methylamino]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-82-5 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl)methylamino]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-83-6 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl)methylamino]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-84-7 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-85-8 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-86-9 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (CA INDEX NAME)

10/513699

yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl)methylamino]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-87-0 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl)methylamino]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-88-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-N-phenyl-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-89-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-phenyl-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-90-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
N-(4-fluorophenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 612074-91-6 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-N-(4-methoxyphenyl)-, (3R,3aS)-rel- (CA INDEX NAME)

10/513699

INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

—OMe


RN 612074-92-7 CAPLUS
CN Benzonitrile, 3-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-93-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-N-(2-methylphenyl)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-94-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
N-(3,4-dimethylphenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-95-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-96-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,

3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, hydrochloride (1:2), (3R,3aS)-rel-
(CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl


RN 612074-97-2 CAPLUS
CN Acetamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-98-3 CAPLUS
CN Propanamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2,2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-99-4 CAPLUS

CN Cyclopropanecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-00-0 CAPLUS

CN Cyclopropanecarboxamide, N-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-01-1 CAPLUS

CN Cyclopropanecarboxamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-

[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-02-2 CAPLUS

CN 2-Propenamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-03-3 CAPLUS

CN Benzamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




10/513699

RN 612075-04-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 612075-05-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 612075-06-6 CAPLUS

CN Carbamic acid, [(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-07-7 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-ethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-08-8 CAPLUS

CN Imidodicarbonic diamide, N,N'-diethyl-2-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-09-9 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-


yl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(1,1-dimethylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-10-2 CAPLUS
CN Urea, N-cyclohexyl-N'-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-11-3 CAPLUS
CN Glycine, N-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]carbonyl]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-12-4 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-13-5 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(3-fluorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-14-6 CAPLUS

CN Methanesulfonamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-

yl]-N-(methylsulfonyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-15-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-16-8 CAPLUS

CN 1-Piperazinecarboximidamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-4-(phenylmethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612075-17-9 CAPLUS

CN 2-Azetidinone, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-18-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(1-pyrrolidinyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.



RN 612075-19-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-7-(1-piperidinyl)-, (3R,3aS)-rel- (CA
 INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 612075-20-4 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-
 methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-
 [1]benzopyrano[4,3-c]isoxazol-7-yl]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


—OEt


RN 612075-21-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 7-(3,4-dihydro-2(1H)-isoquinolinyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinylmethyl]-3a,4-dihydro-, (3R,3aS)-rel-
 (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.


PAGE 1-A






RN 612075-22-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(4-methyl-1-piperazinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 612075-23-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-methyl-1-piperazinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 612075-24-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

10/513699


3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(4-methyl-1-piperazinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-25-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-methyl-1-piperazinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-26-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(4-phenyl-1-piperazinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-27-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7-[4-(phenylmethyl)-1-piperazinyl]-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Ph


RN 612075-28-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7-[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612075-29-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(4-morpholinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-30-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-morpholinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-31-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-7-(4-morpholinyl)-, (3R,3aS)-rel- (CA
 INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-32-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-morpholinyl)-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-33-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX
 NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-34-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



● 2 HCl


RN 612075-35-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3a,4-dihydro-8-methoxy-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 612075-40-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-8-amine,
 3a,4-dihydro-N-(4-methoxyphenyl)-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 612075-42-0 CAPLUS

CN 2-Propenoic acid, 2-methyl-, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612075-43-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-1-pyrrolidinyl-, (3R,3aS)-rel- (CA INDEX NAME)


10/513699

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-44-2 CAPLUS
CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-45-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(1-ethylpropyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-46-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(1-methylpropyl)-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-47-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-4-pyridinyl-, (3R,3aS)-rel-
 (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 612075-48-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(2-methyl-1-pyrrolidinyl)-,
 (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 612075-49-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 7-(1-azetidiny)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX
 NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 612075-50-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-methyl-1-piperidinyl)-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 612075-51-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(2-methylbutyl)-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-52-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
N-ethyl-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-53-3 CAPLUS

CN 2-Propenamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-54-4 CAPLUS

CN 2-Azetidinone, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-55-5 CAPLUS

10/513699

CN Cyclobutanecarboxylic acid, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl)methylamino]ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612075-56-6 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl)methylamino]ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A






RN 612075-57-7 CAPLUS

CN 1,2-Ethanediamine, N2-(1,2-dimethylpropyl)-N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-58-8 CAPLUS

CN 1,2-Ethanediamine, N2-cyclobutyl-N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 612075-59-9 CAPLUS
 CN 2-Butenamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as described by E or Z.

PAGE 1-A




PAGE 1-B

Me

RN 612075-60-2 CAPLUS
 CN Pentanamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 612075-61-3 CAPLUS

CN Butanamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-62-4 CAPLUS

CN Cyclobutanecarboxamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-63-5 CAPLUS

10/513699



CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(2-methylpropyl)-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-64-6 CAPLUS
CN Butanoic acid, 3,3-dimethyl-, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-
2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-
[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (CA
INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-65-7 CAPLUS
CN 1,2-Ethanediamine, N2-(cyclopropylmethyl)-N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-
fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-
3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1-methyl-, rel- (CA INDEX NAME)


<12/04/2007>

Erich Leese

10/513699

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN	612075-66-8	CAPLUS
CN	2-Propanol, 1-[[2-[[[3R,3aS]-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl]amino]-, rel- (CA INDEX NAME)	

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A






RN 612075-67-9 CAPLUS

CN 1,2-Ethanediamine, N2-(1,1-dimethylpropyl)-N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-68-0 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2-dimethyl-N2-2-propen-1-yl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612075-69-1 CAPLUS

CN 1,2-Ethanediamine, N1-(1,1-dimethylethyl)-N2-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612075-70-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-[2-(1-azetidiny)ethyl]-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-N-methyl-, (3R,3aS)-rel- (CA INDEX NAME)

INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 612075-71-5 CAPLUS
CN Urea, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-phenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-72-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(hexahydro-1H-azepin-1-yl)-3a,4-dihydro-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-73-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[(2-methylcyclopropyl)methyl]-
, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me


RN 612075-74-8 CAPLUS

CN Carbamic acid, (1-methylpropyl)-, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-
fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-
[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612075-75-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[(1-methylcyclopropyl)methyl]-
 , (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-76-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-N-(1-methylethyl)-, (3R,3aS)-rel- (CA
 INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.




RN 612075-77-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 N-(cyclopropylmethyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 612075-78-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-N-(1-methylpropyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 612075-79-3 CAPLUS
 CN 2-Propanol, 1-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (CA INDEX NAME)


10/513699

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-80-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinylmethyl]-3a,4-dihydro-N-pentyl-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-81-7 CAPLUS
CN 1-Propanol, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-
1-yl]-1-piperazinylmethyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-
7-yl]amino]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



10/513699


RN 612075-82-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-(3,6-dihydro-1(2H)-pyridinyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-83-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(1-piperazinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-84-0 CAPLUS
CN Urea, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-85-1 CAPLUS

CN Cyclopropanecarboxamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-86-2 CAPLUS

CN 2-Pyrrolidinone, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-3-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-87-3 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(1R,2S)-2-phenylcyclopropyl]methyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-

c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 612075-88-4 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT 452319-29-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of isoxazoline derivs. as antidepressants)

RN 452319-29-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT 452319-78-7 612075-96-4 612075-97-5
612075-98-6


RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of isoxazoline derivs. as antidepressants)

RN 452319-78-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-96-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-bromo-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-97-5 CAPLUS

10/513699

CN Carbamic acid, [(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-98-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-bromo-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:535065 CAPLUS

DOCUMENT NUMBER: 139:292184

TITLE: Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HT uptake inhibiting and α 2-adrenoceptor antagonistic activities: a novel series of potential antidepressants

AUTHOR(S): Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.; Alvarez, Rosa M.; Cid, Jose M.; De Lucas, Ana I.; Fernandez, Javier; Martinez, Sonia; Nieto, Carmen; Pastor, Joaquin; Bakker, Margot H.; Biesmans, Ilse; Heylen, Lieve I.; Megens, Anton A.

CORPORATE SOURCE: Division of Janssen-Cilag, Medicinal Chemistry Department, Jarama s/n, Johnson & Johnson Pharmaceutical Research & Development, Toledo, 45007, Spain

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(16), 2719-2725

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:292184

AB The synthesis of a series of novel

3-piperazinylmethyl-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as novel dual 5-HT re-uptake inhibitors and α 2-adrenoceptor antagonists is described. Their affinity at the three different human

α 2-adrenoceptor subtypes and the 5-HT transporter site is reported.

The in vivo activity of the compds. was measured in two different assays:

(1) inhibition of pCA-induced excitation, which evaluates the ability to block the central 5-HT transporter, and (2) inhibition of xylazine-induced loss of righting, which evaluates the ability to block central α 2-adrenoceptors. Compds. thus prepared included

(3R,3aS)-rel-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazole,

(3R,3aS)-rel-(+)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazole,

(3R,3aS)-rel-(+)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazole and derivs. thereof.

IT 452313-36-9P 452313-43-8P 452313-54-1P

452313-56-3P 452313-77-8P 452314-18-0P

452316-09-5P 452316-15-3P 452316-21-1P

452316-33-5P 452316-36-8P 452316-66-4P

452316-84-6P 452318-20-6P 452318-24-0P

452318-26-2P 452318-93-3P 452318-95-5P

452318-97-7P 452319-25-4P 452319-35-6P

452320-01-3P 608146-10-7P 608146-11-8P

608146-12-9P 608146-13-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL

(Biological study); PREP (Preparation)

(preparation of dihydro[1]benzopyrano[4,3-c]isoxazoles and their activity as 5-HT uptake inhibitors and α 2-adrenoceptor antagonists (potential antidepressants))

RN 452313-36-9 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-

10/513699

piperazinylmethyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452313-43-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-
piperazinylmethyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452313-54-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinylmethyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.


Double bond geometry as shown.



RN 452313-56-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-77-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452314-18-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

10/513699

3a,4-dihydro-7,8-dimethoxy-3-[[4-(phenylmethyl)-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-09-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(benzo[b]thien-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-15-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-quinolinylmethyl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



<12/04/2007>


Erich Leese

10/513699

RN 452316-21-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-phenylethyl)-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-33-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenylpropyl)-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-36-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-(1H-inden-2-ylmethyl)-1-piperazinyl]methyl]-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-66-4 CAPLUS

CN 1-Propanone, 3-[4-[[4-[[3R,3aS]-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-84-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2Z)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-20-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

10/513699

3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-24-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-26-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-93-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-95-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.

Double bond geometry as shown.




RN 452318-97-7 CAPLUS

10/513699

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452319-25-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-35-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



10/513699


RN 452320-01-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 608146-10-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(benzo[b]thien-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 608146-11-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(1-naphthalenylmethyl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/513699



RN 608146-12-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 608146-13-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



IT 452321-75-4P 452321-82-3P 452321-89-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

<12/04/2007>

Erich Leese


(Reactant or reagent)

(preparation of dihydro[1]benzopyrano[4,3-c]isoxazoles and their activity as 5-HT uptake inhibitors and α 2-adrenoceptor antagonists (potential antidepressants))

RN 452321-75-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-82-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452321-89-0 CAPLUS

CN Phosphonium, [2-[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]ethyl]triphenyl-, bromide (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.

10/513699



● Br⁻

REFERENCE COUNT:

29

THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:658130 CAPLUS

DOCUMENT NUMBER: 137:201298

TITLE: Preparation of substituted isoxazolines as anti-depressants

INVENTOR(S): Andres-Gil, Jose Ignacio; Fernandez-Gadea, Francisco Javier; Alcazar-Vaca, Manuel Jesus; Cid-Nunez, Jose Maria; Pastor-Fernandez, Joaquin; Megens, Antonius Adrianus Hendrikus Petrus; Heylen, Godelieve Irma Christine Maria; Langlois, Xavier Jean Michel; Bakker, Margaretha Henrica Maria; Steckler, Thomas Horst Wolfgang

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 100 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1




PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066484	A1	20020829	WO 2002-EP1567	20020213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2437505	A1	20020829	CA 2002-2437505	20020213
AU 2002244717	A1	20020904	AU 2002-244717	20020213
AU 2002244717	B2	20070719		
EP 1368358	A1	20031210	EP 2002-712909	20020213
EP 1368358	B1	20060823		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300398	A	20031215	EE 2003-398	20020213
HU 2003003270	A2	20040128	HU 2003-3270	20020213
HU 2003003270	A3	20070328		
CN 1492871	A	20040428	CN 2002-805243	20020213
CN 100400540	C	20080709		
NZ 526741	A	20040430	NZ 2002-526741	20020213
BR 2002007433	A	20040601	BR 2002-7433	20020213
JP 2004518748	T	20040624	JP 2002-565998	20020213
JP 3953424	B2	20070808		
AT 337322	T	20060915	AT 2002-712909	20020213
ES 2271230	T3	20070416	ES 2002-712909	20020213
EG 23929	A	20080114	EG 2002-197	20020219
TW 257392	B	20060701	TW 2002-91102853	20020220
KR 848898	B1	20080729	KR 2003-708328	20030620
IN 2003DN00968	A	20070525	IN 2003-DN968	20030624
BG 107984	A	20040930	BG 2003-107984	20030708
MX 2003PA07432	A	20031118	MX 2003-PA7432	20030819
NO 2003003700	A	20031021	NO 2003-3700	20030820

ZA 2003006487	A	20041122	ZA 2003-6487	20030820
US 20040122037	A1	20040624	US 2003-468555	20030821
US 7169786	B2	20070130		

PRIORITY APPLN. INFO.: EP 2001-200611 A 20010221
 EP 2001-201264 A 20010405
 WO 2002-EP1567 W 20020213

OTHER SOURCE(S): MARPAT 137:201298
 GI




AB Title compds. I [wherein X = CH₂, NR₇, S or O; R₇ = H, (un)substituted alkyl, Ph, Ph alkyl, etc.; R₁ and R₂ independently = H, OH, CN, halo, OSO₂H, (un)substituted Ph, phenylalkyl, alkoxy, etc.; or R₁ and R₂ may be taken together to form a bivalent radical selected from -CH₂CH₂O-, -OCH₂CH₂-, -OCH₂O-, -CH₂OCH₂- and -OCH₂CH₂O-; m = 1-4; Y = (un)substituted piperidyl or piperazyl radical and R₃ represents an (un)substituted aromatic homocyclic or heterocyclic ring system including a partially or completely hydrogenated hydrocarbon chain of maximum 6 atoms long with which the ring system is attached to the Y radical and which may contain one or more heteroatoms selected from the group of O, N and S], a process for their preparation, pharmaceutical compns. comprising them and their use as a medicine for treating anxiety disorders and disorders of body weight are disclosed. Thus, II was prepared in 60% yield by reaction of III with N-(3-phenyl-2-propenyl)-piperazine. III was prepared by substitution of Me 4-bromo-2-butenate with 2-hydroxy-4,5-dimethoxybenzaldehyde with subsequent condensation with hydroxylamine, cyclization, reduction and sulfonation with methanesulfonyl chloride. The compds. according to the

invention have surprisingly been shown to have a serotonin (5-HT) reuptake inhibitor activity in combination with addnl. α 2-adrenoceptor antagonist activity and show a strong anti-depressant activity without being sedative. I produced an inhibition at the ha2A site (but often also at the ha2B and ha2C sites) and simultaneously at the 5-HT transporter site of more than 50% (pIC50) at a test concentration ranging between 10^{-6} M and 10^{-9} M in a concentration dependent manner. The invention also relates to novel combination of substituted isoxazolines derivs. having anti-depressant activity and/or anxiolytic activity and/or body weight control activity with antidepressants, anxiolytics and/or antipsychotics to improve efficacy and/or onset of action.

IT 452321-75-4P 452321-82-3P 452321-85-6P
 452321-87-8P 452321-89-0P 452321-91-4P
 452321-93-6P 452321-95-8P 452321-97-0P
 452321-99-2P 452322-19-9P 452322-21-3P
 452322-23-5P 452322-29-1P 452322-30-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)
 RN 452321-75-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-82-3 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.


10/513699



RN 452321-85-6 CAPLUS

CN 2-Propanone, 1-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-87-8 CAPLUS

CN Methanone, [4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl] (3,4-dihydro-2-naphthalenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452321-89-0 CAPLUS

CN Phosphonium, [2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]ethyl]triphenyl-, rel- (CA INDEX NAME)

10/513699

bromide (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.




● Br^-

RN 452321-91-4 CAPLUS

CN 2-Propen-1-one, 1-[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-3-iodo-2-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452321-93-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(3-iodo-2-methyl-2-propen-1-yl)-1-piperazinyl)methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.


10/513699



RN 452321-95-8 CAPLUS

CN 1-Piperazineethanol, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]- α -methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-97-0 CAPLUS

CN 1,2-Propanediol, 3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452321-99-2 CAPLUS

CN 1-Piperazineacetaldehyde, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-, rel- (CA INDEX NAME)

10/513699


Relative stereochemistry.



RN 452322-19-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(3R,3aR)-3,3a,4,5-tetrahydro-7,8-dimethoxy-5-(2,2,2-trifluoroacetyl)isoxazolo[4,3-c]quinolin-3-yl)methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-21-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(3R,3aR)-3,3a,4,5-tetrahydro-7,8-dimethoxyisoxazolo[4,3-c]quinolin-3-yl)methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.




10/513699

RN 452322-23-5 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-29-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]amino]methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-30-4 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine, 3a,4-dihydro-7,8-dimethoxy-N-(4-piperidinylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




IT 452323-46-5D, resin bound
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)
 RN 452323-46-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[2-(diphenylphosphino)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 452313-32-5P 452313-68-7P 452313-71-2P
 452313-80-3P 452313-82-5P 452316-78-8P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compound; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)
 RN 452313-32-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
 Double bond geometry as shown.




● 2 HCl

RN 452313-68-7 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel-(+)-
(CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-71-2 CAPLUS


CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aS)-rel-(-)-
(CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-80-3 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
 piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel-(+)- (CA INDEX
 NAME)


Rotation (+). Absolute stereochemistry unknown.



● 2 HCl

RN 452313-82-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
 piperazinyl]methyl]-, hydrochloride (1:2), (3S,3aR)-rel-(-)- (CA INDEX
 NAME)


Rotation (-). Absolute stereochemistry unknown.



● 2 HCl

RN 452316-78-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-, hydrochloride (1:2), (3S,3aR)-rel-(-)- (CA INDEX
 NAME)


Rotation (-). Absolute stereochemistry unknown.
 Double bond geometry as shown.



● 2 HCl

IT 452313-59-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (target compound; preparation and pharmaceutical activity of substituted
 isoxazolines as anti-depressants)
 RN 452313-59-6 CAPLUS
 CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-(2-
 naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 452313-36-9P 452313-40-5P 452313-43-8P
 452313-46-1P 452313-50-7P 452313-54-1P
 452313-56-3P 452313-61-0P 452313-65-4P
 452313-74-5P 452313-77-8P 452313-85-8P
 452313-88-1P 452313-91-6P 452313-93-8P
 452313-98-3P 452314-01-1P 452314-05-5P
 452314-08-8P 452314-11-3P 452314-14-6P
 452314-16-8P 452314-18-0P 452314-20-4P
 452314-23-7P 452314-26-0P 452314-29-3P
 452314-31-7P 452314-34-0P 452314-37-3P
 452314-40-8P 452314-43-1P 452314-46-4P
 452314-49-7P 452314-52-2P 452314-55-5P
 452314-57-7P 452314-60-2P 452314-62-4P
 452314-65-7P 452314-68-0P 452314-71-5P
 452314-74-8P 452314-77-1P 452314-80-6P
 452314-83-9P 452314-86-2P 452314-89-5P
 452314-92-0P 452314-95-3P 452314-98-6P
 452315-01-4P 452315-04-7P 452315-07-0P
 452315-10-5P 452315-13-8P 452315-16-1P
 452315-19-4P 452315-22-9P 452315-24-1P
 452315-27-4P 452315-30-9P 452315-33-2P
 452315-36-5P 452315-38-7P 452315-40-1P
 452315-42-3P 452315-44-5P 452315-46-7P
 452315-48-9P 452315-51-4P 452315-52-5P
 452315-55-8P 452315-58-1P 452315-61-6P
 452315-63-8P 452315-66-1P 452315-70-7P
 452315-73-0P 452315-76-3P 452315-79-6P
 452315-82-1P 452315-85-4P 452315-87-6P
 452315-90-1P 452315-92-3P 452315-94-5P
 452315-97-8P 452316-00-6P 452316-03-9P
 452316-06-2P 452316-09-5P 452316-12-0P
 452316-15-3P 452316-18-6P 452316-21-1P
 452316-24-4P 452316-27-7P 452316-30-2P
 452316-33-5P 452316-36-8P 452316-39-1P
 452316-42-6P 452316-45-9P 452316-48-2P
 452316-51-7P 452316-53-9P 452316-55-1P
 452316-58-4P 452316-64-2P 452316-66-4P
 452316-69-7P 452316-72-2P 452316-75-5P
 452316-81-3P 452316-84-6P 452316-87-9P
 452316-89-1P 452316-91-5P 452316-93-7P
 452316-95-9P 452316-97-1P 452316-99-3P
 452317-02-1P 452317-04-3P 452317-06-5P
 452317-08-7P 452317-10-1P 452317-12-3P
 452317-14-5P 452317-16-7P 452317-18-9P
 452317-20-3P 452317-22-5P 452317-24-7P

452317-26-9P 452317-28-1P 452317-30-5P
 452317-32-7P 452317-34-9P 452317-36-1P
 452317-38-3P 452317-40-7P 452317-42-9P
 452317-44-1P 452317-46-3P 452317-48-5P
 452317-50-9P 452317-52-1P 452317-54-3P
 452317-56-5P 452317-58-7P 452317-60-1P
 452317-64-5P 452317-67-8P 452317-69-0P
 452317-71-4P 452317-73-6P 452317-76-9P
 452317-79-2P 452317-82-7P 452317-84-9P
 452317-86-1P 452317-89-4P 452317-92-9P
 452317-94-1P 452317-96-3P 452317-99-6P
 452318-02-4P 452318-04-6P 452318-07-9P
 452318-09-1P 452318-11-5P 452318-13-7P
 452318-15-9P 452318-18-2P 452318-20-6P
 452318-22-8P 452318-24-0P 452318-27-3P
 452318-30-8P 452318-32-0P 452318-34-2P
 452318-36-4P 452318-38-6P 452318-41-1P
 452318-43-3P 452318-45-5P 452318-47-7P
 452318-49-9P 452318-52-4P 452318-54-6P
 452318-57-9P 452318-60-4P 452318-63-7P
 452318-65-9P 452318-67-1P 452318-69-3P
 452318-71-7P 452318-73-9P 452318-75-1P
 452318-77-3P 452318-79-5P 452318-81-9P
 452318-83-1P 452318-85-3P 452318-87-5P
 452318-89-7P 452318-91-1P 452318-93-3P
 452318-95-5P 452318-97-7P 452318-99-9P
 452319-01-6P 452319-03-8P 452319-05-0P
 452319-07-2P 452319-09-4P 452319-11-8P
 452319-13-0P 452319-15-2P 452319-17-4P
 452319-20-9P 452319-22-1P 452319-24-3P
 452319-25-4P 452319-27-6P 452319-29-8P
 452319-31-2P 452319-33-4P 452319-35-6P
 452319-37-8P 452319-39-0P 452319-41-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


(target compound; preparation and pharmaceutical activity of substituted
 isoxazolines as anti-depressants)

RN 452313-36-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.




RN 452313-40-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 452313-43-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452313-46-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

10/513699

3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-50-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452313-54-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+) (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-56-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3S,3aR)-rel-(-) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-61-0 CAPLUS

CN Ethanone, 1-[(3R,3aR)-3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]isoxazolo[4,3-c]quinolin-5(3H)-yl]-, rel- (CA INDEX
NAME)

Relative stereochemistry.




RN 452313-65-4 CAPLUS


CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-
methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA
INDEX NAME)

10/513699

Relative stereochemistry.
Double bond geometry as shown.




RN 452313-74-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(3-chlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy- (CA INDEX NAME)



RN 452313-77-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452313-85-8 CAPLUS


<12/04/2007>

Erich Leese

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452313-88-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452313-91-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methylphenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452313-93-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(3,4-dihydro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452313-98-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-pyridinyl)-2-propen-1-
yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452314-01-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

10/513699


3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.




RN 452314-05-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-buten-1-yl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452314-08-8 CAPLUS
CN 1-Piperazineethanamine, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-α-methyl-N-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452314-11-3 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[2-(3-fluorophenoxy)propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy- (CA INDEX NAME)



RN 452314-14-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

10/513699


RN 452314-16-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine,
3a,4-dihydro-7,8-dimethoxy-N-[1-(2-naphthalenylmethyl)-4-piperidinyl]-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452314-18-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(phenylmethyl)-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452314-20-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[[2-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 452314-23-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[[3-(trifluoromethyl)phenyl]methyl]-1-
piperazinyl]methyl]- (CA INDEX NAME)




RN 452314-26-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[[4-(trifluoromethyl)phenyl]methyl]-1-
piperazinyl]methyl]- (CA INDEX NAME)




RN 452314-29-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[[2-(1,1,2,2-
tetrafluoroethyl)phenyl]methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 452314-31-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2-bromophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy- (CA INDEX NAME)



RN 452314-34-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(3-bromophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy- (CA INDEX NAME)




RN 452314-37-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(4-bromophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-

10/513699


dimethoxy- (CA INDEX NAME)



RN 452314-40-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(3-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452314-43-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(4-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.




● 2 HCl

RN 452314-46-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
 dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452314-49-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(4-nitrophenyl)methyl]-1-
 piperazinyl]methyl]- (CA INDEX NAME)



10/513699


RN 452314-52-2 CAPLUS

CN Benzenamine, 4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl)methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 452314-55-5 CAPLUS

CN Acetamide, N-[4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl)methyl]phenyl]- (CA INDEX NAME)



RN 452314-57-7 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2-ethoxyphenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 452314-60-2 CAPLUS


10/513699

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-phenoxyphenyl)methyl]-1-
piperazinyl]methyl]- (CA INDEX NAME)




RN 452314-62-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(4-phenoxyphenyl)methyl]-1-
piperazinyl]methyl]- (CA INDEX NAME)



RN 452314-65-7 CAPLUS

CN 1-Propanamine, 3-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-
c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]phenoxy]-N,N-dimethyl- (CA
INDEX NAME)




RN 452314-68-0 CAPLUS

<12/04/2007>

Erich Leese


10/513699

CN Benzoic acid, 4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl)methyl]-, methyl ester (CA INDEX NAME)




RN 452314-71-5 CAPLUS

CN Benzonitrile, 3-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl)methyl]- (CA INDEX NAME)



RN 452314-74-8 CAPLUS

CN Benzonitrile, 4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl)methyl]- (CA INDEX NAME)




RN 452314-77-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(1,1'-biphenyl)-3-ylmethyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-

10/513699


dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452314-80-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2,4-dimethoxyphenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy- (CA INDEX NAME)



RN 452314-83-9 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(3,4-dimethoxyphenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy- (CA INDEX NAME)



10/513699


RN 452314-86-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2,4-dichlorophenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452314-89-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(3,4-dichlorophenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452314-92-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(4-bromo-2-fluorophenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452314-95-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(1-methyl-1H-pyrrol-2-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452314-98-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-01-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-thiazolylmethyl)-1-piperazinyl]methyl]-

10/513699

, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-04-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2-phenyl-4-thiazolyl)methyl]-1-
piperazinylmethyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-07-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(2-furanylmethyl)-1-piperazinylmethyl]-3a,4-dihydro-7,8-dimethoxy-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



10/513699


RN 452315-10-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(5-bromo-2-furanyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-13-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(5-methyl-2-furanyl)methyl]-1-
piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-16-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(3-furanylmethyl)-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-19-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-22-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-24-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-thienylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

10/513699

(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-27-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(5-bromo-2-thienyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-30-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(4-bromo-2-thienyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




10/513699

RN 452315-33-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-thienylmethyl)-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-36-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[[(3R,5S)-3,5-dimethyl-4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-38-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[[(2R,5S)-2,5-dimethyl-4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-40-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[3-methyl-4-(2-naphthalenylmethyl)-1-
 piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-42-3 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-(1-naphthalenylmethyl)-1-
 piperazinyl]methyl]- (CA INDEX NAME)

10/513699



RN 452315-44-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(1-naphthalenylmethyl)-1-
piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl

RN 452315-46-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(1-methoxy-2-naphthalenyl)methyl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-48-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(6-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-51-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-52-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(7-methyl-2-naphthalenyl)methyl]-1-

10/513699

piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-55-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(6-methyl-2-naphthalenyl)methyl]-1-
piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-58-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-methyl-2-naphthalenyl)methyl]-1-
piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




10/513699

RN 452315-61-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(7-fluoro-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-63-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(6-fluoro-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-66-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(5-fluoro-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/513699



RN 452315-70-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(5-chloro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-73-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(1-bromo-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-76-3 CAPLUS


<12/04/2007>

Erich Leese

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(5-nitro-2-naphthalenyl)methyl]-1-
piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-79-6 CAPLUS
CN 1-Naphthalenamine, 6-[[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl)methyl]-, rel-
(CA INDEX NAME)


Relative stereochemistry.



RN 452315-82-1 CAPLUS
CN 1-Naphthalenamine, 6-[[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl)methyl]-N,N-
dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.


10/513699



RN 452315-85-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(6,7-difluoro-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-87-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(5,7-difluoro-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-90-1 CAPLUS


<12/04/2007>

Erich Leese

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(7,8-difluoro-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-92-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(5-bromo-8-methoxy-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-94-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-(1H-indol-2-ylmethyl)-1-piperazinyl)methyl]-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-97-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-(1H-indol-3-ylmethyl)-1-piperazinyl]methyl]-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-00-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(1H-benzimidazol-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

10/513699

RN 452316-03-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(2-benzofuranylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452316-06-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(benzo[b]thien-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452316-09-5 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(benzo[b]thien-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-12-0 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-quinolinylmethyl)-1-
piperazinyl]methyl]- (CA INDEX NAME)



RN 452316-15-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-quinolinylmethyl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-18-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(4-quinolinylmethyl)-1-

10/513699

piperazinyl)methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452316-21-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-phenylethyl)-1-piperazinyl)methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-24-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[2-(1,3-benzodioxol-5-yl)ethyl]-1-piperazinyl)methyl]-3a,4-dihydro-
7,8-dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/513699



● 2 HCl

RN 452316-27-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(2-naphthalenyl)ethyl]-1-
piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl

RN 452316-30-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(1-naphthalenyl)ethyl]-1-
piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl


RN 452316-33-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenylpropyl)-1-piperazinyl]methyl]-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-36-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-3-[[4-(1H-inden-2-ylmethyl)-1-piperazinyl]methyl]-7,8-
 dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-39-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(1H-benzimidazol-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-42-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

10/513699

RN 452316-45-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[2-(1,3-benzodioxol-5-yloxy)ethyl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-48-2 CAPLUS

CN 1H-Inden-1-one, 5-[2-[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]ethoxy]-2,3-
dihydro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-51-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[2-[(2,3-dihydro-5-benzofuranyl)oxy]ethyl]-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-53-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[2-(3-fluorophenoxy)propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-55-1 CAPLUS

CN 3(2H)-Benzofuranone, 6-[2-[4-[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-methylethoxy]-
, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-58-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2R)-6-fluoro-3,4,4a,8a-tetrahydro-2H-1-benzopyran-2-yl]methyl]-1-
piperazinyl]-1-methylethoxy-, rel- (CA INDEX NAME)

10/513699

piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-64-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(1,3-benzodioxol-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-66-4 CAPLUS

CN 1-Propanone, 3-[4-[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-1-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



<12/04/2007>


Erich Leese

10/513699

RN 452316-69-7 CAPLUS

CN 1-Piperazinepropanol, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]- α -phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-72-2 CAPLUS

CN 1-Propanone, 3-[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-1-phenyl-, oxime, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452316-75-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452316-81-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452316-84-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2Z)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452316-87-9 CAPLUS

10/513699

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-propen-1-yl]-
1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX
NAME)


Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl

RN 452316-89-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-methoxyphenyl)-2-propen-1-yl]-
1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.




● 2 HCl

RN 452316-91-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methoxyphenyl)-2-propen-1-yl]-
1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX
NAME)

10/513699


Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl


RN 452316-93-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(4-phenoxyphenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452316-95-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452316-97-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452316-99-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(3E)-3-(3-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-02-1 CAPLUS

10/513699

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.




● 2 HCl

RN 452317-04-3 CAPLUS

CN Naphth[1,2-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)-
(CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452317-06-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2-chlorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-08-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(3-chlorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-10-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(4-chlorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-12-3 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2-bromophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-14-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(3-bromophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 452317-16-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(4-bromophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.

10/513699




RN 452317-18-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[2-(trifluoromethyl)phenyl]-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-20-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[3-(trifluoromethyl)phenyl]-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.



RN 452317-22-5 CAPLUS


<12/04/2007>

Erich Leese

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-24-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[2-(1,1,2,2-tetrafluoroethyl)phenyl]-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-26-9 CAPLUS
CN Benzoic acid, 4-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propen-1-yl]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-28-1 CAPLUS

CN Benzoic acid, 3-[3-[4-[[3R,3aS]-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-1-propen-1-yl]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-30-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-nitrophenyl)-2-propen-1-yl]-1-piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




10/513699

RN 452317-32-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-nitrophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-34-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-methylphenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-36-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-phenoxyphenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-38-3 CAPLUS

CN Benzonitrile, 2-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-1-propen-1-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-40-7 CAPLUS

CN Benzonitrile, 3-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-1-propen-1-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-42-9 CAPLUS

10/513699


CN Benzonitrile, 4-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-1-propen-1-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-44-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(3-[1,1'-biphenyl]-2-yl)-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-46-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3,4-difluorophenyl)-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)




RN 452317-48-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2,4-difluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 452317-50-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2,3-difluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy- (CA INDEX NAME)




RN 452317-52-1 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2,6-difluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-54-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2,5-difluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-56-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(3,5-difluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 452317-58-7 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2,6-dichlorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-60-1 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2-chloro-4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



10/513699


RN 452317-64-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2-chloro-6-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-67-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2,3-dihydro-1H-inden-5-yl)-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452317-69-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-71-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(9H-fluoren-2-yl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-73-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2-dibenzofuranyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-76-9 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(1,3-benzodioxol-5-yl)-2-propen-1-yl]-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452317-79-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2,3-dihydro-5-benzofuranyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452317-82-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(4,5-dimethoxy-2-nitrophenyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-84-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-thienyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-86-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.

Double bond geometry as shown.




10/513699

RN 452317-89-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)-rel(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452317-92-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(4-bromo-2-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 452317-94-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(5-bromo-2-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-96-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2-furanyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-99-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-pyridinyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452318-02-4 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-pyridinyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452318-04-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-[5-(4-chlorophenyl)-2-furanyl]-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-07-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-naphthalenyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452318-09-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(1-naphthalenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



● 2 HCl


RN 452318-11-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(4-quinolinyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.

10/513699




RN 452318-13-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-quinolinyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)



Relative stereochemistry.

Double bond geometry unknown.




RN 452318-15-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(9-anthracenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-
7,8-dimethoxy- (CA INDEX NAME)



RN 452318-18-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-1-methyl-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 452318-20-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-22-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl

RN 452318-24-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)-rel(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
 Double bond geometry as shown.




RN 452318-27-3 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 452318-26-2
 CMF C27 H33 N3 O4

Relative stereochemistry.
 Double bond geometry as shown.

10/513699



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 452318-30-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[(2R,5S)-2,5-dimethyl-4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinylmethyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 452318-32-0 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[(3S,5R)-3,5-dimethyl-4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinylmethyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry as shown.

<12/04/2007>

Erich Leese




RN 452318-34-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-((2S,6R)-2,6-dimethyl-4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-36-4 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2Z)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452318-38-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
 piperazinyl]methyl]- (CA INDEX NAME)




RN 452318-41-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-(2-(2,3-diphenyl-2-propen-1-yl)-1-piperazinyl)methyl]-3a,4-dihydro-7,8-
 dimethoxy- (CA INDEX NAME)



RN 452318-43-3 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-(2-[1,1'-biphenyl]-4-yl-3-phenyl-2-propen-1-yl)-1-
 piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
 NAME)

Relative stereochemistry.
 Double bond geometry unknown.




RN 452318-45-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(2-naphthalenyl)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452318-47-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(phenylmethylene)butyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452318-49-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-(phenylmethylene)heptyl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-52-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2Z)-2-bromo-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-54-6 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2Z)-2-chloro-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-57-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2Z)-2-fluoro-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-60-4 CAPLUS
CN 1-Piperazinepropanenitrile, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-α-(phenylmethylene)-,
(αZ)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-63-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-[4-(1,1-dimethylethyl)phenyl]-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452318-65-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(3-[1,1'-biphenyl]-4-yl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.


Double bond geometry unknown.



10/513699


RN 452318-67-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2Z)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-69-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2Z)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-71-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-73-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-75-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-)- (CA
INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

Double bond geometry as shown.




10/513699

RN 452318-77-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-79-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2-chloro-6-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-81-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2Z)-3-(2,5-difluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-83-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(2,5-difluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
 NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-85-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2Z)-3-(2,3-difluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
 NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-87-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(2,3-difluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
 NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-89-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-methyl-3-(1-naphthalenyl)-2-propen-1-
 yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



10/513699


RN 452318-91-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(2H-1-benzopyran-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452318-93-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-95-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-97-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3S,3aR)-rel-(-) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-99-9 CAPLUS

CN Phenol, 3-[(1E)-3-[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-methyl-1-
propen-1-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-01-6 CAPLUS

10/513699

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-03-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-thienyl)-2-propen-1-
yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-05-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2,5-dimethyl-3-thienyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-07-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2-furanyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-09-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-pyridinyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-11-8 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-methyl-4-thiazolyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-13-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2-phenyl-1-cyclopenten-1-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452319-15-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-propyn-1-yl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452319-17-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[3-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]propyl]-1-
 piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
 NAME)


Relative stereochemistry.



RN 452319-20-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[3-(4-fluorophenoxy)propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
 dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



10/513699


RN 452319-22-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-4-(2-fluorophenyl)-2-methyl-2-buten-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-24-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-[(2E,4E)-5-phenyl-2,4-pentadien-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-25-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-27-6 CAPLUS
 CN Benzoic acid, 4-[(1E)-3-[4-[[(3R,3aS)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propen-1-yl]-, methyl ester, rel-
 (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 452319-29-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 7-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452319-31-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

10/513699

Double bond geometry as shown.




RN 452319-33-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-35-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-37-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel-(+)- (CA INDEX
NAME)

10/513699


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



●2 HCl

RN 452319-39-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



●2 HCl


RN 452319-41-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

yl]-1-piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-45-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-47-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-49-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-2-methyl-3-phenyl-2-

10/513699

propen-1-yl]-1-piperazinyl)methyl]-, hydrochloride (1:2), (3R,3aS)-rel-
(CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl


RN 452319-51-6 CAPLUS
CN Carbamic acid, ethyl-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-53-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-55-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452319-57-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-, 7-propanoate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 452319-59-4 CAPLUS
 CN Acetic acid, 2-methoxy-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-
 phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-
 c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452319-61-8 CAPLUS

CN Cyclopropanecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-63-0 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-65-2 CAPLUS

CN 2-Propenoic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

10/513699

Double bond geometry as shown.




RN 452319-67-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-(cyclopentyloxy)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-69-6 CAPLUS

CN 4-Pyridinecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 452319-71-0 CAPLUS


CN Ethanamine, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-

10/513699

yl]oxy]-N,N-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-73-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-yl,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, 7-(hydrogen sulfate), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-75-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
8-chloro-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-77-6 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
8-chloro-3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-78-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-80-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452319-81-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3S,3aR)-rel-(-) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452319-83-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7,8-difluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-85-6 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
8-fluoro-3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-87-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-phenyl-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-89-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methyl-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-91-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
8-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-7-(methylthio)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-93-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7,8-diol,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



● 2 HCl


RN 452319-95-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-8-ol,
 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 452319-97-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-8-ol,
 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 8-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452319-99-2 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-8-yl]oxy]-, 1-acetate, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-01-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



10/513699


RN 452320-03-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, 7-acetate, (3R,3aS)-rel- (CA
INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-06-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, 7-acetate, (3R,3aS)-rel- (CA
INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-07-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-8-methoxy-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-09-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-(cyclopropylmethoxy)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-11-5 CAPLUS

CN Cyclopropanecarboxylic acid, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




10/513699

RN 452320-13-7 CAPLUS

CN 3-Pyridinecarboxylic acid, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-15-9 CAPLUS

CN Carbamic acid, ethyl-, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-17-1 CAPLUS

CN Ethanamine, 2-[[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-N,N-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-19-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-21-7 CAPLUS

CN Carbonic acid, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



10/513699


RN 452320-23-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(2-propen-1-yloxy)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-25-1 CAPLUS
CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-, hydrochloride (1:2), rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl

RN 452320-27-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 7-methanesulfonate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-29-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-31-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-phenyl-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 452320-34-2 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-7-(methylthio)-, (3R,3aS)-rel-, 2,2,2-trifluoroacetate
(1:1) (CA INDEX NAME)

CM 1

CRN 452320-33-1

CMF C27 H33 N3 O3 S

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1


CMF C2 H H F3 O2



RN 452320-36-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-
propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



10/513699


RN 452320-38-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-40-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-42-2 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-44-4 CAPLUS

CN Isloxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel-(+)-
(CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452320-46-6 CAPLUS

CN Isloxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3S,3aS)-rel-(-)-
(CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452320-48-8 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-50-2 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-52-4 CAPLUS


CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-54-6 CAPLUS
 CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-5-methyl-3-
 [[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-,
 (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452320-56-8 CAPLUS
 CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-2-
 methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-5-(phenylmethyl)-,
 (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 452320-58-0 CAPLUS
 CN Ethanone, 1-[(3R,3aR)-3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-
 propen-1-yl]-1-piperazinyl]methyl]isoxazolo[4,3-c]quinolin-5(3H)-yl]-2,2,2-
 trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452320-60-4 CAPLUS

CN Ethanone, 1-[(3R,3aR)-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]isoxazolo[4,3-c]quinolin-5(3H)-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-62-6 CAPLUS

CN Ethanone, 1-[(3R,3aR)-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]isoxazolo[4,3-c]quinolin-5(3H)-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 452320-64-8 CAPLUS


CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxylic acid, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-,

10/513699

ethyl ester, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-66-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxamide,
N-ethyl-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-68-2 CAPLUS

CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-3-phenyl-
2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aR)-rel-
(CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.


10/513699



● 2 HCl


RN 452320-70-6 CAPLUS
CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-72-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(phenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452320-74-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(3-phenylpropyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

10/513699


Relative stereochemistry.



RN 452320-76-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-
, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452320-78-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




PAGE 1-A

—OMe


RN 452320-80-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
 3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452320-82-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 7-(cyclopropylmethoxy)-3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-
 piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452320-84-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 7-(difluoromethoxy)-3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-
 piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452320-86-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-7-
[(tetrahydro-3-furanyl)oxy]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452320-88-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-,
7-acetate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452320-90-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-8-methoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-
, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452320-92-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-94-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2-fluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-96-6 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-98-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-00-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methoxyphenyl)-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452321-02-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-[3-(trifluoromethyl)phenyl]-2-
buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452321-04-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-
buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452321-06-1 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2-chlorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452321-08-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(3-chlorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-10-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-chlorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452321-12-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methylphenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452321-14-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452321-16-3 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-methoxyphenyl)-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-19-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2Z)-3-fluoro-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX
NAME)


Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl

RN 452321-21-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2,4-difluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452321-23-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(3,4-difluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452321-25-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-pyridinyl)-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




10/513699

RN 452321-27-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-pyridinyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452321-29-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-thienyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452321-31-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2-furanyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452321-33-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-35-6 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452321-37-8 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

10/513699


NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452321-39-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452321-41-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452321-43-6 CAPLUS

10/513699

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(5-fluoro-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-45-8 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(2-(2-naphthalenyloxy)ethyl)-1-piperazinyl)methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-47-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-(2-naphthalenyl)methyl]-1-piperazinyl)methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




10/513699

RN 452321-55-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[2-[4-(2-naphthalenylmethyl)-1-piperazinyl]ethyl]-
, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-57-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine,
3a,4-dihydro-7,8-dimethoxy-N-methyl-N-[1-(2-naphthalenylmethyl)-4-
piperidinyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452321-59-4 CAPLUS

CN Formamide, N-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-
c]isoxazol-3-yl]methyl]-N-[1-(2-naphthalenylmethyl)-4-piperidinyl]-, rel-
(CA INDEX NAME)


Relative stereochemistry.

10/513699

RN 452934-94-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(6-fluoro-3,4,4a,8a-tetrahydro-4-methyl-2H-1,4-benzoxazin-2-yl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:260283 CAPLUS
 DOCUMENT NUMBER: 132:293757
 TITLE: Preparation of novel 4,5-dihydroisoxazole derivatives
 and their use as pharmaceuticals for T cell-mediated
 diseases
 INVENTOR(S): Freyne, Eddy Jean Edgard; Andres-Gil, Jose Ignacio;
 Deroose, Frederik Dirk; Petit, Davy Petrus Franciscus
 Maria; Matesanz-Ballesteros, Maria Encarnacion;
 Alvarez Escobar, Rosa Maria
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 108 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021959	A1	20000420	WO 1999-EP7803	19991007
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2346396	A1	20000420	CA 1999-2346396	19991007
EP 1119568	A1	20010801	EP 1999-953847	19991007
EP 1119568	B1	20040218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002527438	T	20020827	JP 2000-575865	19991007
AU 763460	B2	20030724	AU 2000-10393	19991007
AT 259803	T	20040315	AT 1999-953847	19991007
ES 2216579	T3	20041016	ES 1999-953847	19991007
US 6583141	B1	20030624	US 2001-807149	20010406
HK 1038565	A1	20040618	HK 2002-100274	20020115
US 20040019059	A1	20040129	US 2003-403543	20030331
US 7414048	B2	20080819		
PRIORITY APPLN. INFO.:			EP 1998-203394	A 19981009
			WO 1999-EP7803	W 19991007
			US 2001-807149	A3 20010406
OTHER SOURCE(S):	MARPAT	132:293757		
GI				



I



II

AB The invention concerns title compds. I and their N-oxides, pharmaceutically acceptable addition salts, quaternary ammonium salts, and stereochem. isomeric forms [wherein m, n, p = 0 or 1; R1 = (un)substituted pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl or phenyl; B = amide, ketone, or oxadiazole; D = (un)substituted aryl or heterocyclyl; Q = bond, CO, (un)substituted NH, CONH, CH2, CH(:CH2), C(:NH), SO, SO, 3-oxobutenyl, pyrazole, isoxazole, or thiazole nucleus; L = (un)substituted aryl or heteroaryl; R2, R3 = H, halo, C1-6 alkyloxy, or (un)substituted C1-6 alkyl]. Also disclosed is a process for their preparation, compns. comprising them, and their medical use. The compds. show growth inhibitory activity against T cell blasts and keratinocytes in vitro. The compds. are claimed for use in the treatment of prevention of rheumatic, arthritic, and inflammatory diseases, psoriasis, T cell leukemia, transplant rejection, and graft-vs.-host disease. For instance, base-catalyzed cycloaddn. of N-hydroxy-3-pyridinecarboximidoyl chloride with Me 2-propenoate gave 98% Me 4,5-dihydro-3-(3-pyridinyl)-5-isoxazolecarboxylate, which was amidated with (4-aminophenyl)phenylmethanone to give 58% title compound II. At a concentration of 10-6 M, II gave 81% inhibition of T cell blast formation in human whole blood.


IT 264606-16-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of dihydroisoxazole derivs. as antiproliferatives and immunomodulators)

RN 264606-16-8 CAPLUS

CN Piperidine, 4-(4-fluorobenzoyl)-1-[[[(3R,3aR)-3,3a,4,5-tetrahydroisoxazolo[4,3-c]quinolin-3-yl]carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/513699

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

89.12

269.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-12.80

-12.80

FILE 'REGISTRY' ENTERED AT 16:45:54 ON 22 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 OCT 2008 HIGHEST RN 1064205-90-8

DICTIONARY FILE UPDATES: 21 OCT 2008 HIGHEST RN 1064205-90-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10524123election.str

10/513699



```
chain nodes :
10 12 13 14 15 21 22 23
ring nodes :
1 2 3 4 5 6 7 8 9 17 18 19 20 28
ring/chain nodes :
24 27
chain bonds :
5-14 6-12 6-13 9-10 9-15 10-24 17-22 19-23 20-21 24-27 27-28
ring bonds :
1-2 1-6 2-3 2-17 3-4 3-20 4-5 4-7 5-6 5-9 7-8 8-9 17-18 18-19 19-20
exact/norm bonds :
1-2 1-6 3-4 4-5 4-7 5-6 5-9 5-14 6-12 6-13 7-8 8-9 9-10 9-15 10-24
17-22 19-23 20-21 24-27 27-28
normalized bonds :
2-3 2-17 3-20 17-18 18-19 19-20
isolated ring systems :
containing 1 :
```

G1:C,O,S,N

G2:C,N

G3:H,Ak

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS 17:Atom 18:Atom 19:Atom 20:Atom
21:CLASS 22:CLASS 23:CLASS 24:CLASS 27:CLASS 28:Atom
```

<12/04/2007>

Erich Leese


10/513699

L4 STRUCTURE UPLOADED

=> d 14

L4 HAS NO ANSWERS

L4 STR



G1 C, O, S, N

G2 C, N

G3 H, Ak

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10524123new.str

10/513699



```
chain nodes :
10 12 13 14 15
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
5-14 6-12 6-13 9-10 9-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 5-14 6-12 6-13 7-8 8-9 9-10 9-15
```

G1:C,O,S,N

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS
```

L5 STRUCTURE UPLOADED


=> d 15

L5 HAS NO ANSWERS

L5 STR

<12/04/2007>

Erich Leese



Gl C, O, S, N

Structure attributes must be viewed using STN Express query preparation.

=> s 15 full

FULL SEARCH INITIATED 16:48:04 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 129536 TO ITERATE

100.0% PROCESSED 129536 ITERATIONS

880 ANSWERS

SEARCH TIME: 00.00.02

L6

880 SEA SSS FUL L5

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

179.74

448.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-12.80

FILE 'CAPLUS' ENTERED AT 16:48:10 ON 22 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Oct 2008 VOL 149 ISS 17

FILE LAST UPDATED: 21 Oct 2008 (20081021/ED)

Caplus now includes complete International Patent Classification (IPC)

10/513699

reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l6 full

L7 39 L6

=> d ibib abs hitstr tot

L7 ANSWER 1 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:422092 CAPLUS

DOCUMENT NUMBER: 148:561766

TITLE: Novel synthesis of naphthopyranoisoxazoles and versatile access to naphthopyranoisoxazolines

AUTHOR(S): Liaskopoulos, Theodoros; Skoulika, Stavroula; Tsoungas, Petros G.; Varvounis, George
CORPORATE SOURCE: Department of Chemistry, University of Ioannina, Ioannina, 45110, Greece

SOURCE: Synthesis (2008), (5), 711-718

CODEN: SYNTBF; ISSN: 0039-7881

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

AB 2-(Alkenyloxy)naphthalene-1-carboxaldehyde oximes are oxidized with potassium iodide, iodine, and sodium bicarbonate directly to naphthopyranoisoxazoles. Naphthopyranoisoxazoles are also prepared from 2-[(3-chloroallyl)oxy]naphthalene-1-carboxaldehyde oxime or 2-(alkynyloxy)naphthalene-1-carboxaldehyde oximes by oxidation with sodium hypochlorite and triethylamine. The oxidation of 2-(alkenyloxy)naphthalene-1-carboxaldehyde oximes with sodium hypochlorite and triethylamine afforded the naphthopyranoisoxazolines. The former reaction is tentatively proposed to occur via activation of the alkene side chain by means of an iodonium intermediate and either 1,3-dipolar interaction with a nitrile oxide side group or cyclization with a hydroximic acid iodide side group.


IT 1026773-24-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of naphthopyranoisoxazoles and naphthopyranoisoxazolines from (alkenyloxy)- or (alkynyloxy)naphthalene-1-carboxaldehyde oximes)

RN 1026773-24-9 CAPLUS

CN 3H-Naphtho[1',2':5,6]pyrano[4,3-c]isoxazole, 3a,4-dihydro-3-methyl- (CA INDEX NAME)





REFERENCE COUNT:

46

THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:1364471 CAPLUS
 DOCUMENT NUMBER: 148:33768
 TITLE: Preparation of bridged aryl piperazines derivatives
 useful for the treatment of CNS, gastrointestinal and
 reproductive disorders
 INVENTOR(S): Creighton, Christopher John; Ross, Tina Morgan; Reitz,
 Allen B.; Kordik, Cheryl P.; Paget, Steven
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 122pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007137168	A2	20071129	WO 2007-US69256	20070518
WO 2007137168	A3	20080912		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA US 20080070919 A1 20080320 US 2007-750629 20070518 PRIORITY APPLN. INFO.: US 2006-801439P P 20060518 OTHER SOURCE(S): MARPAT 148:33768 GI				



AB Title compds. represented by the formula I [wherein m = 0 or 1; L1, L2 = independently -alkyl-, -CH2-alkenyl-, -CH2-alkynyl-, etc.; R1, R2 = H, (cyclo)alkyl, aryl, etc.; n = 0 or 1; and pharmaceutically acceptable

salts thereof] were prepared as serotonin transport inhibitors and/or modulators of 5HT1A. For example, II was provided in a multi-step synthesis starting from the reaction of allylglycine Me ester with 2,4-dimethoxybenzaldehyde. I were tested for radioligand binding to the human 5-HT1A receptor and to human 5-HTT, and for [35S]GTPγS binding of 5-HT1A receptor activation and inhibition. Thus, I and their pharmaceutical compns. are useful for the treatment of depression and related disorders.

IT 959408-36-7P 959408-37-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bridged aryl piperazines derivs. useful for treatment of CNS, gastrointestinal and reproductive disorders)

RN 959408-36-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[[(1S,6S)-9-(2-naphthalenyl)-7,9-diazabicyclo[4.2.2]dec-3-en-7-yl]methyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 959408-37-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[[(1S,6S)-9-(2-naphthalenyl)-7,9-diazabicyclo[4.2.2]dec-3-en-7-yl]methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

10/513699



<12/04/2007>

Erich Leese

L7 ANSWER 3 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:936801 CAPLUS

DOCUMENT NUMBER: 149:215053

TITLE: Pharmacophore mapping of tricyclic isoxazoles for their affinity towards alpha-2 adrenoreceptors

AUTHOR(S): Samanta, Soma; Alam, Sk. Mahasin; Panda, Parthasarathi; Jha, Tarun

CORPORATE SOURCE: Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, 700 032, India

SOURCE: Internet Electronic Journal of Molecular Design (2006), 5(10), 503-514
CODEN: IEJMAT; ISSN: 1538-6414
URL: http://biochempress.com/Files/iejmd_2006_5_0503.pdf

PUBLISHER: BioChem Press

DOCUMENT TYPE: Journal; (online computer file)

LANGUAGE: English

AB Motivation: Blockage of alpha-2 adrenoreceptors in brain enhances noradrenergic neurotransmission and increases extracellular dopamine as well as serotonin (5-HT) levels, which is beneficial for depressant patients. To identify pharmacophoric requirements, a quant. structure activity relationship (QSAR) study was performed using electrotopol. state atom (ETSA) indexes and refractotopol. state atom (RTSA) indexes on tricyclic isoxazole derivs. for their affinity towards the alpha-2 adrenoreceptors. Method: Correlation anal. and multiple linear regression anal. were employed to model the exptl. activity. Results: The QSAR models were obtained sep. for alpha-2A and 2C adrenoreceptor binding affinity. Some atoms played important roles to both the activities and some other atoms played different roles in selectivity of compound towards alpha-2A and 2C adrenoreceptor binding affinity. Conclusions: Electrotopol. state atom (ETSA) and refractotopol. state atom (RTSA) indexes have potentiality to determine or recognize the pharmacophoric atoms and combination of these two helps to map pharmacophore of tricyclic isoxazoles.


IT 452318-38-6 1042685-16-4 1042685-19-7
1042685-26-6 1042685-29-9 1042685-33-5
1042685-37-9 1042685-40-4 1042685-43-7
1042685-46-0 1042685-48-2 1042685-50-6
1042685-52-8 1042685-54-0 1042685-57-3
1042685-59-5 1042685-61-9 1042685-63-1
1042685-66-4 1042685-67-5 1042685-69-7
1042685-71-1 1042685-73-3 1042685-75-5
1042685-77-7 1042685-79-9 1042685-81-3
1042685-82-4 1042685-84-6 1042685-85-7
1042685-86-8 1042685-87-9 1042685-88-0
1042685-90-4 1042685-92-6 1042685-94-8

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(pharmacophore mapping of tricyclic isoxazoles for their affinity
towards alpha-2 adrenoreceptors and possible antidepressant use)


RN 452318-38-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-16-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA
INDEX NAME)



RN 1042685-19-7 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]- (CA INDEX NAME)



RN 1042685-26-6 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-buten-1-yl)-1-
piperazinyl]methyl]- (CA INDEX NAME)

10/513699




RN 1042685-29-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-33-5 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-(3-phenyl-2-propen-1-
yl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-37-9 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-(2-
naphthalenylmethyl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-40-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 1042685-43-7 CAPLUS


CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxamide, N-ethyl-3a,4-dihydro-3-[[4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-46-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxylic acid, 3a,4-dihydro-3-[[4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-, ethyl ester (CA INDEX NAME)


10/513699




RN 1042685-48-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1042685-50-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1042685-52-8 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-54-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-57-3 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-buten-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-59-5 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy- (CA INDEX NAME)




RN 1042685-61-9 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 1042685-63-1 CAPLUS


CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 1042685-66-4 CAPLUS


CN Isoxazolo[4,3-c]quinoline, 3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy- (CA INDEX NAME)

10/513699




RN 1042685-67-5 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-5-methyl-3-
[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX
NAME)



RN 1042685-69-7 CAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 1042685-71-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


10/513699




RN 1042685-73-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1042685-75-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a, 4-dihydro-7-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-77-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a, 4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-
(CA INDEX NAME)




RN 1042685-79-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-(2-methoxyethoxy)-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-81-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-[2-(2-ethoxyethoxy)ethoxy]-3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-
propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)




PAGE 1-A



PAGE 1-B


RN 1042685-82-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-(cyclopentyl-oxo)-3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]- (CA INDEX NAME)




RN 1042685-84-6 CAPLUS

CN Ethanamine, 2-[[3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-N,N-
dimethyl- (CA INDEX NAME)




RN 1042685-85-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-
, 7-acetate (CA INDEX NAME)




RN 1042685-86-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-
, 7-propanoate (CA INDEX NAME)




RN 1042685-87-9 CAPLUS

CN Acetic acid, 2-methoxy-, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester (CA INDEX NAME)



RN 1042685-88-0 CAPLUS


CN Cyclopropanecarboxylic acid, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester (CA INDEX NAME)



RN 1042685-90-4 CAPLUS


CN 2-Propenoic acid, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-

piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester (CA INDEX NAME)




RN 1042685-92-6 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester (CA INDEX NAME)



RN 1042685-94-8 CAPLUS

CN 4-Pyridinecarboxylic acid, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester (CA INDEX NAME)



REFERENCE COUNT:

23

THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/513699

<12/04/2007>

Erich Leese

L7 ANSWER 4 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:474148 CAPLUS

DOCUMENT NUMBER: 146:492615

TITLE: Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α 2-adrenoceptor antagonism

AUTHOR(S): Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.; Alvarez, Rosa M.; Bakker, Margot H.; Biesmans, Ilse; Cid, Jose M.; De Lucas, Ana I.; Drinkenburg, Wilhelmus; Fernandez, Javier; Font, Luis M.; Iturrino, Laura; Langlois, Xavier; Lenaerts, Ilse; Martinez, Sonia; Megens, Anton A.; Pastor, Joaquin; Pullan, Shirley; Steckler, Thomas

CORPORATE SOURCE: Research & Early Development-EU, CNS-Psychiatry, Division of Janssen-Cilag, Medicinal Chemistry Department, Johnson & Johnson Pharmaceutical Research & Development, Toledo, 45007, Spain

SOURCE: Bioorganic & Medicinal Chemistry (2007), 15(11), 3649-3660

CODEN: BMECEP; ISSN: 0968-0896


PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:492615

GI



AB In previous articles we have described the discovery of a new series of tricyclic isoxazolines combining central serotonin (5-HT) reuptake inhibition with α 2-adrenoceptor antagonistic activity. We report now on the synthesis, the in vitro binding potency and the primary in vivo activity of six enantiomers within this series, one of which was selected for further pharmacol. evaluation and assigned as R226161 (I). Some addnl. in vivo studies in rats are described with this compound, which proved to be centrally and orally active as a combined 5-HT reuptake inhibitor and α 2-adrenoceptor antagonist.

IT 452313-46-1P 452313-65-4P 452313-68-7P

452313-71-2P 452314-01-1P 452318-73-9P

452318-75-1P 722545-47-3P 936362-34-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and $\alpha 2$ -adrenoceptor antagonism)

RN 452313-46-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-65-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452313-68-7 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-71-2 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aS)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452314-01-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



10/513699


RN 452318-73-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-75-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-)- (CA
INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 722545-47-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 936362-34-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



IT 452313-36-9 452318-26-2


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(Tricyclic isoxazolines: Identification of R226161 as a potential new
antidepressant that combines potent serotonin reuptake inhibition and
 α 2-adrenoceptor antagonism)

RN 452313-36-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-26-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT 452321-71-0 452321-77-6 452321-80-1


RL: RCT (Reactant); RACT (Reactant or reagent)

(Tricyclic isoxazolines: Identification of R226161 as a potential new
antidepressant that combines potent serotonin reuptake inhibition and
 α 2-adrenoceptor antagonism)

RN 452321-71-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-,
3-methanesulfonate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-77-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-, 3-methanesulfonate, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 452321-80-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-, 3-methanesulfonate, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



IT 936362-26-4P 936362-28-6P 936362-31-1P
936362-33-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α_2 -adrenoceptor antagonism)

RN 936362-26-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-, 1,1-dimethylethyl ester, rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 936362-28-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-, 1,1-dimethylethyl ester, rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.




RN 936362-31-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.


10/513699



RN 936362-33-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel-(+)-
(CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.




REFERENCE COUNT:

26

THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 5 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:1113391 CAPLUS
 DOCUMENT NUMBER: 147:301095
 TITLE: A facile synthesis of pyridoquinazoline,
 pyridopyrimidine, benzoxazole, and indazole
 derivatives from chalcones
 AUTHOR(S): Sachar, Anand; Kumar, Surinder; Sharma, R. L.
 CORPORATE SOURCE: Department of Chemistry, University of Jammu, Jammu
 Tawi, 180 006, India
 SOURCE: Indian Journal of Heterocyclic Chemistry (2006),
 16(1), 39-42
 CODEN: IJCHEI; ISSN: 0971-1627
 PUBLISHER: Prof. R. S. Varma
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 147:301095
 AB A facile synthesis of title compds. was achieved by the condensation of
 chalcones ((E)-2-arylidene-cyclohexanones and 1,3-diarylprop-2-ene-1-ones)
 with 2-aminopyridine, hydroxylamine hydrochloride, and hydrazine hydrate,
 resp. The structure of all the compds. were confirmed by spectral studies
 and elemental anal.
 IT 128094-36-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of pyridoquinazoline, pyridopyrimidine, benzoxazole, and
 indazole derivs. by condensation of chalcones with 2-aminopyridine or
 hydroxylamine hydrochloride or hydrazine hydrate)
 RN 128094-36-0 CAPLUS
 CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-(2-phenylethenyl)- (CA INDEX
 NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:511158 CAPLUS
 DOCUMENT NUMBER: 145:27976
 TITLE: Isoxazoline-indole derivatives with an improved
 antipsychotic and anxiolytic activity
 INVENTOR(S): Andres-Gil, Jose Ignacio; Bartolome-Nebreda, Jose
 Manuel; Alcazar-Vaca, Manuel Jesus; Garcia-Martin,
 Maria de las Mercedes; Megens, Antonius Adrianus
 Hendrikus Petrus
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006056600	A1	20060601	WO 2005-EP56229	20051125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005308778	A1	20060601	AU 2005-308778	20051125
CA 2585857	A1	20060601	CA 2005-2585857	20051125
EP 1819713	A1	20070822	EP 2005-816247	20051125
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101084225	A	20071205	CN 2005-80040127	20051125
JP 2008521771	T	20080626	JP 2007-541989	20051125
US 20080113988	A1	20080515	US 2007-791510	20070524
PRIORITY APPLN. INFO.:			EP 2004-106123	A 20041126
			WO 2005-EP56229	W 20051125
OTHER SOURCE(S):	MARPAT 145:27976			
GI				



- AB Title compds. I [X = CH₂, S, O, (un)substituted-N; V = S, O, NH, or NR₄ wherein R₄ = alkyl or covalent bond between the N and the (CH₂)_n moiety; R₁ and R₂ independently = H, halo, OH, aryl, etc.; R₃ = H, CN, halo, alkyl, etc.; q = 0-2; m = 0-3; n = 0-4; A = bivalent radical chosen from (un)substituted piperidinyl which is optionally partially unsatd. or (un)substituted alkyl amine], and their pharmaceutically acceptable salts are prepared and disclosed as having a binding affinity towards dopamine receptors, in particular towards dopamine D₂ and/or D₃ receptors, with selective serotonin reuptake inhibition (SSRI) properties and showing an affinity for the 5-HT_{1A} receptor. Thus, e.g., II was prepared by substitution of 3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazole-3-methanol methanesulfonate ester with 5-fluoro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole. In binding assays for 5-HT_{1A} receptor, I possessed pIC₅₀ values ranging from 6.0-8.9. Further disclosed are pharmaceutical compns. comprising I, the use thereof for the prevention and/or treatment of a range of psychiatric and neurol. disorders, in particular certain psychotic disorders, most in particular schizophrenia and processes for their production
- IT 888727-48-8P 888727-56-8P 888727-58-0P
888727-84-2P 888727-97-7P 888727-98-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of isoxazoline-indole derivs. with antipsychotic and anxiolytic activity)
- RN 888727-48-8 CAPLUS
- CN 1H-Indol-5-ol, 3-[1-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-, rel- (CA INDEX NAME)

10/513699


Relative stereochemistry.



RN 888727-56-8 CAPLUS

CN Ethanol, 2-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-, 1-acetate, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-58-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888727-84-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

3-[[3,6-dihydro-4-(1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 888727-97-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

3-[[4-(5-bromo-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888727-98-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

3-[[3,6-dihydro-4-(5-methoxy-1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 888727-46-6P 888727-47-7P 888727-49-9P
 888727-50-2P 888727-51-3P 888727-52-4P
 888727-53-5P 888727-54-6P 888727-55-7P
 888727-57-9P 888727-59-1P 888727-60-4P
 888727-61-5P 888727-62-6P 888727-63-7P
 888727-65-9P 888727-66-0P 888727-67-1P
 888727-68-2P 888727-69-3P 888727-70-6P
 888727-71-7P 888727-72-8P 888727-73-9P
 888727-74-0P 888727-75-1P 888727-76-2P
 888727-77-3P 888727-78-4P 888727-79-5P
 888727-80-8P 888727-81-9P 888727-82-0P
 888727-83-1P 888727-85-3P 888727-86-4P
 888727-87-5P 888727-88-6P 888727-89-7P
 888727-90-0P 888727-91-1P 888727-92-2P
 888727-93-3P 888727-94-4P 888727-95-5P
 888727-96-6P 888727-99-9P 888728-00-5P
 888728-01-6P 888728-02-7P 888728-03-8P
 888728-04-9P 888728-05-0P 888728-06-1P
 888728-08-3P 888728-09-4P 888728-10-7P
 888728-32-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of isoxazoline-indole derivs. with antipsychotic and anxiolytic
 activity)

RN 888727-46-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
 dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-47-7 CAPLUS

CN 1H-Indol-5-ol, 3-[1-[[[3R,3aS]-3a,4-dihydro-7,8-dimethoxy-3H-
 [1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-4-piperidinyl]-, rel- (CA
 INDEX NAME)


Relative stereochemistry.



RN 888727-49-9 CAPLUS

CN 1H-Indol-6-ol, 1-[1-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-4-piperidinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-50-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(5-methyl-1H-indol-3-yl)-1-piperidinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888727-51-3 CAPLUS

CN 1H-Indol-5-amine, 3-[1-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-4-piperidinyl]-, rel- (CA INDEX NAME)

10/513699

INDEX NAME)


Relative stereochemistry.



RN 888727-52-4 CAPLUS

CN Acetamide, N-[3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-4-piperidinyl]-1H-indol-5-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.




RN 888727-53-5 CAPLUS

CN Urea, N-[3-[1-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]-N'-ethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.






RN 888727-59-1 CAPLUS

CN Acetamide, N-[(3R,3aS)-3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.





RN 888727-60-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[5-[(2-methoxyethoxy)methoxy]-1H-indol-3-yl]-1-piperidinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 888727-61-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(5-phenyl-1H-indol-3-yl)-1-
piperidinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-62-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine,
N-[3-(5-fluoro-1H-indol-3-yl)propyl]-3a,4-dihydro-7,8-dimethoxy-,
(3R,3aS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 888727-63-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine,

10/513699

N-[3-(5-fluoro-1H-indol-3-yl)propyl]-3a,4-dihydro-7,8-dimethoxy-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-65-9 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-(1H-indol-3-yl)-1-piperidinyl]methyl]-7,8-dimethoxy-,
ethanedioate (1:1), (3R,3aS)-rel- (CA INDEX NAME)

CM 1

CRN 888727-64-8

CMF C26 H29 N3 O4

Relative stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 888727-66-0 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

<12/04/2007>

Erich Leese

3-[[4-(4-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-67-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-68-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)- (CA INDEX NAME)


Absolute stereochemistry.



10/513699


RN 888727-69-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3S,3aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 888727-70-6 CAPLUS
CN 3H-[1,4]Dioxino[2',3':6,7][1]benzopyrano[4,3-c]isoxazole,
3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4,8,9-tetrahydro-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-71-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-8-
methoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

10/513699




RN 888727-72-8 CAPLUS

CN Acetic acid, 2-ethoxy-, 2-[[[(3R,3aS)-3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 1-B



RN 888727-73-9 CAPLUS

CN Carbamic acid, ethyl-, 2-[[[(3R,3aS)-3-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



—NHet


RN 888727-74-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-
 dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-75-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-
 dimethoxy-, (3R,3aS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 888727-76-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3S,3aR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 888727-77-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-N-[2-(1-
pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888727-78-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7-(4-
morpholinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

10/513699


Relative stereochemistry.



RN 888727-79-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(7-fluoro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-80-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-chloro-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



<12/04/2007>


Erich Leese

10/513699

RN 888727-81-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-bromo-1H-indol-3-yl)-1-piperidinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-82-0 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-[1-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-4-piperidinyl]-, rel- (CA
INDEX NAME)


Relative stereochemistry.



RN 888727-83-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[3,6-dihydro-4-(1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 888727-85-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(4-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-86-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(4-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 888727-87-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(4-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-

10/513699

dihydro-7,8-dimethoxy-, (3R,3aS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 888727-88-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 888727-89-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3S,3aR)- (CA INDEX NAME)

Absolute stereochemistry.




10/513699

RN 888727-90-0 CAPLUS

CN 3H-[1,4]Dioxino[2',3':6,7][1]benzopyrano[4,3-c]isoxazole,
3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-
3a,4,8,9-tetrahydro-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-91-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-92-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-7-(4-morpholinyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888727-93-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888727-94-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A



—OMe


RN 888727-95-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
 dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888727-96-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-(5-chloro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
 dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888727-99-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[3,6-dihydro-4-(5-methyl-1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-
 dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888728-00-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[3,6-dihydro-4-(5-nitro-1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888728-01-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[3,6-dihydro-4-(5-phenyl-1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888728-02-7 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-[1-[[3,6-dihydro-4-(5-phenyl-1H-indol-3-yl)-1(2H)-pyridinyl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-

10/513699

, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888728-03-8 CAPLUS

CN Urea, N-[3-[1-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]-N'-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.





RN 888728-04-9 CAPLUS

CN Glycine, N-[[[3-[1-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]amino]carbonyl]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 888728-05-0 CAPLUS

CN Acetamide, N-[3-[1-[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]-2-methoxy-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888728-06-1 CAPLUS

CN Acetic acid, 2-[[3-[1-[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]amino]-2-oxo-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888728-08-3 CAPLUS

CN Methanesulfonamide, N-[3-[1-[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-

10/513699


[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-
1H-indol-5-yl]-, rel-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888728-07-2

CMF C27 H30 N4 O6 S

Relative stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 888728-09-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(5-fluoro-1H-indol-3-yl)methyl]-1-piperidinyl)methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



<12/04/2007>


Erich Leese

10/513699

RN 888728-10-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(6-fluoro-3-benzofuranyl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888728-32-3 CAPLUS


CN 1H-Indol-5-amine, 3-[1-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-
rel-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888728-31-2

CMF C26 H28 N4 O4

Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 452321-71-0


RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)

(preparation of isoxazoline-indole derivs. with antipsychotic and anxiolytic activity)

RN 452321-71-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-, 3-methanesulfonate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 888940-91-8P


RL: PUR (Purification or recovery); PREP (Preparation)

(preparation of isoxazoline-indole derivs. with antipsychotic and anxiolytic activity)

RN 888940-91-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-, 3-methanesulfonate, (3R,3aS)- (CA INDEX NAME)

Absolute stereochemistry.



10/513699

IT 888940-92-9P

RL: PUR (Purification or recovery); RCT (Reactant); PREP (Preparation);


RACT (Reactant or reagent)

(preparation of isoxazoline-indole derivs. with antipsychotic and anxiolytic activity)

RN 888940-92-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-, 3-methanesulfonate, (3S,3aR)- (CA INDEX NAME)

Absolute stereochemistry.



IT 452321-69-6


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of isoxazoline-indole derivs. with antipsychotic and anxiolytic activity)

RN 452321-69-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 452321-73-2P 888728-11-8P 888728-12-9P

888728-13-0P 888728-14-1P 888728-17-4P

888728-18-5P 888728-19-6P 888728-20-9P

888728-21-0P 888728-22-1P 888728-23-2P

888728-24-3P 888728-25-4P 888728-26-5P

888728-27-6P 888728-28-7P 888728-29-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of isoxazoline-indole derivs. with antipsychotic and anxiolytic activity)

10/513699


activity)
RN 452321-73-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol,
3a,4-dihydro-7-hydroxy-8-methoxy-, 3-methanesulfonate, (3R,3aS)-rel- (CA
INDEX NAME)

Relative stereochemistry.



RN 888728-11-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7,8-diol,
3a,4-dihydro-3-[(methylsulfonyl)oxy]methyl-, (3R,3aS)-rel- (CA INDEX
NAME)


Relative stereochemistry.



RN 888728-12-9 CAPLUS
CN 3H-[1,4]Dioxino[2',3':6,7][1]benzopyrano[4,3-c]isoxazole-3-methanol,
3a,4,8,9-tetrahydro-, 3-methanesulfonate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/513699



RN 888728-13-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxaldehyde,
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888728-14-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 7-bromo-3a,4-dihydro-,
3-propanoate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 888728-17-4 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 7-bromo-3a,4-dihydro-,
(3R,3aS)-rel- (CA INDEX NAME)

<12/04/2007>

Erich Leese

10/513699


Relative stereochemistry.



RN 888728-18-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-bromo-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-3a,4-dihydro-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888728-19-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-3a,4-dihydro-7-(4-morpholinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888728-20-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol,
3a,4-dihydro-7-(4-morpholinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

10/513699


Relative stereochemistry.



RN 888728-21-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol,
3a,4-dihydro-7-(4-morpholinyl)-, 3-methanesulfonate, (3R,3aS)-rel- (CA
INDEX NAME)


Relative stereochemistry.



RN 888728-22-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol,
3a,4-dihydro-8-hydroxy-7-methoxy-, 3-methanesulfonate, (3R,3aS)-rel- (CA
INDEX NAME)


Relative stereochemistry.



RN 888728-23-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol,
3a,4-dihydro-8-methoxy-7-[(2-methoxyethoxy)methoxy]-, 3-methanesulfonate,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888728-24-3 CAPLUS

CN Carbamic acid, ethyl-, 2-[[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-
[(methylsulfonyl)oxy]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-
yl]oxy]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10/513699

RN 888728-25-4 CAPLUS

CN Carbamic acid, [(3R,3aS)-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 888728-26-5 CAPLUS

CN Carbamic acid, [(3R,3aS)-3a,4-dihydro-3-(hydroxymethyl)-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 888728-27-6 CAPLUS

CN Carbamic acid, [(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[[(methylsulfonyl)oxy]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 888728-28-7 CAPLUS

CN Carbamic acid, [3-[1-[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indol-5-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 888728-29-8 CAPLUS

CN Carbamic acid, [(3R,3aS)-3-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/513699

<12/04/2007>

Erich Leese

L7 ANSWER 7 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:505909 CAPLUS

DOCUMENT NUMBER: 145:95782

TITLE: Synthesis of 7-amino-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazole derivatives displaying combined α 2-adrenoceptor antagonistic and 5-HT reuptake inhibiting activities

AUTHOR(S): Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.; De Lucas, Ana I.; Iturrino, Laura; Biesmans, Ilse; Megens, Anton A.

CORPORATE SOURCE: Medicinal Chemistry Department, Division of Janssen-Cilag, Johnson & Johnson Pharmaceutical Research and Development, Toledo, 45007, Spain

SOURCE: Bioorganic & Medicinal Chemistry (2006), 14(13), 4361-4372

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:95782

AB Following a program searching for dual 5-HT reuptake inhibitors and α 2-adrenoceptor antagonists started at Johnson & Johnson Pharmaceutical Research & Development, we now report on the synthesis of a series of 7-amino-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazole derivs., some of which proved to be the most potent α 2-adrenoceptor blockers within this chemical class of tricyclic isoxazolines, while keeping potent 5-HT reuptake inhibiting activity.

IT 612074-52-9P 612074-56-3P 612074-57-4P
612074-68-7P 612074-81-4P 612074-88-1P
612074-89-2P 612074-90-5P 612074-92-7P
612074-93-8P 612074-94-9P 612074-95-0P
612074-98-3P 612074-99-4P 612075-02-2P
612075-03-3P 612075-07-7P 612075-09-9P
612075-10-2P 612075-11-3P 612075-12-4P
612075-13-5P 612075-15-7P 612075-88-4P
770707-27-2P 895169-63-8P 895169-64-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(benzopyranoisoxazole derivs. displaying combined α 2-adrenoceptor antagonistic and 5-HT reuptake inhibiting activities)

RN 612074-52-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-56-3 CAPLUS

CN Acetamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-57-4 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-[(3,4-dimethoxyphenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 612074-68-7 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-ethyl-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-81-4 CAPLUS
CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-88-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-phenyl-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-89-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,


3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-phenyl-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-90-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
N-(4-fluorophenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-92-7 CAPLUS
CN Benzonitrile, 3-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-93-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-N-(2-methylphenyl)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-94-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
N-(3,4-dimethylphenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-95-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-

piperazinyl)methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-98-3 CAPLUS

CN Propanamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2,2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-99-4 CAPLUS

CN Cyclopropanecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




10/513699

RN 612075-02-2 CAPLUS

CN 2-Propenamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-03-3 CAPLUS

CN Benzamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-07-7 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-ethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-09-9 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(1,1-dimethylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-10-2 CAPLUS

CN Urea, N-cyclohexyl-N'-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 612075-11-3 CAPLUS

CN Glycine, N-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]carbonyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-12-4 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-phenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-13-5 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(3-fluorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




10/513699

RN 612075-15-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-88-4 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 770707-27-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 895169-63-8 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 895169-64-9 CAPLUS

CN Ethanol, 2-[[[(3S,3aR)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 452318-26-2 452319-41-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(benzopyranoisoxazole derivs. displaying combined α 2-adrenoceptor
antagonistic and 5-HT reuptake inhibiting activities)

RN 452318-26-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-41-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT 452319-29-8P 612074-55-2P 612075-92-0P

612075-94-2P 888728-17-4P 895169-59-2P

895169-61-6P 895169-62-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)


(benzopyranoisoxazole derivs. displaying combined α 2-adrenoceptor
antagonistic and 5-HT reuptake inhibiting activities)

RN 452319-29-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 612074-55-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-92-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid,
7-fluoro-3a,4-dihydro-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 612075-94-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 7-fluoro-3a,4-dihydro-,
3-methanesulfonate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 888728-17-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 7-bromo-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 895169-59-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 7-bromo-3a,4-dihydro-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 895169-61-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 7-bromo-3a,4-dihydro-, 3-methanesulfonate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/513699



RN 895169-62-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-bromo-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:153487 CAPLUS
 DOCUMENT NUMBER: 144:390804
 TITLE: Novel approach towards the synthesis of
 3,3a,4,5-tetrahydroquinolino[4,3-c]isoxazole
 derivatives: application to the preparation of
 previously unattainable
 3a,4-dihydroazabenzopyrano[4,3-c]isoxazole scaffolds
 AUTHOR(S): Alcazar, Jesus; Alonso, Jose Manuel; Andres, Jose
 Ignacio; Bartolome, Jose Manuel; Fernandez, Javier
 CORPORATE SOURCE: Johnson and Johnson Pharmaceutical Research and
 Development, Toledo, 45007, Spain
 SOURCE: Synlett (2005), (20), 3139-3141
 CODEN: SYNLES; ISSN: 0936-5214
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 144:390804
 AB A novel synthetic approach towards the preparation of 3-substituted
 7,8-dimethoxy-3,3a,4,5-tetrahydroquinolino[4,3-c]isoxazole derivs. is
 reported. Further application of this methodol. to the preparation of
 previously unattainable 3a,4-dihydroazabenzopyrano[4,3-c]isoxazole derivs.
 is also described.
 IT 882694-35-1P 882694-38-4P 882694-40-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of tetrahydroquinolinoisoxazoles and
 dihydroazabenzopyranoisoxazoles)
 RN 882694-35-1 CAPLUS
 CN Isoxazolo[4,3-c]quinoline-3-methanol, 3,3a,4,5-tetrahydro-7,8-dimethoxy-,
 3-methanesulfonate, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 882694-38-4 CAPLUS
 CN 3H-Isoxazolo[3',4':4,5]pyrano[2,3-c]pyridine-3-methanol, 3a,4-dihydro-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/513699



RN 882694-40-8 CAPLUS

CN 3H-isoxazolo[3',4':4,5]pyrano[2,3-b]pyridine-3-methanol, 3a,4-dihydro-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:920735 CAPLUS

DOCUMENT NUMBER: 142:219240

TITLE: Discovery of a New Series of Centrally Active Tricyclic Isoxazoles Combining Serotonin (5-HT) Reuptake Inhibition with α 2-Adrenoceptor Blocking Activity

AUTHOR(S): Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.; Alvarez, Rosa M.; Bakker, Margot H.; Biesmans, Ilse; Cid, Jose M.; De Lucas, Ana I.; Fernandez, Javier; Font, Luis M.; Hens, Koen A.; Iturrino, Laura; Lenaerts, Ilse; Martinez, Sonia; Megens, Anton A.; Pastor, Joaquin; Vermote, Patrick C. M.; Steckler, Thomas

CORPORATE SOURCE: Johnson Johnson Pharmaceutical Research Development Division of Janssen-Cilag Medicinal Chemistry dept., Jarama s/n, Toledo, 45007, Spain

SOURCE: Journal of Medicinal Chemistry (2005), 48(6), 2054-2071

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:219240

AB The synthesis and pharmacol. of a new series of 3-piperazinylmethyl-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles that combine central serotonin (5-HT) reuptake inhibition with α 2-adrenoceptor blocking activity is described as potential antidepressants. Four compds. were selected for further evaluation, and the combination of both activities was found to be stereoselective, residing mainly in one enantiomer. Reversal of the loss of righting induced by the α 2-agonist medetomidine in rats confirmed the α 2-adrenoceptor blocking activity in vivo and also demonstrated CNS penetration. Antagonism of p-chloroamphetamine (PCA)-induced excitation as well as blockade of the neuronal 5-HT depletion induced by p-CA administration in rats confirmed their ability to block the central 5-HTT, even after oral administration. Replacement of the oxygen atom at the 5-position of the tricyclic scaffold by a nitrogen or a carbon atom, as well as O-substitution at position 7, led also to active compds., both in vitro and in vivo.

IT 452313-54-1P 452318-20-6P 452318-95-5P
608146-13-0P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α 2-adrenoceptor blocking activity)

RN 452313-54-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.


Double bond geometry as shown.



RN 452318-20-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-95-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.




RN 608146-13-0 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.




IT 452319-41-4
RL: PAC (Pharmacological activity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α 2-adrenoceptor blocking activity)
RN 452319-41-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452313-65-4P 452319-33-4P 452320-36-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α 2-adrenoceptor blocking activity)
RN 452313-65-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-33-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-36-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-
propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT 452313-36-9P 452313-59-6P 452313-77-8P
 452318-26-2P 452318-93-3P 452319-43-6P
 452319-55-0P 452319-57-2P 452319-59-4P
 452319-61-8P 452319-63-0P 452319-65-2P
 452319-67-4P 452319-69-6P 452319-71-0P
 452320-40-0P 452320-52-4P 452320-54-6P
 452320-60-4P 452320-62-6P 452320-64-8P

10/513699

452320-66-0P 452320-70-6P 452321-33-4P
452321-35-6P 452321-37-8P 452321-39-0P
452321-41-4P 789484-08-8P 815632-62-3P
815632-63-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(preparation of centrally active tricyclic isoxazoles combining 5-HT
reuptake inhibition with α 2-adrenoceptor blocking activity)

RN 452313-36-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452313-59-6 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-(2-
naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452313-77-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452318-26-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-93-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-43-6 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-(2-methoxyethoxy)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-55-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-57-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 7-propanoate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-59-4 CAPLUS

CN Acetic acid, 2-methoxy-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-61-8 CAPLUS

CN Cyclopropanecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-63-0 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




10/513699

RN 452319-65-2 CAPLUS

CN 2-Propenoic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-67-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopentyloxy)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-69-6 CAPLUS

CN 4-Pyridinecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-71-0 CAPLUS

CN Ethanamine, 2-[[{(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-(1-benzopyrano[4,3-c]isoxazol-7-yl]oxy]-N,N-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-40-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-52-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-[(2E)-3-

10/513699


phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-54-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-5-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-60-4 CAPLUS
CN Ethanone, 1-[(3R,3aR)-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]isoxazolo[4,3-c]quinolin-5(3H)-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-62-6 CAPLUS

CN Ethanone, 1-[(3R,3aR)-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]isoxazolo[4,3-c]quinolin-5(3H)-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-64-8 CAPLUS

CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxylic acid, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, ethyl ester, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-66-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxamide, N-ethyl-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-70-6 CAPLUS

CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452321-33-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452321-35-6 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

10/513699




RN 452321-37-8 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452321-39-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452321-41-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

10/513699

Relative stereochemistry.




RN 789484-08-8 CAPLUS

CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 815632-62-3 CAPLUS

CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 815632-63-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-[2-(2-ethoxyethoxy)ethoxy]-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

10/513699

Double bond geometry as shown.



IT 452313-56-3P 452318-24-0P 452318-97-7P

608146-12-9P

RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)


(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α 2-adrenoceptor blocking activity)

RN 452313-56-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)-rel(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

Double bond geometry as shown.




RN 452318-24-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)-rel(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.


Double bond geometry as shown.



RN 452318-97-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 608146-12-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



IT 452321-71-0P 452321-75-4P 452321-82-3P
452322-05-3P 452322-07-5P 452322-09-7P

10/513699

452322-19-9P 452322-21-3P 452322-23-5P

608146-04-9P 815632-58-7P 815632-59-8P

815632-60-1P 815632-61-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of centrally active tricyclic isoxazoles combining 5-HT
reuptake inhibition with $\alpha 2$ -adrenoceptor blocking activity)

RN 452321-71-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-,
3-methanesulfonate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-75-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel- (CA
INDEX NAME)

Relative stereochemistry.




RN 452321-82-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-, 1,1-dimethylethyl ester, rel-
(CA INDEX NAME)

Relative stereochemistry.


10/513699



RN 452322-05-3 CAPLUS

CN Isoxazolo[4,3-c]quinoline-3-carboxylic acid,
3,3a,4,5-tetrahydro-5-((2,2,2-trifluoroacetyl)-, methyl ester,
(3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-07-5 CAPLUS

CN Isoxazolo[4,3-c]quinoline-3-methanol, 3,3a,4,5-tetrahydro-, (3R,3aR)-rel-
(CA INDEX NAME)


Relative stereochemistry.



RN 452322-09-7 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-(chloromethyl)-3,3a,4,5-tetrahydro-,
(3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-19-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aR)-3,3a,4,5-tetrahydro-7,8-dimethoxy-5-(2,2,2-trifluoroacetyl)isoxazolo[4,3-c]quinolin-3-yl)methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-21-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aR)-3,3a,4,5-tetrahydro-7,8-dimethoxyisoxazolo[4,3-c]quinolin-3-yl)methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452322-23-5 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aR)-rel- (CA INDEX NAME)

10/513699


Relative stereochemistry.



RN 608146-04-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid,
3a,4-dihydro-7,8-dimethoxy-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 815632-58-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aR)-3,3a,4,5-tetrahydronaphth[1,2-c]isoxazol-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 815632-59-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aR)-3,3a,4,5-tetrahydro-7-methoxynaphth[1,2-c]isoxazol-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

10/513699


Relative stereochemistry.



RN 815632-60-1 CAPLUS

CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-(1-piperazinylmethyl)-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 815632-61-2 CAPLUS

CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-(1-piperazinylmethyl)-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

41

THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:760314 CAPLUS

DOCUMENT NUMBER: 141:384410

TITLE: A screening strategy for the development of enantiomeric separation methods in capillary electrophoresis

AUTHOR(S): Jimidar, M. Ilias; van Ael, Willy; van Nyen, Patrick; Peeters, Margot; Redlich, Dirk; de Smet, Maurits

CORPORATE SOURCE: Pharmaceutical Research & Development (J&J-PRD) A division of Janssen Pharmaceutica n.v., Global Analytical Development, Johnson and Johnson, Beerse, Belg.

SOURCE: Electrophoresis (2004), 25(16), 2772-2785

CODEN: ELCTDN, ISSN: 0173-0835

PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Method development of enantiomeric sepns. in capillary electrophoresis (CE) is a time-consuming task, since finding the appropriate chiral selector is usually a "trial and error" process. It is impossible to predict the selectivity of a selector towards a certain enantiomer. Therefore, the affinity of all selectors has to be examined one at a time. In order to speed up this process, a strategy is proposed based on simple exptl. design methodol. The approach includes first a screening in function of the pH to determine the optimal migration conditions followed by a selection of the right chiral selector by means of Taguchi designs. In the approach several variables, such as the type and concentration of cyclodextrin, the concentration of buffer electrolyte, and the percentage of organic modifier, are varied simultaneously to find initial separation conditions rapidly. The resulting initial separation conditions can be optimized in further steps to be more reproducible. We discuss the results of the approach when applied on a number of selected compds. that are recently in development at Johnson & Johnson - Pharmaceutical Research and Development. Parameters, such as quality of the separation and anal. time, are evaluated to determine initial separation conditions for each compound

IT 452318-73-9

RL: ANT (Analyte); ANST (Analytical study)


(screening strategy for development of enantiomeric separation methods in capillary electrophoresis)

RN 452318-73-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:362586 CAPLUS
 DOCUMENT NUMBER: 141:123602
 TITLE: Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HT uptake inhibiting and α 2-adrenoceptor antagonistic activities. Part 2: Further exploration on the cinnamyl moiety
 AUTHOR(S): Pastor, Joaquin; Alcazar, Jesus; Alvarez, Rosa M.; Andres, J. Ignacio; Cid, Jose M.; De Lucas, Ana I.; Diaz, Adolfo; Fernandez, Javier; Font, Luis M.; Iturrino, Laura; Lafuente, Celia; Martinez, Sonia; Bakker, Margot H.; Biesmans, Ilse; Heylen, Lieve I.; Megens, Anton A.
 CORPORATE SOURCE: Division of Janssen-Cilag, Medicinal Chemistry Department, Johnson & Johnson Pharmaceutical Research & Development, Toledo, 45007, Spain
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(11), 2917-2922
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:123602
 AB The synthesis of a series of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, as novel dual 5-HT reuptake inhibitors and α 2-adrenoceptor antagonists is reported.
 IT 452313-36-9P 452313-85-8P 452316-95-9P
 452316-97-1P 452318-26-2P 452318-71-7P
 452318-73-9P 452318-77-3P 452318-83-1P
 452318-87-5P 452318-93-3P 452319-01-6P
 452319-03-8P 452319-07-2P 452319-09-4P
 452320-98-8P 452321-14-1P 452321-21-0P
 452321-29-8P 452321-31-2P 722545-47-3P
 722545-48-4P 722545-55-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as combined 5-HT uptake inhibitors and α 2-adrenoceptor antagonists)
 RN 452313-36-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452313-85-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452316-95-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452316-97-1 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-26-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-71-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-73-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
 NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-77-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-methyl-2-
 propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



10/513699


RN 452318-83-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2,5-difluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-87-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2,3-difluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452318-93-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.

10/513699




RN 452319-01-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-03-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-07-2 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2-furanyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-09-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-pyridinyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-98-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452321-14-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452321-21-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2,4-difluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452321-29-8 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-thienyl)-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-31-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2-furanyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 722545-47-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

10/513699




RN 722545-48-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 722545-55-3 CAPLUS

CN Phenol, 4-[(1E)-3-[[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-methyl-1-
propen-1-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT 452321-75-4

<12/04/2007>


Erich Leese

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as combined 5-HT uptake inhibitors and α_2 -adrenoceptor antagonists)

RN 452321-75-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel- (CA
 INDEX NAME)

Relative stereochemistry.




IT 452321-85-6P 452321-97-0P 452321-99-2P
 722545-56-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as combined 5-HT uptake inhibitors and α_2 -adrenoceptor antagonists)

RN 452321-85-6 CAPLUS

CN 2-Propanone, 1-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-, rel- (CA
 INDEX NAME)

Relative stereochemistry.




RN 452321-97-0 CAPLUS

CN 1,2-Propanediol, 3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-, rel- (CA
 INDEX NAME)

Relative stereochemistry.


10/513699



RN 452321-99-2 CAPLUS

CN 1-Piperazineacetaldehyde, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 722545-56-4 CAPLUS

CN Phosphonic acid, [2-[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-2-oxoethyl]-, diethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 722545-57-5P 722545-58-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as combined 5-HT uptake inhibitors and

10/513699


α 2-adrenoceptor antagonists)

RN 722545-57-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-penten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 722545-58-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(3,3-diphenyl-2-propen-1-yl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT:

15

THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:182890 CAPLUS
 DOCUMENT NUMBER: 140:217631
 TITLE: Preparation of fused heterocyclic isoxazoline derivatives as anti-depressants
 INVENTOR(S): Andres-Gil, Jose Ignacio; Alcazar-Vaca, Manuel Jesus; Bartolome-Nebreda, Jose Manuel; Fernandez-Gadea, Francisco Javier; Bakker, Margaretha Henrica Maria; Megens, Antonius Adrianus Hendrikus Petrus
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018483	A1	20040304	WO 2003-EP50377	20030813
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SJ, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2494557	A1	20040304	CA 2003-2494557	20030813
AU 2003262573	A1	20040311	AU 2003-262573	20030813
EP 1554286	A1	20050720	EP 2003-792431	20030813
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1675224	A	20050928	CN 2003-819462	20030813
JP 2005538144	T	20051215	JP 2004-530272	20030813
US 20060116378	A1	20060601	US 2005-524123	20050210
PRIORITY APPLN. INFO.:			EP 2002-78373	A 20020815
			WO 2003-EP50377	W 20030813
OTHER SOURCE(S):	MARPAT 140:217631			
GI				



II

AB The invention concerns fused heterocyclic isoxazoline derivs. of formula I [X = CH₂, (substituted) NH, S, O; Y = (substituted) heterocyclic ring; Z = (substituted) piperazine, piperidinemethylamine, etc.; R = alkylene-aromatic ring, etc.; m = 1-4], the pharmaceutically acceptable salts thereof, the stereochem. isomeric forms thereof and the N-oxide form thereof, more in particular, tetrahydropyranoisoxazole, hexahydroisoxazolopyridine, tetrahydrothiopyrano isoxazole and hexahydrobenzoisoxazole derivs. fused to a heterocyclic ring system via the 6-membered ring of the bicyclic moiety, as well as processes for their preparation, pharmaceutical compns. comprising them and their use as a medicine, in particular for treating depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders including anorexia nervosa and bulimia. The compds. have been shown to have selective serotonin (5-HT) reuptake inhibitor activity as well as α_2 -adrenoceptor antagonist activity. Thus, II was prepared, and had pIC₅₀ if 8.4 in 5-HT transporter binding experiment

IT 666233-82-5P


RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(preparation of fused heterocyclic isoxazoline derivs. as antidepressants)

RN 666233-82-5 CAPLUS


CN 3H,7H-Isloxazolo[3',4':4,5]pyrano[3,2-f]indole-7-ethanol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




IT 666233-90-5P 666233-91-6P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of fused heterocyclic isoxazoline derivs. as antidepressants)
 RN 666233-90-5 CAPLUS
 CN 3H,7H-Isloxazolo[3',4':4,5]pyrano[3,2-f]indole-7-ethanol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperaziny]methyl]-, (3S,3aR)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 666233-91-6 CAPLUS
 CN 3H,7H-Isloxazolo[3',4':4,5]pyrano[3,2-f]indole-7-ethanol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperaziny]methyl]-, (3R,3aS)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



IT 666233-75-6P 666233-84-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of fused heterocyclic isoxazoline derivs. as antidepressants)
 RN 666233-75-6 CAPLUS
 CN 3H,4H-Isloxazolo[3',4':4,5]pyrano[3,2-f]indole, 3a,7-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperaziny]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 666233-84-7 CAPLUS

CN 3H,7H-Isloxazolo[3',4':4,5]pyrano[3,2-f]indole-7-acetic acid,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, methyl ester, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 666233-76-7P 666233-77-8P 666233-78-9P
666233-79-0P 666233-80-3P 666233-81-4P
666233-83-6P 666233-85-8P 666233-86-9P
666233-87-0P 666233-88-1P 666233-89-2P
666233-93-8P 666233-95-0P 666233-96-1P
666233-98-3P 666234-00-0P 666234-02-2P
666234-03-3P 666234-04-4P 666234-05-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused heterocyclic isoxazoline derivs. as antidepressants)

RN 666233-76-7 CAPLUS

CN 3H,4H-Isloxazolo[3',4':4,5]pyrano[3,2-f]indole,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,7-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 666233-77-8 CAPLUS

CN 3H,4H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,7-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 666233-78-9 CAPLUS

CN 3H,4H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole,
3a,7-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 666233-79-0 CAPLUS

CN 3H,4H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole,
3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3a,7-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 666233-80-3 CAPLUS


CN 3H,4H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole,
3a,7-dihydro-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 666233-81-4 CAPLUS
CN 3H,4H-Isioxazolo[3',4':4,5]pyrano[3,2-f]indole,
3a,7-dihydro-7-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 666233-83-6 CAPLUS
CN 3H,4H-Isioxazolo[3',4':4,5]pyrano[3,2-f]indole,
3a,7-dihydro-7-[(2-methoxyethoxy)methyl]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 666233-85-8 CAPLUS
CN Ethanone, 1-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H,7H-isioxazolo[3',4':4,5]pyrano[3,2-f]indol-7-yl]-, rel- (CA INDEX NAME)


10/513699

Relative stereochemistry.
Double bond geometry as shown.




RN 666233-86-9 CAPLUS
CN Methanone, cyclopropyl[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H,7H-isoxazolo[3',4':4,5]pyrano[3,2-f]indol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 666233-87-0 CAPLUS
CN 3H,7H-Isioxazolo[3',4':4,5]pyrano[3,2-f]indole-7-carboxylic acid, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, methyl ester, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 666233-88-1 CAPLUS
CN Ethanone, 1-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H,7H-isoxazolo[3',4':4,5]pyrano[3,2-f]indol-7-yl]-2-methoxy-, rel- (CA INDEX NAME)


10/513699

Relative stereochemistry.
Double bond geometry as shown.



RN 666233-89-2 CAPLUS
CN 3H,4H-Isioxazolo[3',4':4,5]pyrano[3,2-f]indole,
7-ethyl-3a,7-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 666233-93-8 CAPLUS
CN 3H-Isioxazolo[3',4':4,5]pyrano[2,3-c]pyridine,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, ethanedioate (1:1), (3R,3aS)-rel- (CA INDEX NAME)

CM 1

CRN 666233-92-7
CMF C24 H28 N4 O2

Relative stereochemistry.
Double bond geometry as shown.



<12/04/2007>

Erich Leese

10/513699

CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 666233-95-0 CAPLUS


CN 3H-Isloxazolo[3',4':4,5]pyrano[2,3-c]pyridine,
3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinylmethyl]-,
ethanedioate (1:1), (3R,3aS)-rel- (CA INDEX NAME)

CM 1

CRN 666233-94-9

CMF C25 H26 N4 O2

Relative stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 666233-96-1 CAPLUS

CN 3H-Isloxazolo[3',4':4,5]pyrano[2,3-c]pyridine,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinylmethyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.

<12/04/2007>

Erich Leese

10/513699




RN 666233-98-3 CAPLUS
CN 3H-Isloxazolo[3',4':4,5]pyrano[2,3-c]pyridine,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-, ethanedioate (1:1), (3R,3aS)-rel- (CA
INDEX NAME)

CM 1

CRN 666233-97-2
CMF C24 H27 F N4 O2

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 666234-00-0 CAPLUS
CN 3H-Isloxazolo[3',4':4,5]pyrano[2,3-b]pyridine,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, ethanedioate (1:1), (3R,3aS)-rel- (CA INDEX NAME)


CM 1

CRN 666233-99-4

10/513699

CMF C24 H28 N4 O2

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 666234-02-2 CAPLUS


CN 3H-Isloxazolo[3',4':4,5]pyrano[3,2-b]pyridine,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, ethanedioate (1:2), (3R,3aS)-rel- (CA INDEX NAME)

CM 1

CRN 666234-01-1

CMF C24 H28 N4 O2

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7

CMF C2 H2 O4

<12/04/2007>


Erich Leese

10/513699




RN 666234-03-3 CAPLUS
CN 3H-Isioxazolo[3',4':4,5]pyrano[3,2-b]pyridine,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 666234-04-4 CAPLUS
CN 3H-Isioxazolo[3',4':4,5]pyrano[3,2-b]pyridine,
3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 666234-05-5 CAPLUS
CN 3H-Isioxazolo[3',4':4,5]pyrano[3,2-b]pyridine,
3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



IT 666234-10-2P 666234-11-3P 666234-12-4P
 666234-18-0P 666234-19-1P 666234-20-4P
 666234-24-8P 666234-25-9P 666234-31-7P
 666234-32-8P 666234-33-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of fused heterocyclic isoxazoline derivs. as antidepressants)
 RN 666234-10-2 CAPLUS
 CN 3H,4H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole-3-carboxylic acid,
 7-(2,2-dimethyl-1-oxopropyl)-3a,7-dihydro-, ethyl ester (CA INDEX NAME)




RN 666234-11-3 CAPLUS
 CN 3H,4H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole-3-methanol, 3a,7-dihydro-
 (CA INDEX NAME)




RN 666234-12-4 CAPLUS
 CN 3H,4H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole-3-methanol, 3a,7-dihydro-,
 3-methanesulfonate (CA INDEX NAME)

10/513699




RN 666234-18-0 CAPLUS

CN 3H-Isloxazolo[3',4':4,5]pyrano[2,3-c]pyridine-3-methanol, 3a,4-dihydro-
(CA INDEX NAME)




RN 666234-19-1 CAPLUS

CN 3H-Isloxazolo[3',4':4,5]pyrano[2,3-c]pyridine-3-methanol, 3a,4-dihydro-,
3-methanesulfonate (CA INDEX NAME)



RN 666234-20-4 CAPLUS


CN 3H-Isloxazolo[3',4':4,5]pyrano[2,3-c]pyridine,
3-(bromomethyl)-3a,4-dihydro- (CA INDEX NAME)



RN 666234-24-8 CAPLUS


10/513699

CN 3H-Isloxazolo[3',4':4,5]pyrano[2,3-b]pyridine-3-methanol, 3a,4-dihydro-
(CA INDEX NAME)




RN 666234-25-9 CAPLUS

CN 3H-Isloxazolo[3',4':4,5]pyrano[2,3-b]pyridine,
3-(bromomethyl)-3a,4-dihydro- (CA INDEX NAME)



RN 666234-31-7 CAPLUS


CN 3H-Isloxazolo[3',4':4,5]pyrano[3,2-b]pyridine-3-carboxylic acid,
3a,4-dihydro-, ethyl ester (CA INDEX NAME)



RN 666234-32-8 CAPLUS


CN 3H-Isloxazolo[3',4':4,5]pyrano[3,2-b]pyridine-3-methanol, 3a,4-dihydro-
(CA INDEX NAME)

10/513699



RN 666234-33-9 CAPLUS

CN 3H-Isioxazolo[3',4':4,5]pyrano[3,2-b]pyridine-3-methanol, 3a,4-dihydro-,
3-methanesulfonate (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:182889 CAPLUS
 DOCUMENT NUMBER: 140:235700
 TITLE: Preparation of chromenoisoxazole derivatives and their
 use as anti-depressants
 INVENTOR(S): Andres-Gil, Jose Ignacio; Alcazar-Vaca, Manuel Jesus;
 Matesanz-Ballesteros, Maria Encarnacion; Bakker,
 Margaretha Henrica Maria; Megens, Antonius Adrianus
 Hendrikus Petrus
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018482	A2	20040304	WO 2003-EP9532	20030819
WO 2004018482	A3	20040401		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2495058	A1	20040304	CA 2003-2495058	20030819
AU 2003271567	A1	20040311	AU 2003-271567	20030819
EP 1532155	A2	20050525	EP 2003-753363	20030819
EP 1532155	B1	20080227		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005538143	T	20051215	JP 2004-530256	20030819
AT 387455	T	20080315	AT 2003-753363	20030819
ES 2301816	T3	20080701	ES 2003-753363	20030819
US 20060122167	A1	20060608	US 2005-524989	20050218
PRIORITY APPLN. INFO.:			EP 2002-78844	A 20020821
			WO 2003-EP9532	W 20030819

OTHER SOURCE(S): MARPAT 140:235700
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = CH₂, NR₇, S or O; R₇ = H, alkyl, (un)substituted-aryl, -arylalkyl; R₁, R₂, R₁₄, R₁₅ = independently H, halo, OH, alkyloxy, CN, etc.; m = 1-4; R₃ = (un)substituted aromatic homocyclic or heterocyclic ring; R₈ = independently OH, amino, nitro, CN, halo, or alkyl; n = 0-5; R₉ = H, alkyl, or formyl], a process for their preparation, pharmaceutical compds. comprising them and their use as a

medicine, in particular for the treatment of depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders is disclosed. Thus, e.g., II, was prepared by substitution of 6-bromo-7,8-dimethoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole (preparation given) with N-methylpiperazine. The compds. according to the invention have surprisingly been shown to have a serotonin (5-HT) reuptake inhibitor activity in combination with addnl. α 2-adrenoceptor antagonist activity and show a strong anti-depressant activity without being sedative. I produced an inhibition at least at the α 2A site (but often at the α 2B and α 2C sites) and simultaneously at the 5-HT transporter site of more than 50 % (pIC50) at a test concentration ranging between 10^{-6} M and 10^{-9} M in a concentration-dependent manner. The invention also relates to novel combination of isoxazoline derivs. according to the invention with one or more other compds. selected from the group of antidepressants, anxiolytics, anti-psychotics and anti-Parkinson's disease drugs to improve efficacy and/or onset of action.

IT 667454-35-5P 667454-39-9P 667454-52-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of chromenoisoxazole derivs. as antidepressants)

RN 667454-35-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
6-bromo-3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 667454-39-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-6-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.




RN 667454-52-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-6-iodo-7,8-dimethoxy-, (3R,3aS)-rel- (CA
 INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



IT 667454-36-6P 667454-37-7P 667454-38-8P
 667454-40-2P 667454-41-3P 667454-42-4P
 667454-43-5P 667454-44-6P 667454-45-7P
 667454-46-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (drug candidate; preparation of chromenoisoxazole derivs. as
 antidepressants)
 RN 667454-36-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 6-(4-bromo-1-piperazinyl)-3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-
 3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX
 NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 667454-37-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-6-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 667454-38-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-6-carboxylic acid,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 667454-40-2 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazol-6-ol,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 667454-41-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-6-amine,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-N-4-pyridinyl-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 667454-42-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-9-ol,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 667454-43-5 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-6-yl]oxy]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 667454-44-6 CAPLUS

CN Acetic acid, 2-methoxy-, 2-[[[(3S,3aR)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-6-yl]oxy]ethyl ester, rel-(-) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

Double bond geometry as shown.




RN 667454-45-7 CAPLUS

CN Acetic acid, 2-methoxy-, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-6-yl]oxy]ethyl ester, rel-(+) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.

Double bond geometry as shown.




RN 667454-46-8 CAPLUS

CN Carbamic acid, ethyl-, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-9-yl]oxy]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT 452321-71-0P


RL: PEP (Physical, engineering or chemical process); PUR (Purification or recovery); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)

(intermediate; preparation of chromenoisoxazole derivs. as antidepressants)

RN 452321-71-0 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-, 3-methanesulfonate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 452321-67-4P 452321-69-6P 667454-47-9P
 667454-49-1P 667454-50-4P 667454-51-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of chromenoisoxazole derivs. as antidepressants)
 RN 452321-67-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid,
 3a,4-dihydro-7,8-dimethoxy-, methyl ester, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-69-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/513699



RN 667454-47-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol,
6-bromo-3a,4-dihydro-7,8-dimethoxy-, 3-methanesulfonate, (3R,3aS)-rel-
(CA INDEX NAME)


Relative stereochemistry.



RN 667454-49-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid,
3a,4-dihydro-6-methoxy-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 667454-50-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-6-methoxy-,
(3R,3aS)-rel- (CA INDEX NAME)

10/513699


Relative stereochemistry.



RN 667454-51-5 CAPLUS



CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-6-methoxy-,
3-methanesulfonate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 14 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:162696 CAPLUS
 DOCUMENT NUMBER: 140:217662
 TITLE: Preparation of piperazinylalkylchromenoisoxazolines as antidepressants.
 INVENTOR(S): Andres-gil, Jose Ignacio; Bartolome-nebreda, Jose Manuel; Alvarez-escobar, Rosa Maria; Bakker, Margaretha Henrica Maria; Megens, Antonius Adrianus Hendrikus Petrus
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004016621	A1	20040226	WO 2003-EP50374	20030812
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2494235	A1	20040226	CA 2003-2494235	20030812
AU 2003262571	A1	20040303	AU 2003-262571	20030812
EP 1537124	A1	20050608	EP 2003-787817	20030812
EP 1537124	B1	20070801		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1675222	A	20050928	CN 2003-819483	20030812
CN 1329396	C	20070801		
JP 2005537304	T	20051208	JP 2004-528523	20030812
AT 368669	T	20070815	AT 2003-787817	20030812
ES 2290537	T3	20080216	ES 2003-787817	20030812
US 20050256119	A1	20051117	US 2005-524197	20050210
PRIORITY APPLN. INFO.:			EP 2002-78322	A 20020812
			WO 2003-EP50374	W 20030812
OTHER SOURCE(S):	MARPAT 140:217662			
GI				



AB Title compds. [I; X = CH₂, NR₇, S, O; R₇ = H, alkyl aryl, aralkyl, alkylcarbonyl, alkoxy carbonyl, aminocarbonyl; R₁, R₂ = H, halo, OH, OSO₂H, OSO₂Me, alkoxy, alkyl, aryl, heterocyclyl, etc.; R₁R₂ = (CH₂)₄, CH:CHCH₂CH₂, CH:CHCH:CH, etc.; Pir = (substituted) piperazinyl, aminomethylpiperidinyl; m = 1-4; R₃ = (substituted) (unsatd.) alkylaryl, alkylheteroaryl; with provisos], were prepared Thus, title compound (II) (preparation via intramol. nitrile oxide cycloaddn. given) bound to human platelet 5-HT transporter protein with pIC₅₀ = 7.7.

IT 1055723-13-1 1055723-14-2


RL: PRPH (Prophetic)

(Preparation of piperazinylalkylchromenoisoxazolines as antidepressants.)

RN 1055723-13-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1055723-14-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-bromo-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 452320-31-9P 663933-45-7P,
 8-Methoxy-3-[4-(3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-46-8P,
 8-Methoxy-7-methyl-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-47-9P,
 [8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazol-7-yl]methanol 663933-48-0P,
 7-Methoxymethyl-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-49-1P
 663933-50-4P 663933-51-5P,
 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-7-phenoxy-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-52-6P 663933-53-7P,
 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-7-morpholin-4-ylmethyl-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-54-8P
 663933-55-9P 663933-56-0P,
 3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole-7-carbonitrile 663933-57-1P
 663933-58-2P, 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole-7-carboxylic acid ethylamide 663933-59-3P,
 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-7-phenyl-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-60-6P,
 1-[5-[8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazol-7-yl]thiophen-2-yl]ethanone 663933-61-7P 663933-62-8P 663933-63-9P
 663933-65-1P 663933-66-2P 663933-68-4P
 663933-69-5P 663933-70-8P 663933-71-9P
 663933-72-0P 663933-74-2P 663933-76-4P
 663933-77-5P 663933-78-6P 663933-79-7P
 663933-80-0P 663933-81-1P 663933-89-9P
 663933-90-2P 663933-91-3P 663933-92-4P
 663933-93-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of piperazinylalkylchromenoisoxazolines as antidepressants)

RN 452320-31-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-phenyl-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.




RN 663933-45-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-7-methyl-3-[[4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-
(CA INDEX NAME)



RN 663933-46-8 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-7-methyl-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 663933-47-9 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol,
3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-

piperazinyl)methyl]- (CA INDEX NAME)



RN 663933-48-0 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-(methoxymethyl)-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
piperazinyl)methyl]- (CA INDEX NAME)



RN 663933-49-1 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-7-[[[2-methoxyethoxy)methoxy)methyl]-3-[[4-(2-
methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl)methyl]- (CA INDEX NAME)

PAGE 1-A




—CH₂—CH₂—OMe


RN 663933-50-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol,
 3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
 piperazinyl]methyl]-, 7-acetate (CA INDEX NAME)



RN 663933-51-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
 piperazinyl]methyl]-7-(phenoxymethyl)- (CA INDEX NAME)




RN 663933-52-6 CAPLUS
 CN Ethanol, 2-[[[3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
 piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-
 yl]methyl]methylamino]- (CA INDEX NAME)




RN 663933-53-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]-7-(4-morpholinylmethyl)- (CA INDEX NAME)




RN 663933-54-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde,
3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-
, oxime (CA INDEX NAME)




RN 663933-55-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde,
3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-
, O-methyloxime (CA INDEX NAME)




RN 663933-56-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carbonitrile,
3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-
(CA INDEX NAME)




RN 663933-57-1 CAPLUS

CN Acetamide, N-[[3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methyl]- (CA
INDEX NAME)




RN 663933-58-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxamide,
N-ethyl-3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]- (CA INDEX NAME)




RN 663933-59-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]-7-phenyl- (CA INDEX NAME)



RN 663933-60-6 CAPLUS

CN Ethanone, 1-[5-[3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-
yl)-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-
thienyl]- (CA INDEX NAME)




RN 663933-61-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

10/513699


3a,4-dihydro-8-methoxy-7-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-62-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 663933-63-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

10/513699



● 2 HCl


RN 663933-65-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-7-[[[(2-methoxyethoxy)methoxy]methyl]-3-[[4-[(2E)-2-
methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, ethanedioate (1:1),
(3R,3aS)-rel- (CA INDEX NAME)

CM 1

CRN 663933-64-0

CMF C31 H41 N3 O6

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7

CMF C2 H2 O4



<12/04/2007>

Erich Leese


10/513699

RN 663933-66-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 663933-68-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(phenoxymethyl)-, ethanedioate (1:1), (3R,3aS)-rel- (CA INDEX NAME)


CM 1

CRN 663933-67-3

CMF C33 H37 N3 O4

Relative stereochemistry.

Double bond geometry as shown.



CM 2

CRN 144-62-7

CMF C2 H2 O4

10/513699




RN 663933-69-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-7-(4-morpholinylmethyl)-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 663933-70-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, oxime, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as described by E or Z.




RN 663933-71-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carbonitrile,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 663933-72-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanamine,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 663933-74-2 CAPLUS

CN Acetamide, N-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methyl]-, ethanedioate (1:1), rel- (CA INDEX NAME)


CM 1

CRN 663933-73-1

CMF C28 H34 N4 O3

Relative stereochemistry.

Double bond geometry as shown.



CM 2

10/513699

CRN 144-62-7
CMF C2 H2 O4




RN 663933-76-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7'-carboxamide,
N-ethyl-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, ethanedioate (1:1), (3R,3aS)-rel- (CA INDEX NAME)

CM 1

CRN 663933-75-3
CMF C29 H36 N4 O4

Relative stereochemistry.
Double bond geometry as shown.




CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 663933-77-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 663933-78-6 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methyl]methylamino]-, hydrochloride (1:2), rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




● 2 HCl

RN 663933-79-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(4-morpholinylmethyl)-, (3S,3aR)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




10/513699

RN 663933-80-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(4-morpholinylmethyl)-, (3R,3aS)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 663933-81-1 CAPLUS

CN Ethanone, 1-[4-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-thienyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 663933-89-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-(cyclopropylmethyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 663933-90-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7-(methoxymethyl)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




●2 HCl

RN 663933-91-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde,
 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




10/513699

RN 663933-92-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanamine,
N-ethyl-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(1-methylethyl)-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 663933-93-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-[(4-methyl-1-
piperidinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



PAGE 1-B

Me

IT 663933-85-5P 663933-86-6P 663933-87-7P

<12/04/2007>

Erich Leese

10/513699


663933-88-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of piperazinylalkylchromenoisoxazolines as antidepressants)


RN 663933-85-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid,
7-bromo-3a,4-dihydro-8-methoxy-, ethyl ester (CA INDEX NAME)



RN 663933-86-6 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol,
7-bromo-3a,4-dihydro-8-methoxy- (CA INDEX NAME)



RN 663933-87-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol,
7-bromo-3a,4-dihydro-8-methoxy-, 3-methanesulfonate (CA INDEX NAME)


10/513699



RN 663933-88-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-bromo-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 15 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:892834 CAPLUS

DOCUMENT NUMBER: 139:365764

TITLE: Diblock copolymers for use in pharmaceutical dosage forms

INVENTOR(S): Arieen, Albertina Maria Eduarda; Brewster, Marcus Eli; Nathan, Aruna; Rosenblatt, Joel; Ould-Ouali, Louisa Myriam; Preat, Veronique

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093344	A1	20031113	WO 2003-EP4368	20030424
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2483282	A1	20031113	CA 2003-2483282	20030424
AU 2003222310	A1	20031117	AU 2003-222310	20030424
EP 1504047	A1	20050209	EP 2003-717321	20030424
EP 1504047	B1	20071212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009688	A	20050222	BR 2003-9688	20030424
NZ 536294	A	20050527	NZ 2003-536294	20030424
CN 1649932	A	20050803	CN 2003-809579	20030424
CN 1290893	C	20061220		
JP 2005524730	T	20050818	JP 2004-501483	20030424
AT 380834	T	20071215	AT 2003-717321	20030424
ES 2298510	T3	20080516	ES 2003-717321	20030424
MX 2004PA10778	A	20050307	MX 2004-PA10778	20041029
ZA 2004008854	A	20051102	ZA 2004-8854	20041102
NO 2004005283	A	20050107	NO 2004-5283	20041202
US 20060034797	A1	20060216	US 2005-522456	20050121
PRIORITY APPLN. INFO.:			US 2002-377901P	P 20020503
			WO 2003-EP4368	W 20030424

AB In a diblock copolymer of formula A-B, polymer block A represents a linear pharmaceutically acceptable hydrophilic polymer and polymer block B represents a polymer comprising monomers selected from L-lactic acid, D-lactic acid, D,L-lactic acid, glycolic acid, propiolactone, γ -butyrolactone, δ -valerolactone, γ -valerolactone, ϵ -caprolactone, trimethylene carbonate, p-dioxanone, tetramethylene carbonate, ϵ -lactone, 1,5-dioxepan-2-one or mixts. thereof characterized in that the diblock copolymer is liquid at a temperature below 50°. A polymer was prepared from ϵ -caprolactone,

10/513699

trimethylene carbonate, and polyethylene glycol monomethyl ether initiator.


IT 452314-01-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diblock copolymers for use in pharmaceutical dosage forms)

RN 452314-01-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA
INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 16 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:796712 CAPLUS
 DOCUMENT NUMBER: 139:307799
 TITLE: Preparation of isoxazoline derivatives as antidepressants
 INVENTOR(S): Andres-Gil, Jose Ignacio; Alcazar-Vaca, Manuel Jesus; Bakker, Margaretha Henrica Maria; De Lucas Olivares, Ana Isabel
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082878	A1	20031009	WO 2003-EP3245	20030327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2480113	A1	20031009	CA 2003-2480113	20030327
AU 2003219111	A1	20031013	AU 2003-219111	20030327
BR 2003008309	A	20041228	BR 2003-8309	20030327
EP 1492796	A1	20050105	EP 2003-714897	20030327
EP 1492796	B1	20070905		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1642960	A	20050720	CN 2003-807419	20030327
CN 100349897	C	20071121		
JP 2005522469	T	20050728	JP 2003-580343	20030327
NZ 536109	A	20060630	NZ 2003-536109	20030327
AT 372342	T	20070915	AT 2003-714897	20030327
ES 2292949	T3	20080316	ES 2003-714897	20030327
TW 286138	B	20070901	TW 2003-92107328	20030401
MX 2004PA08626	A	20041206	MX 2004-PA8626	20040906
IN 2004DN02809	A	20050401	IN 2004-DN2809	20040921
ZA 2004007904	A	20051020	ZA 2004-7904	20040930
US 20050222125	A1	20051006	US 2004-510220	20041001
US 7265103	B2	20070904		
NO 2004004645	A	20041027	NO 2004-4645	20041027
PRIORITY APPLN. INFO.:			EP 2002-76239	A 20020402
			WO 2003-EP3245	W 20030327
OTHER SOURCE(S):	MARPAT 139:307799			
GI				



- AB The title isoxazoline derivs. having a piperazinyl subunit with general formula of I [wherein X = CH₂, S, O, or (un)substituted NH; R₁ and R₂ = independently H, OH, CN, halo, OSO₂H, OSO₂Me, alkoxy, alkoxyalkoxy, alkoxyalkoxyalkoxy, tetrahydrofuranlyloxy, alkylthio, (alkoxy)alkylcarboxy, pyridylcarboxy, alkylcarboxyalkoxy, alkoxycarboxy, alkenyloxy, alkenylcarboxy, alkylaminoalkoxy, dialkylaminoalkoxy, or (un)substituted NH₂, with provisos; m = 1-4; A = (un)substituted piperazinyl, piperidinyl, or amino; R₃ = (un)substituted aromatic (hetero)cyclyl] and pharmaceutically acceptable salts, stereoisomers, N-oxides, or prodrugs thereof are prepared as antidepressants for the treatment of depression, anxiety, and/or body weight disorders (no data). For example, the compound II •2HCl was prepared in a multi-step synthesis in moderate yield. II showed pIC₅₀ of 8.9, 9.0, and 8.2 against human *ha2A*, *ha2C*, and 5-HT transporter receptor sites, resp.
- IT 612074-52-9P 612074-55-2P 612074-58-5P
612074-59-6P 612074-62-1P 612074-63-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of isoxazoline derivs. as antidepressants)
- RN 612074-52-9 CAPLUS
- CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-55-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-58-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-59-6 CAPLUS

CN 1,2-Ethanediamine, N2-[(3R,3aR)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-
methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-
c]isoxazol-7-yl]-N1,N1-dimethyl-, rel- (CA INDEX NAME)


10/513699

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-62-1 CAPLUS
CN Ethanone, 1-[(3R,3aR)-3a,4,8,9-tetrahydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H,7H-isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazin-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-63-2 CAPLUS
CN 3H,7H-Isloxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine, 3a,4,8,9-tetrahydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 612074-51-8P 612074-53-0P 612074-54-1P
 612074-56-3P 612074-57-4P 612074-60-9P
 612074-61-0P 612074-64-3P 612074-65-4P
 612074-66-5P 612074-67-6P 612074-68-7P
 612074-69-8P 612074-70-1P 612074-71-2P
 612074-72-3P 612074-73-4P 612074-74-5P
 612074-75-6P 612074-76-7P 612074-77-8P
 612074-78-9P 612074-79-0P 612074-80-3P
 612074-81-4P 612074-82-5P 612074-83-6P
 612074-84-7P 612074-85-8P 612074-86-9P
 612074-87-0P 612074-88-1P 612074-89-2P
 612074-90-5P 612074-91-6P 612074-92-7P
 612074-93-8P 612074-94-9P 612074-95-0P
 612074-96-1P 612074-97-2P 612074-98-3P
 612074-99-4P 612075-00-0P 612075-01-1P
 612075-02-2P 612075-03-3P 612075-04-4P
 612075-05-5P 612075-06-6P 612075-07-7P
 612075-08-8P 612075-09-9P 612075-10-2P
 612075-11-3P 612075-12-4P 612075-13-5P
 612075-14-6P 612075-15-7P 612075-16-8P
 612075-17-9P 612075-18-0P 612075-19-1P
 612075-20-4P 612075-21-5P 612075-22-6P
 612075-23-7P 612075-24-8P 612075-25-9P
 612075-26-0P 612075-27-1P 612075-28-2P
 612075-29-3P 612075-30-6P 612075-31-7P
 612075-32-8P 612075-33-9P 612075-34-0P
 612075-35-1P 612075-36-2P 612075-37-3P
 612075-38-4P 612075-39-5P 612075-40-8P
 612075-41-9P 612075-42-0P 612075-43-1P
 612075-44-2P 612075-45-3P 612075-46-4P
 612075-47-5P 612075-48-6P 612075-49-7P
 612075-50-0P 612075-51-1P 612075-52-2P
 612075-53-3P 612075-54-4P 612075-55-5P
 612075-56-6P 612075-57-7P 612075-58-8P
 612075-59-9P 612075-60-2P 612075-61-3P
 612075-62-4P 612075-63-5P 612075-64-6P
 612075-65-7P 612075-66-8P 612075-67-9P
 612075-68-0P 612075-69-1P 612075-70-4P

612075-71-5P 612075-72-6P 612075-73-7P
 612075-74-8P 612075-75-9P 612075-76-0P
 612075-77-1P 612075-78-2P 612075-79-3P
 612075-80-6P 612075-81-7P 612075-82-8P
 612075-83-9P 612075-84-0P 612075-85-1P
 612075-86-2P 612075-87-3P 612075-88-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


(drug candidate; preparation of isoxazoline derivs. as antidepressants)

RN 612074-51-8 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-
 2-propen-1-yl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-
 yl]-N1,N2,N2-trimethyl-, hydrochloride (1:2), rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




● 2 HCl

RN 612074-53-0 CAPLUS


CN Benzenesulfonamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-
 propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-
 c]isoxazol-7-yl]-4-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




PAGE 1-A




RN 612074-54-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-8-(4-morpholinyl)-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 612074-56-3 CAPLUS
 CN Acetamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-
 1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel-
 (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 612074-57-4 CAPLUS
 CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-
 yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(3,4-

10/513699

dimethoxyphenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-60-9 CAPLUS

CN Acetamide, N-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-61-0 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-64-3 CAPLUS

CN 3H,7H-Isloxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine,
3a,4,8,9-tetrahydro-7-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-
1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-65-4 CAPLUS

CN Ethanone, 2-methoxy-1-[(3R,3aS)-3a,4,8,9-tetrahydro-3-[[4-[(2E)-2-methyl-3-
phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H,7H-
isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazin-7-yl]-, rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry as shown.

10/513699




RN 612074-66-5 CAPLUS

CN 3H,7H-Isioxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine-7-carboxamide,
N-ethyl-3a,4,8,9-tetrahydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-67-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-methyl-, (3R,3aS)-rel- (CA
INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.




RN 612074-68-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 N-ethyl-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 612074-69-8 CAPLUS
 CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-
 propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-
 c]isoxazol-7-yl]-N1-methyl-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



● HC1


RN 612074-70-1 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N2-methyl-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A



● HCl

PAGE 1-B

NHMe


RN 612074-71-2 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A




—NHMe

RN 612074-72-3 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, hydrochloride (1:2), rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl


—NMe₂

RN 612074-73-4 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



● HCl

PAGE 1-B

NMe₂


RN 612074-74-5 CAPLUS

CN 1,2-Ethanediamine, N2-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N1-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A




—NMe₂

RN 612074-75-6 CAPLUS
 CN 1,2-Ethanediamine, N1,N1-diethyl-N2-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N2-methyl-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




● HCl

PAGE 1-B

—NEt₂

RN 612074-76-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 612074-77-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[2-(1-pyrrolidinyl)ethyl]-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612074-78-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-N-[2-(1-pyrrolidinyl)ethyl]-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612074-79-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[2-(1-pyrrolidinyl)ethyl]-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612074-80-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl)methyl]-3a,4-dihydro-N-[2-(4-morpholinyl)ethyl]-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 612074-81-4 CAPLUS
CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-
1-yl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-
yl)methylamino]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-82-5 CAPLUS
CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-
2-propen-1-yl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-
yl)methylamino]-, rel- (CA INDEX NAME)


10/513699

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-83-6 CAPLUS
CN Ethanol, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-84-7 CAPLUS
CN Ethanol, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




10/513699

RN 612074-85-8 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-86-9 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-87-0 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.




RN 612074-88-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-N-phenyl-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 612074-89-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-N-phenyl-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 612074-90-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 N-(4-fluorophenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-

yl]-1-piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-91-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl)methyl]-3a,4-dihydro-N-(4-methoxyphenyl)-, (3R,3aS)-rel- (CA
INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


OMe

RN 612074-92-7 CAPLUS

CN Benzonitrile, 3-[[3-(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-
propen-1-yl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-
yl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-93-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-N-(2-methylphenyl)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-94-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
N-(3,4-dimethylphenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-95-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)


10/513699

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-96-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, hydrochloride (1:2), (3R,3aS)-rel-
(CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl

RN 612074-97-2 CAPLUS
CN Acetamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-98-3 CAPLUS

CN Propanamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2,2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-99-4 CAPLUS

CN Cyclopropanecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-00-0 CAPLUS

CN Cyclopropanecarboxamide, N-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-

10/513699


c[isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-01-1 CAPLUS
CN Cyclopropanecarboxamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-02-2 CAPLUS
CN 2-Propenamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-03-3 CAPLUS

CN Benamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-04-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 612075-05-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, (2S)- (CA INDEX NAME)


10/513699

Absolute stereochemistry.
Double bond geometry as shown.




RN 612075-06-6 CAPLUS
CN Carbamic acid, [(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-07-7 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-ethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-08-8 CAPLUS
CN Imidodicarbonic diamide, N,N'-diethyl-2-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-

3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-09-9 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(1,1-dimethylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-10-2 CAPLUS

CN Urea, N-cyclohexyl-N'-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-11-3 CAPLUS

CN Glycine, N-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]carbonyl]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-12-4 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-13-5 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(3-

fluorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-14-6 CAPLUS

CN Methanesulfonamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N-(methylsulfonyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-15-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-16-8 CAPLUS

CN 1-Piperazinecarboximidamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-4-(phenylmethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612075-17-9 CAPLUS

CN 2-Azetidinone, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-18-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-7-(1-pyrrolidinyl)-, (3R,3aS)-rel- (CA
 INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-19-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-7-(1-piperidinyl)-, (3R,3aS)-rel- (CA
 INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-20-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



—OEt

RN 612075-21-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(3,4-dihydro-2(1H)-isoquinolinyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-22-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-7-(4-methyl-1-piperazinyl)-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-23-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-methyl-1-piperazinyl)-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-24-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7-(4-methyl-1-piperazinyl)-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-25-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-methyl-1-piperazinyl)-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-26-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7-(4-phenyl-1-piperazinyl)-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-27-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7-[4-(phenylmethyl)-1-piperazinyl]-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

Ph

RN 612075-28-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-7-[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


E Ph

RN 612075-29-3 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]-, (3R,3aS)-rel- (CA INDEX NAME)

piperazinyl)methyl]-7-(4-morpholinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-30-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl)methyl]-3a,4-dihydro-8-methoxy-7-(4-morpholinyl)-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-31-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl)methyl]-3a,4-dihydro-7-(4-morpholinyl)-, (3R,3aS)-rel- (CA
INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-32-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-morpholinyl)-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-33-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX
 NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-34-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




● 2 HCl

RN 612075-35-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3a,4-dihydro-8-methoxy-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




10/513699

RN 612075-36-2 CAPLUS

CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4,8,9-tetrahydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-37-3 CAPLUS

CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4,8,9-tetrahydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 612075-38-4 CAPLUS


CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine,
3a,4,8,9-tetrahydro-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-

10/513699

piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 612075-39-5 CAPLUS

CN 3H,7H-Isioxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine,
3a,4,8,9-tetrahydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl)methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 612075-40-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-8-amine,
3a,4-dihydro-N-(4-methoxyphenyl)-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 612075-41-9 CAPLUS

CN 3H,7H-Isioxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine,
3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl)methyl]-3a,4,8,9-tetrahydro-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 612075-42-0 CAPLUS

CN 2-Propenoic acid, 2-methyl-, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl)methylamino]ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 612075-43-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-1-pyrrolidinyl-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 612075-44-2 CAPLUS
 CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-
 propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-
 [1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 612075-45-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
N-(1-ethylpropyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-46-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(1-methylpropyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.




RN 612075-47-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-4-pyridinyl-, (3R,3aS)-rel-
 (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 612075-48-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(2-methyl-1-pyrrolidinyl)-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 612075-49-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 7-(1-azetidiny)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX
 NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 612075-50-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-methyl-1-piperidinyl)-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-51-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(2-methylbutyl)-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-52-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
N-ethyl-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-53-3 CAPLUS

CN 2-Propenamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-
propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-54-4 CAPLUS

CN 2-Azetidinone, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-55-5 CAPLUS

CN Cyclobutanecarboxylic acid, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



PAGE 1-B


RN 612075-56-6 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-

[1]benzopyrano[4,3-c]isoxazol-7-yl)methylamino]ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612075-57-7 CAPLUS

CN 1,2-Ethanediamine, N2-(1,2-dimethylpropyl)-N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A






RN 612075-58-8 CAPLUS

CN 1,2-Ethanediamine, N2-cyclobutyl-N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-59-9 CAPLUS

CN 2-Butenamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as described by E or Z.




Me

RN 612075-60-2 CAPLUS

CN Pentanamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-61-3 CAPLUS

CN Butanamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-62-4 CAPLUS

CN Cyclobutanecarboxamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.



RN 612075-63-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(2-methylpropyl)-,
 (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.




RN 612075-64-6 CAPLUS
 CN Butanoic acid, 3,3-dimethyl-, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-
 2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-
 [1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (CA
 INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612075-65-7 CAPLUS

CN 1,2-Ethanediamine, N2-(cyclopropylmethyl)-N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612075-66-8 CAPLUS

CN 2-Propanol, 1-[[2-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-

propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl)methylamino]ethyl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612075-67-9 CAPLUS

CN 1,2-Ethanediamine, N2-(1,1-dimethylpropyl)-N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A






RN 612075-68-0 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2-dimethyl-N2-2-propen-1-yl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-69-1 CAPLUS

CN 1,2-Ethanediamine, N1-(1,1-dimethylethyl)-N2-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

Bu-t

RN 612075-70-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 N-[2-(1-azetidinyl)ethyl]-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-N-methyl-, (3R,3aS)-rel- (CA
 INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612075-71-5 CAPLUS
 CN Urea, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-

10/513699

piperazinyl)methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-72-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-7-(hexahydro-1H-azepin-1-yl)-3a,4-dihydro-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-73-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-8-methoxy-N-[(2-methylcyclopropyl)methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


Me

RN 612075-74-8 CAPLUS


CN Carbamic acid, (1-methylpropyl)-, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612075-75-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,

3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[(1-methylcyclopropyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-76-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-N-(1-methylethyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-77-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
N-(cyclopropylmethyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-78-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-N-(1-methylpropyl)-, (3R,3aS)-rel- (CA
 INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-79-3 CAPLUS

CN 2-Propanol, 1-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-
 1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-
 7-yl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-80-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine,


3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-N-pentyl-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-81-7 CAPLUS
CN 1-Propanol, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-82-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-(3,6-dihydro-1(2H)-pyridinyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-83-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-7-(1-piperazinyl)-, (3R,3aS)-rel- (CA
 INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-84-0 CAPLUS

CN Urea, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-,
 rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-85-1 CAPLUS

CN Cyclopropanecarboxamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-86-2 CAPLUS

CN 2-Pyrrolidinone, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-3-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 612075-87-3 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(1R,2S)-2-phenylcyclopropyl]methyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 612075-88-4 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT 452319-29-8P 612075-92-0P 612075-93-1P

612075-94-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of isoxazoline derivs. as antidepressants)


RN 452319-29-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.

10/513699




RN 612075-92-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid,
7-fluoro-3a,4-dihydro-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 612075-93-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 7-fluoro-3a,4-dihydro-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 612075-94-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 7-fluoro-3a,4-dihydro-,
3-methanesulfonate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 452319-78-7 612075-96-4 612075-97-5

612075-98-6 612075-99-7

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of isoxazoline derivs. as antidepressants)

RN 452319-78-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-96-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-bromo-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




10/513699

RN 612075-97-5 CAPLUS

CN Carbamic acid, [(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-98-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-bromo-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-99-7 CAPLUS

CN Ethanone, 1-[(3R,3aR)-3a,4,8,9-tetrahydro-3-[[[(methylsulfonyl)oxy]methyl]-3H,7H-isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazin-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

10/513699



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

<12/04/2007>

Erich Leese

L7 ANSWER 17 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:535065 CAPLUS

DOCUMENT NUMBER: 139:292184

TITLE: Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HT uptake inhibiting and α 2-adrenoceptor antagonistic activities: a novel series of potential antidepressants

AUTHOR(S): Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.; Alvarez, Rosa M.; Cid, Jose M.; De Lucas, Ana I.; Fernandez, Javier; Martinez, Sonia; Nieto, Carmen; Pastor, Joaquin; Bakker, Margot H.; Biesmans, Ilse; Heylen, Lieve I.; Megens, Anton A.

CORPORATE SOURCE: Division of Janssen-Cilag, Medicinal Chemistry Department, Jarama s/n, Johnson & Johnson Pharmaceutical Research & Development, Toledo, 45007, Spain

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(16), 2719-2725

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:292184

AB The synthesis of a series of novel

3-piperazinylmethyl-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as novel dual 5-HT re-uptake inhibitors and α 2-adrenoceptor antagonists is described. Their affinity at the three different human α 2-adrenoceptor subtypes and the 5-HT transporter site is reported.

The in vivo activity of the compds. was measured in two different assays:

(1) inhibition of pCA-induced excitation, which evaluates the ability to block the central 5-HT transporter, and (2) inhibition of xylazine-induced loss of righting, which evaluates the ability to block central α 2-adrenoceptors. Compds. thus prepared included

(3R,3aS)-rel-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazole, (3R,3aS)-rel-(+)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazole, (3R,3aS)-rel-(+)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazole and derivs. thereof.

IT 452313-36-9P 452313-43-8P 452313-54-1P

452313-56-3P 452313-77-8P 452314-18-0P

452316-09-5P 452316-15-3P 452316-21-1P

452316-33-5P 452316-36-8P 452316-66-4P

452316-84-6P 452318-20-6P 452318-24-0P

452318-26-2P 452318-93-3P 452318-95-5P

452318-97-7P 452319-25-4P 452319-35-6P

452320-01-3P 608146-10-7P 608146-11-8P

608146-12-9P 608146-13-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of dihydro[1]benzopyrano[4,3-c]isoxazoles and their activity as 5-HT uptake inhibitors and α 2-adrenoceptor antagonists (potential antidepressants))

RN 452313-36-9 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-

10/513699

piperazinylmethyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452313-43-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-
piperazinylmethyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452313-54-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinylmethyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.


Double bond geometry as shown.



RN 452313-56-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-77-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452314-18-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

10/513699

3a,4-dihydro-7,8-dimethoxy-3-[[4-(phenylmethyl)-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-09-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(benzo[b]thien-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-15-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-quinolinylmethyl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




10/513699

RN 452316-21-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-phenylethyl)-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-33-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenylpropyl)-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-36-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-(1H-inden-2-ylmethyl)-1-piperazinyl]methyl]-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/513699



RN 452316-66-4 CAPLUS

CN 1-Propanone, 3-[4-[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-84-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2Z)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-20-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

10/513699

3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-24-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-26-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-93-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-95-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.

Double bond geometry as shown.




RN 452318-97-7 CAPLUS

10/513699

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452319-25-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-35-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



10/513699


RN 452320-01-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 608146-10-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(benzo[b]thien-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 608146-11-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(1-naphthalenylmethyl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/513699



RN 608146-12-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 608146-13-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



IT 452321-69-6P 452321-71-0P 452321-75-4P
452321-82-3P 452321-89-0P 608146-03-8P

10/513699

608146-04-9P 608146-05-0P 608146-06-1P
608146-07-2P 608146-08-3P 608146-09-4P
608146-14-1P 608146-15-2P 608146-16-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of dihydro[1]benzopyrano[4,3-c]isoxazoles and their activity as
5-HT uptake inhibitors and α 2-adrenoceptor antagonists (potential
antidepressants))

RN 452321-69-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-71-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-,
3-methanesulfonate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-75-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel- (CA
INDEX NAME)


Relative stereochemistry.



RN 452321-82-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-89-0 CAPLUS

CN Phosphonium, [2-[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]ethyl]triphenyl-, bromide (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.




10/513699

RN 608146-03-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 3a,4-dihydro-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 608146-04-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 3a,4-dihydro-7,8-dimethoxy-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 608146-05-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 3a,4-dihydro-7-methoxy-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




10/513699

RN 608146-06-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid,
3a,4-dihydro-8-methoxy-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 608146-07-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-,
3-methanesulfonate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 608146-08-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7-methoxy-,
3-methanesulfonate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 608146-09-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-8-methoxy-,

10/513699

3-methanesulfonate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 608146-14-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 608146-15-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7-methoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 608146-16-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

29

THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 18 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:953007 CAPLUS

DOCUMENT NUMBER: 138:153469

TITLE: Synthesis, high-resolution NMR spectroscopic analysis, and single-crystal X-ray diffraction of isoxazoline tetracycles

AUTHOR(S): Fascio, Mirta L.; Alvarez-Larena, Angel; D'Accorso, Norma B.

CORPORATE SOURCE: Facultad de Ciencias Exactas y Naturales, Departamento de Química Organica, Centro de Investigaciones de Hidratos de Carbono (CIHIDECAR), Universidad de Buenos Aires, Buenos Aires, 1428, Argent.

SOURCE: Carbohydrate Research (2002), 337(24), 2419-2425

CODEN: CRBRAT; ISSN: 0008-6215



PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:153469

GI



AB Three isoxazoline tetracycles I (R1 = H, R2 = Me; R1 = H, R2 = Ph; R1 = R2 = Me) were obtained enantiomerically pure by intramol. 1,3-dipolar cycloaddn. of mono-oxime α -D-glucofuranose derivs. II, derived from 1,2:5,6-di-O-isopropylidene- α -D-glucofuranose. The characterization of the new compds. was performed by high-resolution 1H and 13C NMR spectroscopy. The relative configuration of the new chiral centers was determined by NOESY expts. and confirmed by single-crystal X-ray structural anal.

IT 495413-22-4P


RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (synthesis of isoxazoline tetracycles by intramol. 1,3-dipolar cycloaddn. of mono-oxime alkenyl-di-O-isopropylidene- α -D-glucofuranose derivs. and crystal structure)

RN 495413-22-4 CAPLUS

CN 3H,4H,5bH-[1,3]Dioxolo[4',5']furo[2',3':5,6]pyrano[4,3-c]isoxazole, 3a,5a,8a,9a-tetrahydro-3,7,7-trimethyl-, (3R,3aR,5aS,5bR,8aR,9aR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

10/513699



REFERENCE COUNT:

11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 19 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:658130 CAPLUS

DOCUMENT NUMBER: 137:201298

TITLE: Preparation of substituted isoxazolines as anti-depressants

INVENTOR(S): Andres-Gil, Jose Ignacio; Fernandez-Gadea, Francisco Javier; Alcazar-Vaca, Manuel Jesus; Cid-Nunez, Jose Maria; Pastor-Fernandez, Joaquin; Megens, Antonius Adrianus Hendrikus Petrus; Heylen, Godelieve Irma Christine Maria; Langlois, Xavier Jean Michel; Bakker, Margaretha Henrica Maria; Steckler, Thomas Horst Wolfgang

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 100 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1




PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066484	A1	20020829	WO 2002-EP1567	20020213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2437505	A1	20020829	CA 2002-2437505	20020213
AU 2002244717	A1	20020904	AU 2002-244717	20020213
AU 2002244717	B2	20070719		
EP 1368358	A1	20031210	EP 2002-712909	20020213
EP 1368358	B1	20060823		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300398	A	20031215	EE 2003-398	20020213
HU 2003003270	A2	20040128	HU 2003-3270	20020213
HU 2003003270	A3	20070328		
CN 1492871	A	20040428	CN 2002-805243	20020213
CN 100400540	C	20080709		
NZ 526741	A	20040430	NZ 2002-526741	20020213
BR 2002007433	A	20040601	BR 2002-7433	20020213
JP 2004518748	T	20040624	JP 2002-565998	20020213
JP 3953424	B2	20070808		
AT 337322	T	20060915	AT 2002-712909	20020213
ES 2271230	T3	20070416	ES 2002-712909	20020213
EG 23929	A	20080114	EG 2002-197	20020219
TW 257392	B	20060701	TW 2002-91102853	20020220
KR 848898	B1	20080729	KR 2003-708328	20030620
IN 2003DN00968	A	20070525	IN 2003-DN968	20030624
BG 107984	A	20040930	BG 2003-107984	20030708
MX 2003PA07432	A	20031118	MX 2003-PA7432	20030819
NO 2003003700	A	20031021	NO 2003-3700	20030820

ZA 2003006487	A	20041122	ZA 2003-6487	20030820
US 20040122037	A1	20040624	US 2003-468555	20030821
US 7169786	B2	20070130		

PRIORITY APPLN. INFO.: EP 2001-200611 A 20010221
 EP 2001-201264 A 20010405
 WO 2002-EP1567 W 20020213

OTHER SOURCE(S): MARPAT 137:201298
 GI




AB Title compds. I [wherein X = CH₂, NR₇, S or O; R₇ = H, (un)substituted alkyl, Ph, Ph alkyl, etc.; R₁ and R₂ independently = H, OH, CN, halo, OSO₂H, (un)substituted Ph, phenylalkyl, alkoxy, etc.; or R₁ and R₂ may be taken together to form a bivalent radical selected from -CH₂CH₂O-, -OCH₂CH₂-, -OCH₂O-, -CH₂OCH₂- and -OCH₂CH₂O-; m = 1-4; Y = (un)substituted piperidyl or piperazyl radical and R₃ represents an (un)substituted aromatic homocyclic or heterocyclic ring system including a partially or completely hydrogenated hydrocarbon chain of maximum 6 atoms long with which the ring system is attached to the Y radical and which may contain one or more heteroatoms selected from the group of O, N and S], a process for their preparation, pharmaceutical compns. comprising them and their use as a medicine for treating anxiety disorders and disorders of body weight are disclosed. Thus, II was prepared in 60% yield by reaction of III with N-(3-phenyl-2-propenyl)-piperazine. III was prepared by substitution of Me 4-bromo-2-butenate with 2-hydroxy-4,5-dimethoxybenzaldehyde with subsequent condensation with hydroxylamine, cyclization, reduction and sulfonation with methanesulfonyl chloride. The compds. according to the

invention have surprisingly been shown to have a serotonin (5-HT) reuptake inhibitor activity in combination with addnl. α 2-adrenoceptor antagonist activity and show a strong anti-depressant activity without being sedative. I produced an inhibition at the ha2A site (but often also at the ha2B and ha2C sites) and simultaneously at the 5-HT transporter site of more than 50% (pIC50) at a test concentration ranging between 10⁻⁶ M and 10⁻⁹ M in a concentration dependent manner. The invention also relates to novel combination of substituted isoxazolines derivs. having anti-depressant activity and/or anxiolytic activity and/or body weight control activity with antidepressants, anxiolytics and/or antipsychotics to improve efficacy and/or onset of action.

IT 452321-67-4P 452321-69-6P 452321-71-0P
 452321-73-2P 452321-75-4P 452321-77-6P
 452321-80-1P 452321-82-3P 452321-85-6P
 452321-87-8P 452321-89-0P 452321-91-4P
 452321-93-6P 452321-95-8P 452321-97-0P
 452321-99-2P 452322-05-3P 452322-07-5P
 452322-09-7P 452322-19-9P 452322-21-3P
 452322-23-5P 452322-29-1P 452322-30-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)
 RN 452321-67-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid,
 3a,4-dihydro-7,8-dimethoxy-, methyl ester, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-69-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/513699



RN 452321-71-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-, 3-methanesulfonate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-73-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7-hydroxy-8-methoxy-, 3-methanesulfonate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452321-75-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

10/513699

3a,4-dihydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-77-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-, 3-methanesulfonate, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 452321-80-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-, 3-methanesulfonate, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.




10/513699

RN 452321-82-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-85-6 CAPLUS

CN 2-Propanone, 1-[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-87-8 CAPLUS

CN Methanone, [4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl](3,4-dihydro-2-naphthalenyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-89-0 CAPLUS

CN Phosphonium, [2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]ethyl]triphenyl-, bromide (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.


● Br⁻

RN 452321-91-4 CAPLUS

CN 2-Propen-1-one, 1-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-3-iodo-2-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452321-93-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-(3-iodo-2-methyl-2-propen-1-yl)-1-piperazinyl]methyl]-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 452321-95-8 CAPLUS

CN 1-Piperazineethanol, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-α-methyl-, rel- (CA
INDEX NAME)

Relative stereochemistry.




RN 452321-97-0 CAPLUS

CN 1,2-Propanediol, 3-[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-α-methyl-, rel- (CA
INDEX NAME)

10/513699

[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-99-2 CAPLUS

CN 1-Piperazineacetaldehyde, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-05-3 CAPLUS

CN Isoxazolo[4,3-c]quinoline-3-carboxylic acid, 3,3a,4,5-tetrahydro-5-(2,2,2-trifluoroacetyl)-, methyl ester, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452322-07-5 CAPLUS

10/513699

CN Isoxazolo[4,3-c]quinoline-3-methanol, 3,3a,4,5-tetrahydro-, (3R,3aR)-rel-
(CA INDEX NAME)


Relative stereochemistry.



RN 452322-09-7 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-(chloromethyl)-3,3a,4,5-tetrahydro-,
(3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-19-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aR)-3,3a,4,5-tetrahydro-7,8-
dimethoxy-5-(2,2,2-trifluoroacetyl)isoxazolo[4,3-c]quinolin-3-yl)methyl]-,
1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452322-21-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aR)-3,3a,4,5-tetrahydro-7,8-
dimethoxyisoxazolo[4,3-c]quinolin-3-yl)methyl]-, 1,1-dimethylethyl ester,

10/513699

rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-23-5 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-(1-piperazinylmethyl)-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-29-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]amino]methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452322-30-4 CAPLUS


10/513699

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine,
3a,4-dihydro-7,8-dimethoxy-N-(4-piperidinylmethyl)-, (3R,3aS)-rel- (CA
INDEX NAME)

Relative stereochemistry.




IT 452322-32-6D, resin bound 452323-46-5D, resin bound
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and pharmaceutical activity of substituted isoxazolines as
anti-depressants)
RN 452322-32-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 3a,4-dihydro-7,8-dimethoxy-,
3-methanesulfonate (CA INDEX NAME)




RN 452323-46-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[2-(diphenylphosphino)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 452313-32-5P 452313-68-7P 452313-71-2P
 452313-80-3P 452313-82-5P 452316-78-8P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (target compound; preparation and pharmaceutical activity of substituted
 isoxazolines as anti-depressants)
 RN 452313-32-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel-(+)- (CA INDEX
 NAME)


Rotation (+). Absolute stereochemistry unknown.
 Double bond geometry as shown.



● 2 HCl

RN 452313-68-7 CAPLUS
 CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-
 methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel-(+)-
 (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
 Double bond geometry as shown.



RN 452313-71-2 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aS)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-80-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



● 2 HCl

RN 452313-82-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-
 piperazinyl]methyl]-, hydrochloride (1:2), (3S,3aR)-rel-(-)- (CA INDEX
 NAME)


Rotation (-). Absolute stereochemistry unknown.



● 2 HCl

RN 452316-78-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-, hydrochloride (1:2), (3S,3aR)-rel-(-)- (CA INDEX
 NAME)

Rotation (-). Absolute stereochemistry unknown.
 Double bond geometry as shown.



●2 HCl


IT 452313-59-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (target compound; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)

RN 452313-59-6 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 452313-36-9P 452313-40-5P 452313-43-8P
 452313-46-1P 452313-50-7P 452313-54-1P
 452313-56-3P 452313-61-0P 452313-65-4P
 452313-74-5P 452313-77-8P 452313-85-8P
 452313-88-1P 452313-91-6P 452313-93-8P
 452313-98-3P 452314-01-1P 452314-05-5P
 452314-08-8P 452314-11-3P 452314-14-6P
 452314-16-8P 452314-18-0P 452314-20-4P
 452314-23-7P 452314-26-0P 452314-29-3P
 452314-31-7P 452314-34-0P 452314-37-3P
 452314-40-8P 452314-43-1P 452314-46-4P
 452314-49-7P 452314-52-2P 452314-55-5P
 452314-57-7P 452314-60-2P 452314-62-4P
 452314-65-7P 452314-68-0P 452314-71-5P
 452314-74-8P 452314-77-1P 452314-80-6P
 452314-83-9P 452314-86-2P 452314-89-5P

452314-92-0P 452314-95-3P 452314-98-6P
452315-01-4P 452315-04-7P 452315-07-0P
452315-10-5P 452315-13-8P 452315-16-1P
452315-19-4P 452315-22-9P 452315-24-1P
452315-27-4P 452315-30-9P 452315-33-2P
452315-36-5P 452315-38-7P 452315-40-1P
452315-42-3P 452315-44-5P 452315-46-7P
452315-48-9P 452315-51-4P 452315-52-5P
452315-55-8P 452315-58-1P 452315-61-6P
452315-63-8P 452315-66-1P 452315-70-7P
452315-73-0P 452315-76-3P 452315-79-6P
452315-82-1P 452315-85-4P 452315-87-6P
452315-90-1P 452315-92-3P 452315-94-5P
452315-97-8P 452316-00-6P 452316-03-9P
452316-06-2P 452316-09-5P 452316-12-0P
452316-15-3P 452316-18-6P 452316-21-1P
452316-24-4P 452316-27-7P 452316-30-2P
452316-33-5P 452316-36-8P 452316-39-1P
452316-42-6P 452316-45-9P 452316-48-2P
452316-51-7P 452316-53-9P 452316-55-1P
452316-58-4P 452316-64-2P 452316-66-4P
452316-69-7P 452316-72-2P 452316-75-5P
452316-81-3P 452316-84-6P 452316-87-9P
452316-89-1P 452316-91-5P 452316-93-7P
452316-95-9P 452316-97-1P 452316-99-3P
452317-02-1P 452317-04-3P 452317-06-5P
452317-08-7P 452317-10-1P 452317-12-3P
452317-14-5P 452317-16-7P 452317-18-9P
452317-20-3P 452317-22-5P 452317-24-7P
452317-26-9P 452317-28-1P 452317-30-5P
452317-32-7P 452317-34-9P 452317-36-1P
452317-38-3P 452317-40-7P 452317-42-9P
452317-44-1P 452317-46-3P 452317-48-5P
452317-50-9P 452317-52-1P 452317-54-3P
452317-56-5P 452317-58-7P 452317-60-1P
452317-64-5P 452317-67-8P 452317-69-0P
452317-71-4P 452317-73-6P 452317-76-9P
452317-79-2P 452317-82-7P 452317-84-9P
452317-86-1P 452317-89-4P 452317-92-9P
452317-94-1P 452317-96-3P 452317-99-6P
452318-02-4P 452318-04-6P 452318-07-9P
452318-09-1P 452318-11-5P 452318-13-7P
452318-15-9P 452318-18-2P 452318-20-6P
452318-22-8P 452318-24-0P 452318-27-3P
452318-30-8P 452318-32-0P 452318-34-2P
452318-36-4P 452318-38-6P 452318-41-1P
452318-43-3P 452318-45-5P 452318-47-7P
452318-49-9P 452318-52-4P 452318-54-6P
452318-57-9P 452318-60-4P 452318-63-7P
452318-65-9P 452318-67-1P 452318-69-3P
452318-71-7P 452318-73-9P 452318-75-1P
452318-77-3P 452318-79-5P 452318-81-9P
452318-83-1P 452318-85-3P 452318-87-5P
452318-89-7P 452318-91-1P 452318-93-3P
452318-95-5P 452318-97-7P 452318-99-9P
452319-01-6P 452319-03-8P 452319-05-0P
452319-07-2P 452319-09-4P 452319-11-8P

452319-13-0P 452319-15-2P 452319-17-4P
 452319-20-9P 452319-22-1P 452319-24-3P
 452319-25-4P 452319-27-6P 452319-29-8P
 452319-31-2P 452319-33-4P 452319-35-6P
 452319-37-8P 452319-39-0P 452319-41-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(target compound; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)

RN 452313-36-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452313-40-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452313-43-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

10/513699


Relative stereochemistry.



RN 452313-46-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-50-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




10/513699

RN 452313-54-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-56-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-61-0 CAPLUS

CN Ethanone, 1-[(3R,3aR)-3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]isoxazolo[4,3-c]quinolin-5(3H)-yl]-, rel- (CA INDEX
NAME)

Relative stereochemistry.




RN 452313-65-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.



RN 452313-74-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-chlorophenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)




RN 452313-77-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

10/513699

Relative stereochemistry.




RN 452313-85-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452313-88-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452313-91-6 CAPLUS

<12/04/2007>


Erich Leese

10/513699

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methylphenyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452313-93-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(3,4-dihydro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452313-98-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-pyridinyl)-2-propen-1-
yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452314-01-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA
 INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
 Double bond geometry as shown.



RN 452314-05-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-buten-1-yl)-1-
 piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry unknown.




10/513699

RN 452314-08-8 CAPLUS


CN 1-Piperazineethanamine, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]- α -methyl-N-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452314-11-3 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(3-fluorophenoxy)propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 452314-14-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl


RN 452314-16-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine,
 3a,4-dihydro-7,8-dimethoxy-N-[1-(2-naphthalenylmethyl)-4-piperidinyl]-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452314-18-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-(phenylmethyl)-1-piperazinyl]methyl]-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452314-20-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[2-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 452314-23-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[3-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 452314-26-0 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[4-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 452314-29-3 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[2-(1,1,2,2-
 tetrafluoroethyl)phenyl]methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 452314-31-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2-bromophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
 dimethoxy- (CA INDEX NAME)



RN 452314-34-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(3-bromophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-


10/513699

dimethoxy- (CA INDEX NAME)



RN 452314-37-3 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(4-bromophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy- (CA INDEX NAME)



RN 452314-40-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(3-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452314-43-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

10/513699

3-[[4-[(4-fluorophenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452314-46-4 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2-fluorophenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452314-49-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(4-nitrophenyl)methyl]-1-piperazinyl)methyl]- (CA INDEX NAME)




RN 452314-52-2 CAPLUS

CN Benzenamine, 4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 452314-55-5 CAPLUS

CN Acetamide, N-[4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]phenyl]- (CA INDEX NAME)




RN 452314-57-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2-ethoxyphenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)




RN 452314-60-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-phenoxyphenyl)methyl]-1-
piperazinyl]methyl]- (CA INDEX NAME)




RN 452314-62-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(4-phenoxyphenyl)methyl]-1-
piperazinyl]methyl]- (CA INDEX NAME)




RN 452314-65-7 CAPLUS

CN 1-Propanamine, 3-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-
c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]phenoxy]-N,N-dimethyl- (CA
INDEX NAME)




RN 452314-68-0 CAPLUS

CN Benzoic acid, 4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]-, methyl ester (CA INDEX NAME)



RN 452314-71-5 CAPLUS


CN Benzonitrile, 3-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 452314-74-8 CAPLUS

CN Benzonitrile, 4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)


10/513699



RN 452314-77-1 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-((1,1'-biphenyl)-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452314-80-6 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-((2,4-dimethoxyphenyl)methyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy- (CA INDEX NAME)



RN 452314-83-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,


3-[[4-[(3,4-dimethoxyphenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 452314-86-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2,4-dichlorophenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452314-89-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(3,4-dichlorophenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




10/513699

RN 452314-92-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(4-bromo-2-fluorophenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452314-95-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(1-methyl-1H-pyrrol-2-yl)methyl]-1-
piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452314-98-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-
piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/513699



RN 452315-01-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-thiazolylmethyl)-1-piperazinyl]methyl]-
, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-04-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2-phenyl-4-thiazolyl)methyl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-07-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(2-furanylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-,
(3R,3aS)-rel- (CA INDEX NAME)

10/513699

(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-10-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(5-bromo-2-furanyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-13-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(5-methyl-2-furanyl)methyl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



10/513699


RN 452315-16-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(3-furanylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-19-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-22-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/513699



RN 452315-24-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-thienylmethyl)-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-27-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(5-bromo-2-thienyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-30-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(4-bromo-2-thienyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-

10/513699

dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-33-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-thienylmethyl)-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-36-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[[(3R,5S)-3,5-dimethyl-4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




<12/04/2007>

Erich Leese

10/513699


RN 452315-38-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[(2R,5S)-2,5-dimethyl-4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-40-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[3-methyl-4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-42-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(1-naphthalenylmethyl)-1-
piperazinyl]methyl]- (CA INDEX NAME)

10/513699



RN 452315-44-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(1-naphthalenylmethyl)-1-
piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl

RN 452315-46-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(1-methoxy-2-naphthalenyl)methyl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-48-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(6-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-51-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-52-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(7-methyl-2-naphthalenyl)methyl]-1-

10/513699

piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-55-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(6-methyl-2-naphthalenyl)methyl]-1-
piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-58-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-methyl-2-naphthalenyl)methyl]-1-
piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




10/513699

RN 452315-61-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(7-fluoro-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-63-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(6-fluoro-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-66-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(5-fluoro-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-70-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(5-chloro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-73-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(1-bromo-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-76-3 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(5-nitro-2-naphthalenyl)methyl]-1-
piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-79-6 CAPLUS
CN 1-Naphthalenamine, 6-[[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl)methyl]-, rel-
(CA INDEX NAME)


Relative stereochemistry.



RN 452315-82-1 CAPLUS
CN 1-Naphthalenamine, 6-[[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl)methyl]-N,N-
dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.


10/513699



RN 452315-85-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(6,7-difluoro-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-87-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(5,7-difluoro-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-90-1 CAPLUS


<12/04/2007>

Erich Leese

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(7,8-difluoro-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-92-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(5-bromo-8-methoxy-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-94-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-(1H-indol-2-ylmethyl)-1-piperazinyl)methyl]-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-97-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-(1H-indol-3-ylmethyl)-1-piperazinyl]methyl]-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-00-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(1H-benzimidazol-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

10/513699

RN 452316-03-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(2-benzofuranylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452316-06-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(benzo[b]thien-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452316-09-5 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(benzo[b]thien-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-12-0 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-quinolinylmethyl)-1-
piperazinyl]methyl]- (CA INDEX NAME)



RN 452316-15-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-quinolinylmethyl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-18-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(4-quinolinylmethyl)-1-

10/513699

piperazinyl)methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452316-21-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-phenylethyl)-1-piperazinyl)methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-24-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[2-(1,3-benzodioxol-5-yl)ethyl]-1-piperazinyl)methyl]-3a,4-dihydro-
7,8-dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl

RN 452316-27-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(2-naphthalenyl)ethyl]-1-
 piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl

RN 452316-30-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(1-naphthalenyl)ethyl]-1-
 piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl


RN 452316-33-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenylpropyl)-1-piperazinyl]methyl]-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-36-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-3-[[4-(1H-inden-2-ylmethyl)-1-piperazinyl]methyl]-7,8-
 dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-39-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(1H-benzimidazol-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-42-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

10/513699

RN 452316-45-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[2-(1,3-benzodioxol-5-yloxy)ethyl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-48-2 CAPLUS

CN 1H-Inden-1-one, 5-[2-[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]ethoxy]-2,3-
dihydro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-51-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[2-[(2,3-dihydro-5-benzofuranyl)oxy]ethyl]-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-53-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[2-(3-fluorophenoxy)propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-55-1 CAPLUS

CN 3(2H)-Benzofuranone, 6-[2-[4-[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-methylethoxy]-
, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-58-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2R)-6-fluoro-3,4,4a,8a-tetrahydro-2H-1-benzopyran-2-yl]methyl]-1-
piperazinyl]-1-methylethoxy-, rel- (CA INDEX NAME)

10/513699

piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-64-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(1,3-benzodioxol-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-66-4 CAPLUS

CN 1-Propanone, 3-[4-[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



<12/04/2007>


Erich Leese

10/513699

RN 452316-69-7 CAPLUS

CN 1-Piperazinepropanol, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]- α -phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-72-2 CAPLUS

CN 1-Propanone, 3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-1-phenyl-, oxime, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452316-75-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452316-81-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452316-84-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2Z)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452316-87-9 CAPLUS

10/513699

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-propen-1-yl]-
1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX
NAME)


Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl

RN 452316-89-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-methoxyphenyl)-2-propen-1-yl]-
1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.




● 2 HCl

RN 452316-91-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methoxyphenyl)-2-propen-1-yl]-
1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX
NAME)

10/513699


Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl


RN 452316-93-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(4-phenoxyphenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452316-95-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452316-97-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452316-99-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(3-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-02-1 CAPLUS

10/513699

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.




● 2 HCl

RN 452317-04-3 CAPLUS

CN Naphth[1,2-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)-
(CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452317-06-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2-chlorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-08-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(3-chlorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-10-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(4-chlorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-12-3 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2-bromophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-14-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(3-bromophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 452317-16-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(4-bromophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-
7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.

10/513699




RN 452317-18-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[2-(trifluoromethyl)phenyl]-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-20-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[3-(trifluoromethyl)phenyl]-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-22-5 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-24-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[2-(1,1,2,2-tetrafluoroethyl)phenyl]-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-26-9 CAPLUS
CN Benzoic acid, 4-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propen-1-yl]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-28-1 CAPLUS

CN Benzoic acid, 3-[3-[4-[[3R,3aS]-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-1-propen-1-yl]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-30-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-nitrophenyl)-2-propen-1-yl]-1-piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




10/513699

RN 452317-32-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-nitrophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-34-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-methylphenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-36-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-phenoxyphenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-38-3 CAPLUS

CN Benzonitrile, 2-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-1-propen-1-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-40-7 CAPLUS

CN Benzonitrile, 3-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-1-propen-1-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-42-9 CAPLUS

10/513699


CN Benzonitrile, 4-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-1-propen-1-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-44-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(3-[1,1'-biphenyl]-2-yl)-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-46-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3,4-difluorophenyl)-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)




RN 452317-48-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2,4-difluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 452317-50-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2,3-difluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy- (CA INDEX NAME)




RN 452317-52-1 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2,6-difluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-54-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2,5-difluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-56-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(3,5-difluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 452317-58-7 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2,6-dichlorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-60-1 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2-chloro-4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



10/513699


RN 452317-64-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2-chloro-6-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-67-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2,3-dihydro-1H-inden-5-yl)-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452317-69-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-71-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(9H-fluoren-2-yl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-73-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2-dibenzofuranyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-76-9 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(1,3-benzodioxol-5-yl)-2-propen-1-yl]-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452317-79-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2,3-dihydro-5-benzofuranyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452317-82-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(4,5-dimethoxy-2-nitrophenyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-84-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-thienyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-86-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.

Double bond geometry as shown.




10/513699

RN 452317-89-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)-rel(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452317-92-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(4-bromo-2-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-94-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(5-bromo-2-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.

10/513699




RN 452317-96-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(2-furanyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-99-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-pyridinyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.



RN 452318-02-4 CAPLUS


<12/04/2007>

Erich Leese

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-pyridinyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452318-04-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-[5-(4-chlorophenyl)-2-furanyl]-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-07-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-naphthalenyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452318-09-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(1-naphthalenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



● 2 HCl


RN 452318-11-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(4-quinolinyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.

10/513699




RN 452318-13-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-quinolinyl)-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.




RN 452318-15-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(9-anthracenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-
7,8-dimethoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 452318-18-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-1-methyl-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 452318-20-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-22-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl

RN 452318-24-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
 Double bond geometry as shown.




RN 452318-27-3 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 452318-26-2
 CMF C27 H33 N3 O4

Relative stereochemistry.
 Double bond geometry as shown.

10/513699



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 452318-30-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[(2R,5S)-2,5-dimethyl-4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinylmethyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 452318-32-0 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[(3S,5R)-3,5-dimethyl-4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinylmethyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry as shown.

<12/04/2007>

Erich Leese




RN 452318-34-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-((2S,6R)-2,6-dimethyl-4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-36-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2Z)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.




10/513699

RN 452318-38-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]- (CA INDEX NAME)




RN 452318-41-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(2-(2,3-diphenyl-2-propen-1-yl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy- (CA INDEX NAME)



RN 452318-43-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(2-(1,1'-biphenyl)-4-yl-3-phenyl-2-propen-1-yl)-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452318-45-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(2-naphthalenyl)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452318-47-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(phenylmethylene)butyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452318-49-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-(phenylmethylene)heptyl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-52-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2Z)-2-bromo-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-54-6 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2Z)-2-chloro-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-57-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2Z)-2-fluoro-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-60-4 CAPLUS
CN 1-Piperazinepropanenitrile, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-α-(phenylmethylene)-,
(αZ)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-63-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-[4-(1,1-dimethylethyl)phenyl]-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452318-65-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(3-[1,1'-biphenyl]-4-yl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.


Double bond geometry unknown.



10/513699


RN 452318-67-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2Z)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-69-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2Z)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-71-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-73-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
 NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-75-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-)- (CA
 INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

Double bond geometry as shown.




10/513699

RN 452318-77-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-79-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2-chloro-6-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-81-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2Z)-3-(2,5-difluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-83-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2,5-difluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-85-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2Z)-3-(2,3-difluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-87-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(2E)-3-(2,3-difluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452318-89-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-methyl-3-(1-naphthalenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



10/513699


RN 452318-91-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-(2H-1-benzopyran-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452318-93-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-95-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-97-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3S,3aR)-rel-(-) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-99-9 CAPLUS

CN Phenol, 3-[(1E)-3-[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-
[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-methyl-1-
propen-1-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-01-6 CAPLUS

10/513699

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-03-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-thienyl)-2-propen-1-
yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-05-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2,5-dimethyl-3-thienyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-07-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2-furanyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-09-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-pyridinyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-11-8 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-methyl-4-thiazolyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-13-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2-phenyl-1-cyclopenten-1-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452319-15-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-propyn-1-yl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452319-17-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]propyl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)


Relative stereochemistry.



RN 452319-20-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[3-(4-fluorophenoxy)propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-
dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



10/513699


RN 452319-22-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-4-(2-fluorophenyl)-2-methyl-2-buten-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-24-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-[(2E,4E)-5-phenyl-2,4-pentadien-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-25-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-27-6 CAPLUS
 CN Benzoic acid, 4-[(1E)-3-[4-[[(3R,3aS)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propen-1-yl]-, methyl ester, rel-
 (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 452319-29-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 7-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452319-31-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

10/513699

Double bond geometry as shown.




RN 452319-33-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-35-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-37-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel-(+)- (CA INDEX
NAME)

10/513699


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



●2 HCl

RN 452319-39-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



●2 HCl

RN 452319-41-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452319-43-6P 452319-45-8P 452319-47-0P
 452319-49-2P 452319-51-6P 452319-53-8P
 452319-55-0P 452319-57-2P 452319-59-4P
 452319-61-8P 452319-63-0P 452319-65-2P
 452319-67-4P 452319-69-6P 452319-71-0P
 452319-73-2P 452319-75-4P 452319-77-6P
 452319-78-7P 452319-80-1P 452319-81-2P
 452319-83-4P 452319-85-6P 452319-87-8P
 452319-89-0P 452319-91-4P 452319-93-6P
 452319-95-8P 452319-97-0P 452319-99-2P
 452320-01-3P 452320-03-5P 452320-06-8P
 452320-07-9P 452320-09-1P 452320-11-5P
 452320-13-7P 452320-15-9P 452320-17-1P
 452320-19-3P 452320-21-7P 452320-23-9P
 452320-25-1P 452320-27-3P 452320-29-5P
 452320-31-9P 452320-34-2P 452320-36-4P
 452320-38-6P 452320-40-0P 452320-42-2P
 452320-44-4P 452320-46-6P 452320-48-8P
 452320-50-2P 452320-52-4P 452320-54-6P
 452320-56-8P 452320-58-0P 452320-60-4P
 452320-62-6P 452320-64-8P 452320-66-0P
 452320-68-2P 452320-70-6P 452320-72-8P
 452320-74-0P 452320-76-2P 452320-78-4P
 452320-80-8P 452320-82-0P 452320-84-2P
 452320-86-4P 452320-88-6P 452320-90-0P
 452320-92-2P 452320-94-4P 452320-96-6P
 452320-98-8P 452321-00-5P 452321-02-7P
 452321-04-9P 452321-06-1P 452321-08-3P
 452321-10-7P 452321-12-9P 452321-14-1P
 452321-16-3P 452321-19-6P 452321-21-0P
 452321-23-2P 452321-25-4P 452321-27-6P
 452321-29-8P 452321-31-2P 452321-33-4P
 452321-35-6P 452321-37-8P 452321-39-0P
 452321-41-4P 452321-43-6P 452321-45-8P
 452321-47-0P 452321-49-2P 452321-51-6P
 452321-53-8P 452321-55-0P 452321-57-2P
 452321-59-4P 452321-61-8P 452934-93-9P
 452934-94-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(target compound; preparation and pharmaceutical activity of substituted
 isoxazolines as anti-depressants)


RN 452319-43-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

3a,4-dihydro-7-(2-methoxyethoxy)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-45-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-47-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-49-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,

3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl


RN 452319-51-6 CAPLUS
CN Carbamic acid, ethyl-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-53-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-55-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-57-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, 7-propanoate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-59-4 CAPLUS

CN Acetic acid, 2-methoxy-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-
phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-
c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-61-8 CAPLUS

CN Cyclopropanecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-63-0 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-65-2 CAPLUS

CN 2-Propenoic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

10/513699

Double bond geometry as shown.




RN 452319-67-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-(cyclopentyloxy)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-69-6 CAPLUS

CN 4-Pyridinecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 452319-71-0 CAPLUS


CN Ethanamine, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-

10/513699

yl]oxy]-N,N-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-73-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-yl,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, 7-(hydrogen sulfate), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-75-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
8-chloro-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-77-6 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
8-chloro-3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-78-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-80-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452319-81-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3S,3aR)-rel-(-) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452319-83-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7,8-difluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-85-6 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
8-fluoro-3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-87-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-phenyl-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-89-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methyl-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-91-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
8-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-7-(methylthio)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-93-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7,8-diol,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



● 2 HCl


RN 452319-95-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-8-ol,
 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 452319-97-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-8-ol,
 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 8-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452319-99-2 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-8-yl]oxy]-, 1-acetate, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-01-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



10/513699


RN 452320-03-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, 7-acetate, (3R,3aS)-rel- (CA
INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-06-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, 7-acetate, (3R,3aS)-rel- (CA
INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-07-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-8-methoxy-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-09-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
7-(cyclopropylmethoxy)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-11-5 CAPLUS

CN Cyclopropanecarboxylic acid, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




10/513699

RN 452320-13-7 CAPLUS

CN 3-Pyridinecarboxylic acid, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-15-9 CAPLUS

CN Carbamic acid, ethyl-, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-17-1 CAPLUS

CN Ethanamine, 2-[[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-N,N-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-19-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-21-7 CAPLUS

CN Carbonic acid, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



10/513699


RN 452320-23-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(2-propen-1-yloxy)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-25-1 CAPLUS
CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-, hydrochloride (1:2), rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl

RN 452320-27-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 7-methanesulfonate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-29-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-31-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-7-phenyl-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 452320-34-2 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-7-(methylthio)-, (3R,3aS)-rel-, 2,2,2-trifluoroacetate
(1:1) (CA INDEX NAME)

CM 1

CRN 452320-33-1

CMF C27 H33 N3 O3 S

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 452320-36-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-
propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



10/513699


RN 452320-38-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-40-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-42-2 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-44-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel-(+)-
(CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452320-46-6 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3S,3aS)-rel-(-)-
(CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452320-48-8 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-50-2 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-52-4 CAPLUS


CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-54-6 CAPLUS
 CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-5-methyl-3-
 [[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-,
 (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452320-56-8 CAPLUS
 CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-2-
 methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-5-(phenylmethyl)-,
 (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 452320-58-0 CAPLUS
 CN Ethanone, 1-[(3R,3aR)-3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-
 propen-1-yl]-1-piperazinyl]methyl]isoxazolo[4,3-c]quinolin-5(3H)-yl]-2,2,2-
 trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452320-60-4 CAPLUS

CN Ethanone, 1-[(3R,3aR)-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]isoxazolo[4,3-c]quinolin-5(3H)-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-62-6 CAPLUS

CN Ethanone, 1-[(3R,3aR)-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]isoxazolo[4,3-c]quinolin-5(3H)-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 452320-64-8 CAPLUS


CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxylic acid, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, rel-

10/513699

ethyl ester, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-66-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxamide,
N-ethyl-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-68-2 CAPLUS

CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-3-phenyl-
2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aR)-rel-
(CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.


10/513699



● 2 HCl


RN 452320-70-6 CAPLUS
CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-72-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(phenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452320-74-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(3-phenylpropyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

10/513699


Relative stereochemistry.



RN 452320-76-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-
, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452320-78-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-(2-naphthalenylmethyl)-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




PAGE 1-A

—OMe


RN 452320-80-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
 3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452320-82-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 7-(cyclopropylmethoxy)-3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-
 piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452320-84-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 7-(difluoromethoxy)-3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-
 piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452320-86-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-7-
[(tetrahydro-3-furanyl)oxy]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452320-88-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-,
7-acetate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452320-90-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-8-methoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-
, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452320-92-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol,
3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-94-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2-fluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-96-6 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(3-fluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-98-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-fluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-00-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methoxyphenyl)-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452321-02-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-[3-(trifluoromethyl)phenyl]-2-
buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452321-04-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-
buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452321-06-1 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2-chlorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452321-08-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(3-chlorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-10-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(4-chlorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452321-12-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methylphenyl)-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452321-14-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452321-16-3 CAPLUS

10/513699


CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-methoxyphenyl)-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-19-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2Z)-3-fluoro-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-
dihydro-7,8-dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX
NAME)


Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl

RN 452321-21-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2,4-difluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452321-23-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(3,4-difluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-
3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452321-25-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-pyridinyl)-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




10/513699

RN 452321-27-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-pyridinyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452321-29-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-thienyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452321-31-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3-[[4-[(2E)-3-(2-furanyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452321-33-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-35-6 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452321-37-8 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

10/513699


NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452321-39-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452321-41-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452321-43-6 CAPLUS

10/513699

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(5-fluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-45-8 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(2-(2-naphthalenyloxy)ethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-47-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-(2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



10/513699

RN 452321-49-2 CAPLUS
CN [1,3]Dioxolo[6,7]naphth[1,2-c]isoxazole,
3,3a,4,5-tetrahydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-,
hydrochloride (1:2), (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 452321-51-6 CAPLUS
CN [1,3]Dioxolo[6,7]naphth[1,2-c]isoxazole,
3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




●2 HCl

RN 452321-53-8 CAPLUS
CN Furo[2',3':6,7]naphth[1,2-c]isoxazole,
3,3a,4,5,8,9-hexahydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452321-55-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
3a,4-dihydro-7-methoxy-3-[2-[4-(2-naphthalenylmethyl)-1-piperazinyl]ethyl]-
, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-57-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine,
3a,4-dihydro-7,8-dimethoxy-N-methyl-N-[1-(2-naphthalenylmethyl)-4-
piperidinyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452321-59-4 CAPLUS

CN Formamide, N-[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-
c]isoxazol-3-yl)methyl]-N-[1-(2-naphthalenylmethyl)-4-piperidinyl]-, rel-
(CA INDEX NAME)

10/513699


Relative stereochemistry.



RN 452321-61-8 CAPLUS

CN 1-Piperazinemethanamine, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-N-2-naphthalenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452934-93-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(7-fluoro-2,3,4a,8a-tetrahydro-1,4-dioxino[2,3-b]pyridin-3-yl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452934-94-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole,
 3-[[4-[(6-fluoro-3,4,4a,8a-tetrahydro-4-methyl-2H-1,4-benzoxazin-2-yl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT:


2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 20 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:385709 CAPLUS
 DOCUMENT NUMBER: 137:201371
 TITLE: Novel ene-like cycloisomerization reaction of nitrile oxides with a tethered allyltrimethylsilyl group
 AUTHOR(S): Ishikawa, Teruhiko; Urano, Jin; Ikeda, Shushiro; Kobayashi, Yasuhiro; Saito, Seiki
 CORPORATE SOURCE: Department of Bioscience and Biotechnology, Faculty of Engineering, Okayama University, Okayama, 700-8530, Japan
 SOURCE: Angewandte Chemie, International Edition (2002), 41(9), 1586-1588
 CODEN: ACIEF5; ISSN: 1433-7851
 PUBLISHER: Wiley-VCH Verlag GmbH
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:201371
 GI



I



II

AB Rather than the expected [3+2] cycloaddn., a novel ene-like cycloisomerization occurs on deprotonation of allyltrimethylsilyl-oxime compds. when the β -sp² carbon atom of the allyltrimethylsilyl moiety is tethered to the oxime unit. The resulting nitrile oxide functional group serves as an enophile, and the final cyclized product still has two functional groups suitable for further manipulations. Thus, ene-like cycloisomerization of allyltrimethylsilyl-oxime I with NaOCl in CH₂Cl₂ gave 82% cyclized product II.


IT 452306-05-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 452306-05-7 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[(trimethylsilyl)methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



10/513699

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 21 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:260283 CAPLUS

DOCUMENT NUMBER: 132:293757

TITLE: Preparation of novel 4,5-dihydroisoxazole derivatives and their use as pharmaceuticals for T cell-mediated diseases

INVENTOR(S): Freyne, Eddy Jean Edgard; Andres-Gil, Jose Ignacio; Deroose, Frederik Dirk; Petit, Davy Petrus Franciscus Maria; Matesanz-Ballesteros, Maria Encarnacion; Alvarez Escobar, Rosa Maria

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 108 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021959	A1	20000420	WO 1999-EP7803	19991007
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2346396	A1	20000420	CA 1999-2346396	19991007
EP 1119568	A1	20010801	EP 1999-953847	19991007
EP 1119568	B1	20040218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002527438	T	20020827	JP 2000-575865	19991007
AU 763460	B2	20030724	AU 2000-10393	19991007
AT 259803	T	20040315	AT 1999-953847	19991007
ES 2216579	T3	20041016	ES 1999-953847	19991007
US 6583141	B1	20030624	US 2001-807149	20010406
HK 1038565	A1	20040618	HK 2002-100274	20020115
US 20040019059	A1	20040129	US 2003-403543	20030331
US 7414048	B2	20080819		
PRIORITY APPLN. INFO.:			EP 1998-203394	A 19981009
			WO 1999-EP7803	W 19991007
			US 2001-807149	A3 20010406

OTHER SOURCE(S): MARPAT 132:293757

GI




AB The invention concerns title compds. I and their N-oxides, pharmaceutically acceptable addition salts, quaternary ammonium salts, and stereochem. isomeric forms [wherein m, n, p = 0 or 1; R1 = (un)substituted pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl or phenyl; B = amide, ketone, or oxadiazole; D = (un)substituted aryl or heterocyclyl; Q = bond, CO, (un)substituted NH, CONH, CH2, CH(:CH2), C(:NH), SO, SO, 3-oxobutenyl, pyrazole, isoxazole, or thiazole nucleus; L = (un)substituted aryl or heteroaryl; R2, R3 = H, halo, C1-6 alkyloxy, or (un)substituted C1-6 alkyl]. Also disclosed is a process for their preparation, compns. comprising them, and their medical use. The compds. show growth inhibitory activity against T cell blasts and keratinocytes in vitro. The compds. are claimed for use in the treatment of prevention of rheumatic, arthritic, and inflammatory diseases, psoriasis, T cell leukemia, transplant rejection, and graft-vs.-host disease. For instance, base-catalyzed cycloaddn. of N-hydroxy-3-pyridinecarboximidoyl chloride with Me 2-propenoate gave 98% Me 4,5-dihydro-3-(3-pyridinyl)-5-isoxazolecarboxylate, which was amidated with (4-aminophenyl)phenylmethanone to give 58% title compound II. At a concentration of 10-6 M, II gave 81% inhibition of T cell blast formation in human whole blood.

IT 264606-57-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of dihydroisoxazole derivs. as antiproliferatives and immunomodulators)

RN 264606-57-7 CAPLUS

CN Isoxazolo[4,3-c]quinoline-3-carboxylic acid, 3,3a,4,5-tetrahydro- (CA INDEX NAME)



10/513699

IT 264606-16-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of dihydroisoxazole derivs. as antiproliferatives and immunomodulators)

RN 264606-16-8 CAPLUS

CN Piperidine, 4-(4-fluorobenzoyl)-1-[[(3R,3aR)-3,3a,4,5-tetrahydroisoxazolo[4,3-c]quinolin-3-yl]carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 22 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:191138 CAPLUS

DOCUMENT NUMBER: 128:257364

ORIGINAL REFERENCE NO.: 128:50951a,50954a

TITLE: Intramolecular cycloaddition of nitrones and nitrile oxides with sulfur-substituted dienes and its synthetic applications

AUTHOR(S): Chou, Shang-Shing P.; Yu, Yu-Ju

CORPORATE SOURCE: Dep. Chem., Fu Jen Catholic Univ., Taichung, 242, Taiwan

SOURCE: Journal of the Chinese Chemical Society (Taipei)

(1998), 45(1), 163-173

CODEN: JCCTAC; ISSN: 0009-4536

Chinese Chemical Society

PUBLISHER: Journal

DOCUMENT TYPE: English

LANGUAGE: CASREACT 128:257364

AB A series of sulfur-substituted dienyl nitrones and oximes were conveniently prepared from the 3-sulfolene precursors. Regiospecific intramol. 1,3-dipolar cycloaddns. of nitrones and nitrile oxides with sulfur-substituted dienes have been efficiently carried out from the suitable 3-sulfolene precursors. The stereochem. of the cycloaddn. of nitrones depends on the structure of the substituent (sulfide or sulfone) on the diene as well as on the chain length connecting the diene and nitrone. The fused bicyclic products obtained from these reactions have been converted to some interesting heterocyclic compds. which have the useful structure of vinyl sulfide or sulfone.

IT 205110-63-0P


RL: SPN (Synthetic preparation); PREP (Preparation)

(intramol. cycloaddn. of nitrones and nitrile oxides with sulfur-substituted dienes)

RN 205110-63-0 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylthio)ethenyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT:

73


THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 23 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:431584 CAPLUS
 DOCUMENT NUMBER: 127:149098
 ORIGINAL REFERENCE NO.: 127:28805a,28808a
 TITLE: A convenient synthesis of 3- and 3,4-substituted
 4,5-dihydroisoxazole-5-acetic acids
 AUTHOR(S): Eichinger, Karl; Wokurek, Michael; Zauner, Bernd;
 Rostami, Mohammad Reza
 CORPORATE SOURCE: Institute of Organic Chemistry, Vienna University of
 Technology, Vienna, A-1060, Austria
 SOURCE: Synthetic Communications (1997), 27(16), 2733-2742
 CODEN: SYNCAV; ISSN: 0039-7911
 PUBLISHER: Dekker
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 127:149098
 GI



AB The 4,5-dihydroisoxazole-5-acetic acids I [R1 = Ph, Me, 4-ClC6H4,
 4-MeOC6H4, 4-PhC6H4, R2 = H, SPh, OPh, 4-ClC6H4; R1R2 = (CH2)4, (CH2)10,
 1,2,3,4-tetrahydronaphth-1,2-diyl] were prepared from the ketoximes
 R1C(CH2R2):NOH, 2,2-dimethyl-5-methoxymethylene-1,3-dioxan-4,6-dione and
 butyllithium in yields from 35 to 79 %.
 IT 193267-45-7P 193267-49-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of isoxazoleacetic acids)
 RN 193267-45-7 CAPLUS
 CN Naphth[1,2-c]isoxazole-3-acetic acid, 3,3a,4,5-tetrahydro-, (3R,3aS)-rel-
 (CA INDEX NAME)


Relative stereochemistry.



RN 193267-49-1 CAPLUS
 CN 2,1-Benzisoxazole-3-acetic acid, 3,3a,4,5,6,7-hexahydro-, (3R,3aS)-rel-
 (CA INDEX NAME)

Relative stereochemistry.

10/513699




REFERENCE COUNT:

16


THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/513699


L7 ANSWER 24 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:390560 CAPLUS
DOCUMENT NUMBER: 125:168364
ORIGINAL REFERENCE NO.: 125:31565a,31568a
TITLE: A highly convergent enantioselective total synthesis
of marine natural product, furanoterpene
AUTHOR(S): Bando, Toshikazu; Shishido, Kozo
CORPORATE SOURCE: Inst. for Medicinal Resources, Univ. Tokushima, Sho,
770, Japan
SOURCE: Chemical Communications (Cambridge) (1996), (11),
1357-1358
CODEN: CHCOFS; ISSN: 1359-7345
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 125:168364
GI




AB The enantioselective total convergent synthesis of marine furanoterpene
(I) is achieved and the absolute configuration of the only existing quaternary
stereogenic center is found to be S.
IT 180333-99-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(a highly convergent enantioselective total synthesis of furanoterpene)
RN 180333-99-7 CAPLUS
CN 2,1-Benzisoxazole-3-methanol, 3,3a,4,5,6,7-hexahydro-7-
[(methoxymethoxy)methyl]-7-methyl-, 3-acetate (CA INDEX NAME)



L7 ANSWER 25 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:29561 CAPLUS
 DOCUMENT NUMBER: 124:232296
 ORIGINAL REFERENCE NO.: 124:43031a,43034a
 TITLE: Effect of the α -alkyl substituent of conjugated nitroolefins on the formation of cyclic nitronic esters vs. nitrocyclopropanes in their reaction with sulfur ylides
 AUTHOR(S): Kumaran, G.; Kulkarni, Gurunath H.
 CORPORATE SOURCE: Div. Org. Chem., Natl. Chem. Lab., Pune, 411008, India
 SOURCE: Synthesis (1995), (12), 1545-8
 CODEN: SYNTBF; ISSN: 0039-7881
 PUBLISHER: Thieme
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 124:232296
 AB The formation of cyclic nitronic esters, isoxazoline N-oxides vs. nitrocyclopropanes in the reaction of conjugated nitroolefins with sulfur ylides depends on the presence of an α -alkyl substituent in the conjugated nitroolefins.
 IT 174574-89-1P 174574-92-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (effect of alkyl substituent on cyclic nitronate and nitrocyclopropane formation in cycloaddn. of conjugated nitroolefins with sulfur ylides)
 RN 174574-89-1 CAPLUS
 CN 2,1-Benzisoxazole-3-carboxylic acid, 3,3a,4,5,6,7-hexahydro-, ethyl ester, 1-oxide (CA INDEX NAME)



RN 174574-92-6 CAPLUS
 CN Methanone, (3,3a,4,5,6,7-hexahydro-1-oxido-2,1-benzisoxazol-3-yl)phenyl- (CA INDEX NAME)



10/513699

<12/04/2007>

Erich Leese

L7 ANSWER 26 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:228191 CAPLUS

DOCUMENT NUMBER: 122:81272

ORIGINAL REFERENCE NO.: 122:15443a,15446a

TITLE: Nitrile oxide [3 + 2] cycloaddition: application to the synthesis of 6-substituted 3(2H)-pyridazinones and 6-substituted 4,5-dihydro-4-hydroxy-3(2H)-pyridazinones

AUTHOR(S): Baraldi, P. G.; Bigoni, A.; Cacciari, B.; Caldari, C.; Manfredini, S.; Spalluto, G.

CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Univ. di Ferrara, Ferrara, I-44100, Italy

SOURCE: Synthesis (1994), (11), 1158-62

CODEN: SYNTBF; ISSN: 0039-7881

PUBLISHER: Thieme

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 122:81272

AB An efficient method for the preparation of 6-substituted 3(2H)-pyridazinones and 6-substituted 4,5-dihydro-4-hydroxy-3(2H)-pyridazinones starting from 3,5-disubstituted 4,5-dihydroisoxazoles is described. N-O bond cleavage of the isoxazoline ring promoted by molybdenum hexacarbonyl or by catalytic hydrogenation afforded the α -hydroxy γ -keto esters RCOCH₂CH(OH)CO₂Et (I, R = Me, Bu, 2-, 4-pyridyl, 4-HOC₆H₄) which were converted into 6-substituted 4,5-dihydro-4-hydroxy-3(2H)-pyridazinones for 6-substituted 3(2H)-pyridazinones on treatment with hydrazine hydrate at room temperature or reflux in high yield starting from I. An intramol. version of this methodol. has been developed to prepare the known antiulcer tricyclic 5H-[1]-benzopyrano[4,3-c]pyridazin-3(2H)-one.


IT 160427-31-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(nitrile oxide [3 + 2] cycloaddn. to pyridazinones)

RN 160427-31-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 3a,4-dihydro-, methyl ester (CA INDEX NAME)




L7 ANSWER 27 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:94454 CAPLUS
 DOCUMENT NUMBER: 123:111970
 ORIGINAL REFERENCE NO.: 123:20005a,20008a
 TITLE: Pyridazin-3(2H)-ones via Δ^2 -isoxazoline
 intermediates: synthetic studies
 AUTHOR(S): Baraldi, Pier Giovanni; Spalluto, Giampiero;
 Manfredini, Stefano; Simoni, Daniele
 CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Universita di
 Ferrara, Ferrara, Italy
 SOURCE: Acta Chimica Slovenica (1994), 41(2), 149-72
 CODEN: ACSLE7; ISSN: 1318-0207
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



- AB An efficient method for the preparation of
 6-substituted-4,5-dihydro-3(2H)pyridazinones I (R = alkyl, benzyl, etc.)
 was described. The synthetic strategy is based on Δ^2 -isoxazolines
 chemical which were unmasked by N-O bond cleavage and cyclized to the target
 compound Utilizing the same approach was possible to obtain both
 6-substituted-3(2H)-pyridazinones and
 6-substituted-4-hydroxy-4,5-dihydro-3(2H)-pyridazinones. This protocol
 was also extended to a C-nucleoside starting from
 β -ribofuranosylnitromethane. Moreover, an intramol. version of this
 methodol. has been developed to prepare a known antiulcer tricyclic
 3(2H)-pyridazinone. The unusual transformation of compds. I into the
 corresponding 3-(1-naphthyl)propionic acid Et ester derivs. was also
 reported.
- IT 160427-31-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of benzpyranopyridazinone)
- RN 160427-31-6 CAPLUS
- CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 3a,4-dihydro-, methyl
 ester (CA INDEX NAME)

10/513699




<12/04/2007>

Erich Leese

L7 ANSWER 28 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1993:560649 CAPLUS
 DOCUMENT NUMBER: 119:160649
 ORIGINAL REFERENCE NO.: 119:28813a,28816a
 TITLE: Preparation of secosteroids having vitamin D activities.
 INVENTOR(S): Sotojima, Fukuo
 PATENT ASSIGNEE(S): Juki Gosei Yakuhin Kogyo Kk, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05058991	A	19930309	JP 1991-254255	19910906
PRIORITY APPLN. INFO.:			JP 1991-254255	19910906
OTHER SOURCE(S):			CASREACT 119:160649; MARPAT 119:160649	

GI




AB The title compds. [R1, R2 = H, protecting group] are prepared in many steps from a heptenetriol derivative, e.g., HO-CH2-CH:CH-CH2-CHQ-CH2-CH2-O-Q1 [Q = tert-butylidiphenylsilyl, Q1 = p-methoxyphenyl]. E.g., the (nitrooctenylidene)cyclohexane derivative II (multistep preparation given) was cyclized in benzene contg Et3N and Ph isocyanate to give III diastereomers, one of which in H2O containing B(OMe)3 was treated with Raney Ni in EtOH to give I [R1 = R2 = Q1].

IT 149741-09-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and ring cleavage of)

RN 149741-09-3 CAPLUS

CN 2,1-Benzisoxazole, 3-(cyclohexylidenemethyl)-7-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]-3,3a,4,5,6,7-hexahydro- (CA INDEX NAME)

10/513699



<12/04/2007>

Erich Leese

L7 ANSWER 29 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:234262 CAPLUS

DOCUMENT NUMBER: 118:234262

ORIGINAL REFERENCE NO.: 118:40591a,40594a

TITLE: A general synthetic route to fused furans. Total synthesis of (+)-pallascensin A

AUTHOR(S): Shishido, Kozo; Umimoto, Koji; Ouchi, Mikiko; Irie, Osamu; Omodani, Tomoki; Takata, Takeshi; Shibuya, Masayuki

CORPORATE SOURCE: Inst. Med. Resour., Univ. Tokushima, Tokushima, 770, Japan


SOURCE: Journal of Chemical Research, Synopses (1993), (2), 58-9

CODEN: JRPSDC; ISSN: 0308-2342

DOCUMENT TYPE: Journal

LANGUAGE: English

GI




AB A general and facile synthetic route to fused furans has been developed. The key step of the transformation involves the intramol. [3+2] dipolar cycloaddn. reaction of nitrile oxides which were generated in situ from the corresponding oxime acetates. Reductive hydrolysis of the resulting dihydroisoxazoles followed by alkaline hydrolysis provided β,γ -dihydroxy ketones which were immediately treated with a catalytic amount of p-toluenesulfonic acid to afford the fused furans I (R = Me, R1 = H; R = H, R1 = Me). Alternatively, the alcs., derived by hydrolysis of the dihydroisoxazoles, were submitted to a sequential reductive hydrolysis and acid treatment to provide I. Addnl. dihydroisoxazole alcs., prepared from com. available phthalide, were similarly treated to give the tricyclic fused furans II (R2 = H, Me, R3 = Me; R2 = Me, R3 = H) in reasonable yields. The methodol. developed here has been successfully applied to a total synthesis of (+)-pallascensin A (III) starting with (+)-Wieland-Miescher ketone.

IT 147378-13-0P 147511-14-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and deacetylation of)


RN 147378-13-0 CAPLUS

CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro- α -methyl-, acetate (ester), [3a(5'),3aa]- (9CI) (CA INDEX NAME)



RN 147511-14-6 CAPLUS

CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro-α-methyl-, acetate (ester), [3α(R*),3α]- (9CI) (CA INDEX NAME)




IT 129302-93-8P 147378-09-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and reductive hydrolysis of)

RN 129302-93-8 CAPLUS


CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5,5a,6,7,8,9,9a-decahydro-6,6,9a-trimethyl-, acetate (ester), [3R-(3α,3αa,5αβ,9αa)]- (9CI) (CA INDEX NAME)



RN 147378-09-4 CAPLUS

CN 2,1-Benzisoxazole-3-methanol, 3,3a,4,5,6,7-hexahydro-7,7-dimethyl-, acetate (ester), cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 147378-18-5P

10/513699


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation, deacetylation, and cyclization of)

RN 147378-18-5 CAPLUS

CN 2,1-Benzisoxazole-3-methanol, 3,3a,4,5,6,7-hexahydro-7,7-dimethyl-, cis-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 147378-22-1P 147511-12-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation, hydrolysis, and cyclization of)

RN 147378-22-1 CAPLUS

CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro- α -methyl-,
[3 α (S*),3aa]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 147511-12-4 CAPLUS

CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro- α -methyl-,
[3 α (R*),3aa]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 30 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:570854 CAPLUS

DOCUMENT NUMBER: 117:170854

ORIGINAL REFERENCE NO.: 117:29525a, 29528a

TITLE: Preparation of (dihydroxyethyl)cyclohexanone derivatives as intermediates for ring A fragments of compounds having vitamin D-like activity

INVENTOR(S): Sotojima, Fukuo

PATENT ASSIGNEE(S): Yuki Gosei Yakuhin Kogyo K. K., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04082856	A	19920316	JP 1990-194847	19900725
PRIORITY APPLN. INFO.:			JP 1990-194847	19900725
OTHER SOURCE(S):	CASREACT	117:170854; MARPAT	117:170854	

GI



AB The title compds. I (R1-R4 = H, OH-protecting group) are prepared from CH2:CHCH2CH2OR5 (R5 = H, OH-protecting group) via intermediates such as epoxides (II), alkynes R3OCH2C.tplbond.CCH2CH(OR1)CH2CH2OR5 (III; R1, R3, R5 = same as above), olefins [IV; R = CH2OR5, CHO, CH(OR2)CH2NO2; R1, R2, R3, R5 = same as above], and isoxazole derivs. (V; R1-R3 = same as above). Thus, ring-opening addition reaction of II (R5 = CH2C6H4OMe-p) (preparation given) with HC.tplbond.CCH2OThp (Thp = tetrahydropyranyl) in the presence of BF3.Et2O after metalation with BuLi, conversion of the resulting III (R1 = H, R3 = THP, R5 = CH2C6H4OMe-p) into IV (R = CHO, R1 = SiPh2Bu-tert, R3 = THP) via silylation, debenzoylation, partial hydrogenation over Lindlar catalyst, and oxidation with pyridinium chlorochromate, and addition reaction of

the aldehyde with MeNO₂ in the presence of KF and 18-crown-6 gave IV [R = CH(OH)CH₂NO₂, R₁ = SiPh₂Bu-tert, R₃ = THP]. Silylation of the last with CF₃SO₃SiMe₂Bu-tert in the presence of 2,6-lutidine, cyclization of the resulting IV [R = CH(OSiMe₂Bu-tert)CH₂NO₂, R₁ = SiPh₂Bu-tert, R₃ = THP] by treatment with Et₃N and PhCNO, and hydrogenation of the resulting V (R₁, R₃ = same as above; R₂ = SiMe₂Bu-tert) over Raney nickel in the presence of H₂O gave I (R = SiPh₂Bu-tert, R₂ = SiMe₂Bu-tert, R₃ = THP, R₄ = H).

IT 142860-74-0P 142860-82-0P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of, in preparation of cyclohexanone derivative as intermediate

for ring

A fragment of vitamin D analog)


RN 142860-74-0 CAPLUS

CN 2,1-Benzisoxazole, 7-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]-3,3a,4,5,6,7-hexahydro-3-[[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]- (CA INDEX NAME)



RN 142860-82-0 CAPLUS

CN 2,1-Benzisoxazole, 5,7-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3,3a,4,5,6,7-hexahydro-3-[[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]- (CA INDEX NAME)



L7 ANSWER 31 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1990:532531 CAPLUS

DOCUMENT NUMBER: 113:132531

ORIGINAL REFERENCE NO.: 113:22531a,22534a

TITLE: An alternative total synthesis of (+)-pallescensin A based on the intramolecular [3+2] cycloaddition reaction

AUTHOR(S): Shishido, Kozo; Umimoto, Koji; Shibuya, Masayuki
CORPORATE SOURCE: Fac. Pharm. Sci., Univ. Tokushima, Tokushima, 770, Japan

SOURCE: Heterocycles (1990), 31(4), 597-8


CODEN: HTCYAM; ISSN: 0385-5414

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 113:132531

GI



I




II

AB An alternative total synthesis of optically active pallescensin A (I) features a furan construction via the intramol. [3+2] cycloaddn. of nitrile oxide II.

IT 129302-93-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and isoxazoline reductive hydrolysis of)

RN 129302-93-8 CAPLUS

CN Naphth[1,2-c]isoxazole-3-methanol,
3,3a,4,5,5a,6,7,8,9,9a-decahydro-6,6,9a-trimethyl-, acetate (ester),
[3R-(3α,3αa,5αβ,9αa)]- (9CI) (CA INDEX NAME)

L7 ANSWER 32 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1990:458998 CAPLUS

DOCUMENT NUMBER: 113:58998

ORIGINAL REFERENCE NO.: 113:9979a,9982a

TITLE: Reaction of α,α -dithiooximes with functionalized carbonyl compounds. Part 2. Reaction with α -chloroketones and α,β -unsaturated aldehydes and ketones

AUTHOR(S): Jarrar, Adil A.; Hussein, Ahmad Q.; Madi, Ahmad S.

CORPORATE SOURCE: Fac. Sci., Univ. Jordan, Amman, Jordan

SOURCE: Journal of Heterocyclic Chemistry (1990), 27(2), 275-8


CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 113:58998

GI



II



IV


AB Reaction of LiON:CRCHR1Li (I; R = Ph, 4-MeC6H4; R1 = H) with 4-R2C6H4COCH2Cl (R2 = H, Me) afforded (hydroxymethyl)isoxazoline II in 62-77% yield. Similar reaction of I [R = Ph, 4-MeC6H4, 4-BrC6H4, R1 = H; RR1 = (CH2)4] with R3COCH:CR3R4 (R3 = H, Me; R4 = H, Me, Ph) gave HON:CRCHR1CR3(OH)CH:CR3R4 (III) in 63-80% yield. Treatment of III with P2O5 gave vinylisoxazolines IV.

IT 128094-36-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 128094-36-0 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-(2-phenylethenyl)- (CA INDEX NAME)



L7 ANSWER 33 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1989:477887 CAPLUS

DOCUMENT NUMBER: 111:77887

ORIGINAL REFERENCE NO.: 111:13127a,13130a

TITLE: Stepwise intramolecular cycloaddition of nitrile oxide equivalents derived from the Lewis acid-promoted reaction of 1-nitroalkadienes and allylic stannanes
 Uno, Hidemitsu; Goto, Kenichi; Watanabe, Noriko; Suzuki, Hitomi

AUTHOR(S): Fac. Sci., Ehime Univ., Matsuyama, 790, Japan

CORPORATE SOURCE: Journal of the Chemical Society, Perkin Transactions

SOURCE: 1: Organic and Bio-Organic Chemistry (1972-1999) (1989), (2), 289-95

CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 111:77887

AB The Lewis acid-promoted reaction of 1-nitroalka-1,5-(or 1,6-)dienes with allylic stannanes has been studied. In the presence of TiCl_4 , 1-nitrohexa-1,5-diene reacted smoothly with allyltrimethylstannane to give a diastereoisomeric mixture of 6-allyl-3a,4,5,6-tetrahydro-3H-cyclopent[c]isoxazoles, while the reaction using AlCl_3 as catalyst led to an allylated cyclohexanone oxime derivative in good yield. Similar reaction of 1-nitrohepta-1,6-diene, however, gave a bicyclic dihydroisoxazole irresp. of the Lewis acids employed. In the latter case, nitrile oxide equivs. derived from 1-nitroalka-1,6-dienes underwent a stepwise cycloaddn. as shown by the lack of stereospecificity in the reactions of (1E,6Z)-1-nitro-7-phenylhepta-1,6-diene and (1E,6Z)-1-nitroocta-1,6-diene.


IT 121948-65-0P 122045-15-2P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and spectra of)

RN 121948-65-0 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-methyl-7-(2-propenyl)-, (3a,3a α ,7 β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 122045-15-2 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-methyl-7-(2-propenyl)-, (3a,3a β ,7a)- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/513699



<12/04/2007>

Erich Leese

L7 ANSWER 34 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1988:21762 CAPLUS
 DOCUMENT NUMBER: 108:21762
 ORIGINAL REFERENCE NO.: 108:3691a,3694a
 TITLE: Stereoselective intramolecular nitrile oxide
 cycloaddition to chiral allyl ethers
 AUTHOR(S): Annunziata, Rita; Cinquini, Mauro; Cozzi, Franco;
 Raimondi, Laura
 CORPORATE SOURCE: Dip. Chim. Org. Ind., Univ. Milano, Milano, I-20133,
 Italy
 SOURCE: Journal of the Chemical Society, Chemical
 Communications (1987), (8), 529-30
 CODEN: JCCCAT; ISSN: 0022-4936
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 108:21762
 GI




AB Intramol. nitrile oxide cycloaddn. reactions on (Z)- and (E)-chiral allyl ethers occur with poor to good stereoselectivity (diastereoisomeric ratios up to 86:14), which depends on the double bond configuration as well as on steric and stereoelectronic effects. Thus, $\text{PhCH}_2\text{OCHMeCH:CH(CH}_2)_4\text{CH:NOH}$ was treated with NaOCl to give isoxazole derivs. I and II.

IT 109960-80-7P 109960-81-8P 110013-28-0P
 110013-29-1P 110013-30-4P 110013-31-5P
 110013-32-6P 110013-33-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 109960-80-7 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3R-[3 α (S*),3 $\alpha\beta$]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 109960-81-8 CAPLUS

CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3S-[3 α (S*),3 $\alpha\beta$]]- (9CI) (CA INDEX NAME)

10/513699


Absolute stereochemistry.



RN 110013-28-0 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3S-[3α(R*),3αβ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 110013-29-1 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3R-[3α(S*),3αα]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 110013-30-4 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-, [3S-[3α(R*),3αα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/513699

RN 110013-31-5 CAPLUS

CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3R-[3 α (R*),3 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 110013-32-6 CAPLUS

CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3S-[3 α (S*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 110013-33-7 CAPLUS

CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3R-[3 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/513699



<12/04/2007>

Erich Leese

L7 ANSWER 35 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1987:575238 CAPLUS

DOCUMENT NUMBER: 107:175238

ORIGINAL REFERENCE NO.: 107:28111a,28114a

TITLE: Stereoselectivity of intramolecular nitrile oxide cycloadditions to Z and E chiral alkenes

AUTHOR(S): Annunziata, Rita; Cinquini, Mauro; Cozzi, Franco; Gennari, Cesare; Raimondi, Laura

CORPORATE SOURCE: Dip. Chim. Org. Ind., Univ. Milano, Milan, I-20133, Italy

SOURCE: Journal of Organic Chemistry (1987), 52(21), 4674-81
CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 107:175238

AB Treatment of (E)- and (Z)-RCHR1CH:CHCH2CH2(CH2)nCH:NOH [R = PhCH2O, PhCH2OCH2, Me2CH; R1 = Me, PhCH2O; RR1 = O(CH2)5OCH2] with NaOCl gave nitrile oxides, which were trapped by intramol. cycloaddn. to give isoxazoline diastereoisomer mixts. The anal. of the products was combined with MM2 calcs. on the transition structures. With the (E)-alkenes, electronic factors govern the stereoselectivity; with the (Z)-alkenes steric factors are more important.


IT 109960-99-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reduction of)

RN 109960-99-8 CAPLUS

CN 1,2-Ethanediol, 1-(3,3a,4,5,6,7-hexahydro-2,1-benzisoxazol-3-yl)-, 2-(4-methylbenzenesulfonate), [3S-[3 α (S*),3 α]]- (9CI) (CA INDEX NAME)




IT 109960-98-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and tosylation of)

RN 109960-98-7 CAPLUS

CN 1,2-Ethanediol, 1-(3,3a,4,5,6,7-hexahydro-2,1-benzisoxazol-3-yl)-, [3S-[3 α (S*),4 β]]- (9CI) (CA INDEX NAME)




IT 109960-80-7P 109960-81-8P 109960-83-0P
 110013-28-0P 110013-29-1P 110013-30-4P
 110013-31-5P 110013-32-6P 110013-33-7P
 110013-37-1P 110013-38-2P 110013-39-3P
 110013-46-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 109960-80-7 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-,
 [3R-[3 α (S*),3a β]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 109960-81-8 CAPLUS

CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-
 , [3S-[3 α (S*),3a β]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 109960-83-0 CAPLUS

CN 2,1-Benzisoxazole, 3-[(1R)-1,2-dimethylpropyl]-3,3a,4,5,6,7-hexahydro-
 (3S,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 110013-28-0 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-,

10/513699

[3S-[3 α (R*),3 $\alpha\beta$]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 110013-29-1 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-,
[3R-[3 α (S*),3 $\alpha\alpha$]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 110013-30-4 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-,
[3S-[3 α (R*),3 $\alpha\alpha$]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 110013-31-5 CAPLUS

CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-,
[3R-[3 α (R*),3 $\alpha\beta$]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/513699



RN 110013-32-6 CAPLUS

CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3S-[3a(S*),3aa]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 110013-33-7 CAPLUS

CN 2,1-Benzisoxazole, 3-[1,2-bis(phenylmethoxy)ethyl]-3,3a,4,5,6,7-hexahydro-, [3R-[3a(R*),3aa]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/513699



RN 110013-37-1 CAPLUS


CN 2,1-Benzisoxazole, 3-[(1R)-1,2-dimethylpropyl]-3,3a,4,5,6,7-hexahydro-,
(3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 110013-38-2 CAPLUS

CN 2,1-Benzisoxazole, 3-[(1R)-1,2-dimethylpropyl]-3,3a,4,5,6,7-hexahydro-,
[3a(S*),4a]- (9CI) (CA INDEX NAME)




RN 110013-39-3 CAPLUS

CN 2,1-Benzisoxazole, 3-[(1R)-1,2-dimethylpropyl]-3,3a,4,5,6,7-hexahydro-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

10/513699



RN 110013-46-2 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-[1-(phenylmethoxy)ethyl]-,
[3S-[3 α (S*),4 β]]- (9CI) (CA INDEX NAME)



L7 ANSWER 36 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1985:560616 CAPLUS

DOCUMENT NUMBER: 103:160616

ORIGINAL REFERENCE NO.: 103:25793a,25796a

TITLE: Oxidative fragmentation of β -stannyl oximes:
stereospecific formation of unsaturated nitrile oxides
AUTHOR(S): Nishiyama, Hisao; Arai, Hiroyuki; Ohki, Takashi; Itoh,
Kenji

CORPORATE SOURCE: Sch. Mater. Sci., Toyohashi Univ. Technol., Tempaku,
440, Japan


SOURCE: Journal of the American Chemical Society (1985),
107(18), 5310-12
CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 103:160616

GI



AB A new stereospecific oxidative-fragmentation was found by treatment of cyclic (E)- β -tributylstannyl oximes (I, R = H, R1 = Me; R = Me, R1 = H) with lead tetraacetate to give the unsatd. nitrile oxides II which gave in one-pot the Δ^2 -isoxazolines III, resp., via intramol. 1,3-dipolar cycloaddn. Dramatic conversion of their cyclic skeleton was completely controlled by the stannyl function. It is noteworthy that the linear (Z)- β -stannyl oximes IV (R1 = Ph, Me3C) gave directly the cyclization products V. Stereoselectivity of the fragmentation of several linear oximes was also demonstrated. Stereocontrolled homolytic process via iminoxyl radicals, generated by oxidation of the oximes, could be postulated.

IT 97782-43-9P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 97782-43-9 CAPLUS


CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-(phenylmethyl)-, trans- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

10/513699




L7 ANSWER 37 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1983:505163 CAPLUS
 DOCUMENT NUMBER: 99:105163
 ORIGINAL REFERENCE NO.: 99:16189a,16192a
 TITLE: Reduction of A2-isoxazolines. 3. Raney nickel catalyzed formation of β -hydroxy ketones
 AUTHOR(S): Curran, Dennis P.
 CORPORATE SOURCE: Dep. Chem., Univ. Pittsburgh, Pittsburgh, PA, 15260, USA
 SOURCE: Journal of the American Chemical Society (1983), 105(18), 5826-33
 CODEN: JACSAT; ISSN: 0002-7863
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 99:105163
 GI



AB Olefins underwent [2 + 3] dipolar cycloaddn. with nitrile oxides to give 2-isoxazolines, which were transformed to β -hydroxy ketones with Raney Ni catalyst, boric acid, 5:1 MeOH-H₂O, and H. This cycloaddn.-reduction sequence allowed diastereospecific formation of threo and erythro products. Thus cycloaddn. of RCNO (R = Me, Ph) with trans-2-butene gave isoxazolines trans-I, which were reduced to threo-RCOCHMeCHMeOH (threo-II), while cis-2-butene gave cis-I, and erythro-II upon reduction
 IT 82150-04-7P 82150-10-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reduction of, β -hydroxyketones by)
 RN 82150-04-7 CAPLUS
 CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-methyl-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 82150-10-5 CAPLUS
 CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

10/513699



<12/04/2007>

Erich Leese

L7 ANSWER 38 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1982:509909 CAPLUS

DOCUMENT NUMBER: 97:109909

ORIGINAL REFERENCE NO.: 97:18285a,18288a

TITLE: Reduction of A2-isoxazolines: a conceptually different approach to the formation of aldol adducts
Curran, Dennis P.

CORPORATE SOURCE: Dep. Chem., Univ. Pittsburgh, Pittsburgh, PA, 15260, USA


SOURCE: Journal of the American Chemical Society (1982), 104(14), 4024-6

CODEN: JACSAT; ISSN: 0002-7863


DOCUMENT TYPE: Journal

LANGUAGE: English


GI




I



II



III



IV

AB The isoxazolines I [R1 = H, Me, Pr; R2 = H, Me; R3 = Me, Pr, Bu, Ph; R1R2 = (CH2)4, (CH2)3, R3 = H], prepared by nitrile oxide-olefin cycloaddn., underwent reduction by H2 in presence of Raney Ni to give the aldol adducts II. The cycloalkaisoxazoline III (n = 1, 2; R3 = H, Me, Ph; R4 = H, Me, Ph, CH2OAc) were similarly reduced to give the aldol adducts IV.


IT 82150-04-7 82150-10-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(catalytic reduction of)

RN 82150-04-7 CAPLUS

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 82150-10-5 CAPLUS

10/513699

CN 2,1-Benzisoxazole, 3,3a,4,5,6,7-hexahydro-3-methyl-, trans- (9CI) (CA
INDEX NAME)

Relative stereochemistry.



L7 ANSWER 39 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1972:488371 CAPLUS

DOCUMENT NUMBER: 77:88371

ORIGINAL REFERENCE NO.: 77:14589a,14592a

TITLE: Reaction of keto-stabilized sulfonium and arsonium ylides with α -chlorooximes. New synthesis of Δ^2 -isoxazolines

AUTHOR(S): Bravo, P.; Gaudiano, G.; Ponti, P. P.; Ticozzi, C.

CORPORATE SOURCE: Ist. Chim., Politec. Milano, Milan, Italy

Tetrahedron (1972), 28(14), 3845-54

CODEN: TETRAB; ISSN: 0040-4020

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 77:88371

GI For diagram(s), see printed CA Issue.

AB The reaction of α -chloro oximes or the isomeric nitroso chlorides with keto-stabilized dimethylsulfonium or triphenylarsonium ylides gave trans-5-acyl-2-isoxazolines (I, e.g., R, R1 = Me, Ph, R2 = Bz). The NOCI adducts of Et propenyl ether and Et styryl ether on reaction with dimethylsulfonium phenacylide gave 3-substituted 5-benzoylisoxazoles. Dimethylsulfonium carbethoxymethylide (II) and 2-chloro-2-phenylacetone oxime gave Et β -acetylcinnamate oxime. II and 2-chlorocyclooctanone oxime gave the thioether (III).


IT 37543-31-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 37543-31-0 CAPLUS

CN Methanone, (3,3a,4,5,6,7-hexahydro-2,1-benzisoxazol-3-yl)phenyl-, cis-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



10/513699

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

214.95

663.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-31.20

-44.00

FILE 'REGISTRY' ENTERED AT 16:51:05 ON 22 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 OCT 2008 HIGHEST RN 1064205-90-8

DICTIONARY FILE UPDATES: 21 OCT 2008 HIGHEST RN 1064205-90-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10524123.str

10/513699



```
chain nodes :
10 12 13 14 15
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
5-14 6-12 6-13 9-10 9-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 5-14 6-12 6-13 7-8 8-9 9-10 9-15
isolated ring systems :
containing 1 :
```

G1:C,O,S,N

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS
```

L8 STRUCTURE UPLOADED

=> d 18


L8 HAS NO ANSWERS

L8 STR

<12/04/2007>

Erich Leese

10/513699



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10524123new.str



chain nodes :
10 12 13 14 15
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
5-14 6-12 6-13 9-10 9-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9
exact/norm bonds :

<12/04/2007>

Erich Leese

10/513699

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 5-14 6-12 6-13 7-8 8-9 9-10 9-15

G1:C,O,S,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS

L9 STRUCTURE UPLOADED

=> d l9

L9 HAS NO ANSWERS

L9 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 16:39:01 ON 22 OCT 2008)

FILE 'REGISTRY' ENTERED AT 16:42:26 ON 22 OCT 2008

L1 STRUCTURE UPLOADED

L2 736 S L1 FULL

FILE 'CAPLUS' ENTERED AT 16:43:42 ON 22 OCT 2008

L3 16 S L2 FULL

FILE 'REGISTRY' ENTERED AT 16:45:54 ON 22 OCT 2008

L4 STRUCTURE UPLOADED

L5 STRUCTURE UPLOADED

L6 880 S L5 FULL

FILE 'CAPLUS' ENTERED AT 16:48:10 ON 22 OCT 2008

L7 39 S L6 FULL

FILE 'REGISTRY' ENTERED AT 16:51:05 ON 22 OCT 2008

L8 STRUCTURE UPLOADED

<12/04/2007>

Erich Leese

10/513699

L9 STRUCTURE UPLOADED

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.92

664.81

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-44.00

STN INTERNATIONAL LOGOFF AT 16:52:33 ON 22 OCT 2008